https://www.oncobites.tv/news/un-modelo-basado-en-pet%2Fct-y-c%C3%A9lulas-tumorales-circulantes-predice-con-precisi%C3%B3n-el-grado-del-adenocarcinoma-de-pulm%C3%B3n 2026-04-20 https://www.oncobites.tv/news/el-alta-en-el-mismo-d%C3%ADa-en-c%C3%A1ncer-de-ovario-avanzado%3A-un-hito-quir%C3%BArgico-que-exige-una-rigurosa-selecci%C3%B3n-de-pacientes 2026-04-20 https://www.oncobites.tv/news/eficacia-y-seguridad-del-r%C3%A9gimen-neoadyuvante-acortado-12wtchp-en-c%C3%A1ncer-de-mama-her2%2B 2026-04-20 https://www.oncobites.tv/news/la-mutaci%C3%B3n-tp53-podr%C3%ADa-predecir-la-resistencia-a-la-terapia-con-taxanos-en-el-adenocarcinoma-de-intestino-delgado 2026-04-20 https://www.oncobites.tv/news/keynote-905%3A-enfortumab-vedotina-%2B-pembrolizumab-perioperatorio-en-c%C3%A1ncer-de-vejiga-musculo-invasivo 2026-04-20 https://www.oncobites.tv/news/disparidades-en-el-mieloma-m%C3%BAltiple%3A-el-impacto-real-en-la-esperanza-de-vida 2026-04-13 https://www.oncobites.tv/news/riesgo-de-segundas-neoplasias-en-pacientes-con-mieloma-m%C3%BAltiple%3A-lecciones-de-un-gran-metaan%C3%A1lisis 2026-04-13 https://www.oncobites.tv/news/caremm-001%3A-eficacia-de-la-terapia-car-t-anti-bcma-como-primera-l%C3%ADnea-en-mieloma-m%C3%BAltiple-de-nuevo-diagn%C3%B3stico 2026-04-15 https://www.oncobites.tv/news/%C2%A1vamos-a-contarte-eado-2026! 2026-04-13 https://www.oncobites.tv/news/radiograf%C3%ADa-a-dos-d%C3%A9cadas-de-investigaci%C3%B3n-sobre-el-pron%C3%B3stico-del-c%C3%A1ncer-papilar-de-tiroides 2026-04-13 https://www.oncobites.tv/news/la-mutaci%C3%B3n-braf-se-perfila-como-clave-para-personalizar-el-tratamiento-del-melanoma-en-estadio-iii 2026-04-13 https://www.oncobites.tv/news/vigilancia-por-imagen-en-c%C3%A1ncer-de-pr%C3%B3stata%3A-progresi%C3%B3n-radiogr%C3%A1fica-sin-elevaci%C3%B3n-del-psa-bajo-tratamiento-con-enzalutamida 2026-04-13 https://www.oncobites.tv/news/azacitidina-%2B-pembrolizumab-en-el-tratamiento-de-segunda-l%C3%ADnea-del-adenocarcinoma-ductal-pancre%C3%A1tico-avanzado 2026-04-13 https://www.oncobites.tv/news/extrem-ion%3A-irradiaci%C3%B3n-neoadyuvante-hipofraccionada-con-protones-o-iones-de-carbono-en-sarcoma-de-tejidos-blandos 2026-04-15 https://www.oncobites.tv/news/campass%3A-benmelstobart-%2B-anlotinib-vs.-pembrolizumab-en-cpnm-avanzado-pd-l1-positivo 2026-04-13 https://www.oncobites.tv/news/radioterapia-hipofraccionada-preoperatoria%3A-una-alternativa-segura-y-eficaz-para-sarcomas-de-tejidos-blandos 2026-04-16 https://www.oncobites.tv/news/la-disfunci%C3%B3n-tiroidea-por-inmunoterapia-mejora-el-pron%C3%B3stico-en-pacientes-con-c%C3%A1ncer-nasofar%C3%ADngeo-avanzado 2026-04-20 https://www.oncobites.tv/news/%22mostrar-algo-de-empat%C3%ADa%22%3A-integrar-las-condiciones-sociales-en-el-cuidado-del-c%C3%A1ncer-de-ovario 2026-04-20 https://www.oncobites.tv/news/a%C3%B1adir-inmunoterapia-a-la-quimioterapia-mejora-la-calidad-de-vida-en-el-c%C3%A1ncer-de-mama-triple-negativo-metast%C3%A1sico 2026-04-20 https://www.oncobites.tv/news/envelope%3A-enfortumab-vedotina-en-adenocarcinoma-de-intestino-delgado-avanzado-refractario-a-platino 2026-04-20 https://www.oncobites.tv/news/saffron-301%3A-sitravatinib-%2B-tislelizumab-frente-a-docetaxel-en-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-avanzado 2026-04-20 https://www.oncobites.tv/news/biopsia-del-ganglio-centinela%3A-reducci%C3%B3n-de-mortalidad-y-recurrencia-en-melanoma-cut%C3%A1neo 2026-04-20 https://www.oncobites.tv/news/estudio-fase-ii-de-pegaspargasa-en-pacientes-pedi%C3%A1tricos-con-lla%3A-formulaci%C3%B3n-liofilizada-vs.-l%C3%ADquida 2026-04-13 https://www.oncobites.tv/news/elda%3A-nueva-plataforma-para-predecir-en-tiempo-real-la-respuesta-a-f%C3%A1rmacos-en-leucemia-linfobl%C3%A1stica-aguda 2026-04-13 https://www.oncobites.tv/news/las-alteraciones-en-tp53-predicen-el-fracaso-de-la-terapia-car-t-en-leucemia-linfobl%C3%A1stica-aguda 2026-04-13 https://www.oncobites.tv/news/validaci%C3%B3n-de-cask-como-nueva-diana-terap%C3%A9utica-en-el-osteosarcoma 2026-04-15 https://www.oncobites.tv/news/prevenci%C3%B3n-y-manejo-de-complicaciones-por-traqueotom%C3%ADa-tras-c%C3%A1ncer-de-laringe%3A-nueva-s%C3%ADntesis-de-evidencia 2026-04-15 https://www.oncobites.tv/news/la-expresi%C3%B3n-de-retrovirus-end%C3%B3genos-humanos%3A-un-posible-biomarcador-de-pron%C3%B3stico-y-respuesta-en-melanoma-cut%C3%A1neo 2026-04-13 https://www.oncobites.tv/news/la-analgesia-multimodal-acelera-la-recuperaci%C3%B3n-y-reduce-complicaciones-en-la-cirug%C3%ADa-del-c%C3%A1ncer-de-endometrio 2026-04-13 https://www.oncobites.tv/news/nuevas-tendencias-en-el-manejo-del-c%C3%A1ncer-de-pr%C3%B3stata-localizado 2026-04-15 https://www.oncobites.tv/news/tropion-breast02%3A-datopotamab-deruxtec%C3%A1n-frente-a-quimioterapia-en-c%C3%A1ncer-de-mama-triple-negativo-avanzado 2026-04-13 https://www.oncobites.tv/news/paloma-2%3A-amivantamab-subcut%C3%A1neo-y-lazertinib-consolidan-su-eficacia-a-largo-plazo-en-el-nsclc-avanzado-con-mutaci%C3%B3n-de-egfr 2026-04-13 https://www.oncobites.tv/news/rosetta-lung-01%3A-un-paso-adelante-en-el-tratamiento-de-primera-l%C3%ADnea-del-sclc-con-el-anticuerpo-biespec%C3%ADfico-pumitamig 2026-04-13 https://www.oncobites.tv/news/airgenomics%3A-inteligencia-artificial-y-biopsia-l%C3%ADquida-para-predecir-la-respuesta-a-la-inmunoterapia-en-cpnm-sin-mutaciones-driver 2026-04-13 https://www.oncobites.tv/news/be-lung%3A-radiograf%C3%ADa-del-mundo-real-sobre-biomarcadores-y-supervivencia-en-el-nsclc-temprano 2026-04-13 https://www.oncobites.tv/news/keynote-671-a-5-a%C3%B1os%3A-beneficio-de-pembrolizumab-perioperatorio-en-nsclc-en-estadio-temprano 2026-04-13 https://www.oncobites.tv/news/beamion-lung-1%3A-zongertinib-en-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-her2-metast%C3%A1sico%2C-incluyendo-met%C3%A1stasis-cerebrales 2026-04-13 https://www.oncobites.tv/news/asteroid%3A-sbrt-%2B-durvalumab-en-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-temprano 2026-04-13 https://www.oncobites.tv/news/bl-b01d1%3A-iza-bren-%2B-serplulimab-en-c%C3%A1ncer-de-pulm%C3%B3n-de-c%C3%A9lulas-peque%C3%B1as-en-estadio-extenso 2026-04-13 https://www.oncobites.tv/news/atezolizumab-subcut%C3%A1neo-en-espa%C3%B1a%3A-superioridad-en-satisfacci%C3%B3n-y-conveniencia-para-el-paciente-con-cpnm 2026-04-13 https://www.oncobites.tv/news/el-paisaje-molecular-de-las-met%C3%A1stasis-clivales-en-c%C3%A1ncer-de-pr%C3%B3stata-revela-nuevas-vulnerabilidades-terap%C3%A9uticas 2026-04-13 https://www.oncobites.tv/news/disulfiram-y-cobre%3A-una-prometedora-combinaci%C3%B3n-para-vencer-la-radiorresistencia-en-el-cordoma 2026-04-13 https://www.oncobites.tv/news/quimiorradioterapia-'sandwich'-frente-a-secuencial-en-c%C3%A1ncer-de-endometrio-estadio-iii%3A-eficacia-y-toxicidad-temporal 2026-04-13 https://www.oncobites.tv/news/flower%3A-ftd%2Ftpi-%2B-bevacizumab-en-pacientes-con-c%C3%A1ncer-colorrectal-metast%C3%A1sico-en-la-pr%C3%A1ctica-cl%C3%ADnica-real 2026-04-13 https://www.oncobites.tv/news/validado-en-espa%C3%B1a-el-nuevo-cuestionario-europeo-qlq-br42-para-medir-la-calidad-de-vida-en-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/reca%C3%ADda-en-carcinoma-de-cabeza-y-cuello%3A-el-impacto-del-tratamiento-previo-y-el-estado-del-vph 2026-04-13 https://www.oncobites.tv/news/diagnosticar-c%C3%A1ncer-de-piel%3A-evaluaci%C3%B3n-de-la-evoluci%C3%B3n-temporal-con-un-nuevo-modelo-de-inteligencia-artificial 2026-04-13 https://www.oncobites.tv/news/un-%C3%ADndice-din%C3%A1mico-predice-la-respuesta-a-la-inmunoterapia-en-el-carcinoma-nasofar%C3%ADngeo-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/aramis%3A-el-valor-del-psa-indetectable-y-la-necesidad-de-pruebas-de-imagen-en-la-progresi%C3%B3n-del-c%C3%A1ncer-de-pr%C3%B3stata-no-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/eribulina-en-sarcoma-de-tejidos-blandos%3A-eficacia-y-tolerabilidad-en-la-pr%C3%A1ctica-cl%C3%ADnica-real 2026-04-13 https://www.oncobites.tv/news/hipec-en-c%C3%A1ncer-de-ovario%3A-beneficio-claro-en-diagn%C3%B3stico-reciente%2C-pero-incierto-en-reca%C3%ADdas 2026-04-13 https://www.oncobites.tv/news/her2climb-02%3A-tucatinib-%2B-t-dm1-en-c%C3%A1ncer-de-mama-localmente-avanzado-y-metast%C3%A1sico-her2%2B 2026-04-13 https://www.oncobites.tv/news/ccsp%3A-una-prote%C3%ADna-clave-para-predecir-la-supervivencia-tras-cirug%C3%ADa-de-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/an%C3%A1lisis-final-de-jupiter-06%3A-eficacia-de-toripalimab-%2B-quimioterapia-y-estudio-de-biomarcadores-en-carcinoma-de-c%C3%A9lulas-escamosas-de-es%C3%B3fago-avanzado 2026-04-13 https://www.oncobites.tv/news/%C2%A1todo-listo-para-elcc! 2026-04-13 https://www.oncobites.tv/news/aml18%3A-cpx-351-frente-a-dago2-en-pacientes-mayores-con-leucemia-mieloide-aguda 2026-04-16 https://www.oncobites.tv/news/kc-wise%3A-anbenitamab-%2B-quimioterapia-en-c%C3%A1ncer-g%C3%A1strico-o-de-la-uni%C3%B3n-gastroesof%C3%A1gica-her2-positivo-previamente-tratado 2026-04-13 https://www.oncobites.tv/news/validaci%C3%B3n-prospectiva-del-score-grant-en-el-ensayo-prosper-para-carcinoma-de-c%C3%A9lulas-renales 2026-04-13 https://www.oncobites.tv/news/braquiterapia-guiada-por-rm%3A-mejora-de-precisi%C3%B3n-y-reducci%C3%B3n-de-toxicidad-en-c%C3%A1ncer-de-c%C3%A9rvix-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/nuevas-fronteras-de-la-inmunoterapia-en-el-carcinoma-escamoso-de-pulm%C3%B3n-avanzado 2026-04-13 https://www.oncobites.tv/news/el-%C3%ADndice-piv-pretratamiento-se-consolida-como-un-potente-biomarcador-de-supervivencia-en-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/rehabilitaci%C3%B3n-cut%C3%A1nea-postoncol%C3%B3gica%3A-el-nuevo-reto-en-la-supervivencia-al-c%C3%A1ncer 2026-04-13 https://www.oncobites.tv/news/master-key%3A-resultados-en-el-mundo-real-confirman-la-necesidad-urgente-de-nuevas-terapias-para-el-liposarcoma-avanzado 2026-04-13 https://www.oncobites.tv/news/nuevas-estrategias-dirigidas-a-flt3-redefinen-el-tratamiento-de-la-leucemia-mieloide-aguda 2026-04-13 https://www.oncobites.tv/news/paradigm%3A-azacitidina-%2B-venetoclax-vs.-quimioterapia-de-inducci%C3%B3n-en-adultos-%22fit%22-con-lma-de-nuevo-diagn%C3%B3stico 2026-04-13 https://www.oncobites.tv/news/sure-02%3A-sacituzumab-govitecan-%2B-pembrolizumab-permite-la-preservaci%C3%B3n-vesical-en-c%C3%A1ncer-de-vejiga-m%C3%BAsculo-invasivo 2026-04-15 https://www.oncobites.tv/news/nuevas-estrategias-terap%C3%A9uticas-para-reca%C3%ADdas-de-tumores-de-c%C3%A9lulas-de-la-granulosa-de-ovario%3A-del-descubrimiento-al-avance-cl%C3%ADnico 2026-04-13 https://www.oncobites.tv/news/consenso-de-expertos%3A-recomendaciones-para-el-uso-de-ctdna-en-carcinoma-orofar%C3%ADngeo-vph%2B 2026-04-13 https://www.oncobites.tv/news/chopin%3A-perfusi%C3%B3n-hep%C3%A1tica-percut%C3%A1nea-combinada-con-ipilimumab-y-nivolumab-en-melanoma-uveal-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/p%C3%A9rdida-del-gen-atrx-en-sarcomas%3A-alteraci%C3%B3n-de-la-regulaci%C3%B3n-g%C3%A9nica-y-reducci%C3%B3n-de-supervivencia 2026-04-13 https://www.oncobites.tv/news/orchard%3A-osimertinib-%2B-datopotamab-deruxtecan-tras-progresi%C3%B3n-a-osimertinib-en-nsclc 2026-04-13 https://www.oncobites.tv/news/planet%3A-pembrolizumab-a-baja-dosis-como-paso-hacia-la-equidad-en-el-c%C3%A1ncer-de-mama-triple-negativo 2026-04-13 https://www.oncobites.tv/news/tomas2%3A-%C2%BFha-llegado-la-era-de-la-oncolog%C3%ADa-de-precisi%C3%B3n-al-leiomiosarcoma-uterino%3F 2026-04-13 https://www.oncobites.tv/news/keyvibe-010%3A-vibostolimab-coformulado-con-pembrolizumab-en-melanoma-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/nimotuzumab-%2B-radioterapia-tras-inducci%C3%B3n%3A-mejora-en-supervivencia-en-c%C3%A1ncer-de-cabeza-y-cuello-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/axinet%3A-axitinib-%2B-octreotida-lar-en-tumores-neuroendocrinos-extrapancre%C3%A1ticos-avanzados 2026-04-13 https://www.oncobites.tv/news/monstar-screen-3-demuestra-que-la-detecci%C3%B3n-ultrasensible-de-ctdna-mediante-wgs-identifica-enfermedad-residual-m%C3%ADnima-y-estratifica-el-riesgo-de-reca%C3%ADda-en-carcinoma-renal-resecable 2026-04-13 https://www.oncobites.tv/news/spot-on-cml%3A-secuenciaci%C3%B3n-en-gotas-de-sangre-seca-para-monitorizar-la-leucemia-mieloide-cr%C3%B3nica 2026-04-13 https://www.oncobites.tv/news/an%C3%A1lisis-interino-de-vorolanib-combinado-con-cadonilimab-en-pacientes-con-arcc-no-tratados-previamente 2026-04-13 https://www.oncobites.tv/news/resultados-iniciales-de-escalada-de-dosis-de-cbm588-%2B-nivolumab%2Fipilimumab-en-carcinoma-de-c%C3%A9lulas-renales-metast%C3%A1sico-(mrcc) 2026-04-13 https://www.oncobites.tv/news/ifuca%3A-impacto-de-las-alteraciones-en-fgfr3-sobre-la-quimioterapia-basada-en-platino-en-primera-l%C3%ADnea-en-carcinoma-urotelial-metast%C3%A1sico-o-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/enfants-guard%3A-datos-en-vida-real-de-enfortumab-vedotina-en-pacientes-con-c%C3%A1ncer-urotelial-avanzado-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/indi-blade%3A-ipilimumab-m%C3%A1s-nivolumab-de-inducci%C3%B3n-seguidos-de-quimiorradioterapia-de-consolidaci%C3%B3n-como-estrategia-de-preservaci%C3%B3n-vesical-en-carcinoma-urotelial-estadio-ii%2Fiii 2026-04-13 https://www.oncobites.tv/news/triton3%3A-rucaparib-frente-a-docetaxel-o-inhibidores-de-segunda-generaci%C3%B3n-del-receptor-androg%C3%A9nico-en-pacientes-con-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-resistente-a-la-castraci%C3%B3n-con-mutaciones-en-brca-seg%C3%BAn-el-estado-funcional-ecog 2026-04-13 https://www.oncobites.tv/news/fruquintinib-%2B-serplulimab-en-primera-l%C3%ADnea-para-nccrcc-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/din%C3%A1mica-del-ctdna-como-br%C3%BAjula-terap%C3%A9utica%3A-atezolizumab-adyuvante-redefine-el-manejo-del-c%C3%A1ncer-de-vejiga-m%C3%BAsculo-invasivo 2026-04-13 https://www.oncobites.tv/news/el-perfil-de-ctdna-predice-el-pron%C3%B3stico-en-carcinoma-urotelial-metast%C3%A1sico-tratado-con-enfortumab-vedotin 2026-04-13 https://www.oncobites.tv/news/transiciones-de-tratamiento-y-carga-hospitalaria-en-c%C3%A1ncer-de-pr%C3%B3stata-mcrpc-en-colombia%3A-datos-de-vida-real 2026-04-13 https://www.oncobites.tv/news/el-tratamiento-con-%C2%B9%E2%81%B7%E2%81%B7lu-psma-617-se-asocia-a-deterioro-renal-frecuente-pero-mayoritariamente-transitorio-en-mcrpc 2026-04-13 https://www.oncobites.tv/news/firmas-del-microbioma-intestinal-vinculadas-a-la-respuesta-a-inhibidores-parp-en-mcrpc 2026-04-13 https://www.oncobites.tv/news/nuevas-estrategias-terap%C3%A9uticas-que-redefinen-el-tratamiento-del-mcrpc-resistente-a-moduladores-del-receptor-androg%C3%A9nico 2026-04-13 https://www.oncobites.tv/news/brcaway%3A-la-combinaci%C3%B3n-de-abiraterona-y-olaparib-prolonga-la-supervivencia-global-m%C3%A1s-de-5-a%C3%B1os-en-mcrpc-con-alteraciones-en-brca1%2F2-o-atm 2026-04-13 https://www.oncobites.tv/news/las-3-claves-para-reducir-la-mortalidad-por-c%C3%A1ncer-de-cuello-uterino 2026-04-13 https://www.oncobites.tv/news/calidad-de-vida-y-miedo-a-la-reca%C3%ADda%3A-el-peso-del-nivel-socioecon%C3%B3mico-en-supervivientes-de-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/la-fda-acelera-la-primera-terapia-g%C3%A9nica-inhalable-para-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/nuevo-sistema-de-puntuaci%C3%B3n-para-predecir-la-supervivencia-en-leucemia-mieloide-cr%C3%B3nica-en-fase-bl%C3%A1stica 2026-04-13 https://www.oncobites.tv/news/endure%3A-ropeginterferon-alfa-2b-vs.-vigilancia-tras-discontinuaci%C3%B3n-de-tki-en-leucemia-mieloide-cr%C3%B3nica 2026-04-13 https://www.oncobites.tv/news/ascent-04%2Fkeynote-d19%3A-sacituzumab-govitecan-%2B-pembrolizumab-en-c%C3%A1ncer-de-mama-triple-negativo-avanzado 2026-04-13 https://www.oncobites.tv/news/osteosarcoma%3A-de-la-quimioterapia-a-la-cura-funcional-mediante-multi%C3%B3mica-y-nanotecnolog%C3%ADa 2026-04-13 https://www.oncobites.tv/news/tinci%C3%B3n-dual-vs.-citolog%C3%ADa%3A-un-nuevo-est%C3%A1ndar-para-el-triaje-en-c%C3%A1ncer-de-c%C3%A9rvix-en-mujeres-vph-positivas 2026-04-13 https://www.oncobites.tv/news/papillon%3A-amivantamab-%2B-quimioterapia-en-poblaci%C3%B3n-asi%C3%A1tica-con-nsclc-y-mutaci%C3%B3n-egfr-ex20ins 2026-04-13 https://www.oncobites.tv/news/carga-lesional-y-respuesta-al-tratamiento%3A-predictores-clave-de-recurrencia-en-queratosis-act%C3%ADnica-m%C3%BAltiple 2026-04-13 https://www.oncobites.tv/news/estado-libre-de-progresi%C3%B3n-a-24-meses-en-c%C3%A1ncer-de-orofaringe-vph%2B 2026-04-13 https://www.oncobites.tv/news/monitorizaci%C3%B3n-de-la-din%C3%A1mica-de-la-enfermedad-residual-m%C3%ADnima-para-guiar-la-pr%C3%A1ctica-cl%C3%ADnica-en-mieloma-m%C3%BAltiple 2026-04-13 https://www.oncobites.tv/news/majestec-3%3A-teclistamab-%2B-daratumumab-vs.-elecci%C3%B3n-del-investigador-en-mieloma-m%C3%BAltiple-reca%C3%ADdo%2Frefractario 2026-04-13 https://www.oncobites.tv/news/recomendaciones-de-expertos-para-la-administraci%C3%B3n-de-anticuerpos-biespec%C3%ADficos-en-mieloma-m%C3%BAltiple-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/cobertura-especial-de-ascogu-2026 2026-04-13 https://www.oncobites.tv/news/seguridad-de-la-suspensi%C3%B3n-electiva-de-cemiplimab-tras-remisi%C3%B3n-completa-en-carcinoma-cut%C3%A1neo-de-c%C3%A9lulas-escamosas 2026-04-13 https://www.oncobites.tv/news/inhibidores-trk-neoadyuvantes-superan-a-la-quimioterapia-en-sarcomas-avanzados-con-fusi%C3%B3n-ntrk 2026-04-13 https://www.oncobites.tv/news/norse%3A-erdafitinib-vs.-erdafitinib-%2B-cetrelimab-en-carcinoma-urotelial-con-alteraciones-de-fgfr 2026-04-13 https://www.oncobites.tv/news/neoteric%3A-atezolizumab-%2B-tiragolumab-tras-quimiorradioterapia-en-c%C3%A1ncer-de-recto-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/puntuaci%C3%B3n-kelim%3A-un-marcador-clave-de-quimiosensibilidad-en-c%C3%A1ncer-de-ovario 2026-04-13 https://www.oncobites.tv/news/calidad-de-vida-y-complicaciones-de-la-osteorradionecrosis-tras-la-reconstrucci%C3%B3n-mandibular 2026-04-13 https://www.oncobites.tv/news/arts%3A-aumolertinib-adyuvante-en-pacientes-con-nsclc-resecado-estadio-ii-iiib-y-mutaci%C3%B3n-egfr 2026-04-13 https://www.oncobites.tv/news/unidad-territorial-cirug%C3%ADa-oncol%C3%B3gica-peritoneal-(utcop)%3A-una-alianza-entre-consorci-sanitari-integral-y-hospital-universitario-de-bellvitge%2C-para-potenciar-la-atenci%C3%B3n-de-la-carcinomatosis-peritoneal 2026-04-13 https://www.oncobites.tv/news/melatorch%3A-toripalimab-vs.-dacarbazina-como-primera-l%C3%ADnea-en-melanoma-avanzado-de-subtipo-acral 2026-04-13 https://www.oncobites.tv/news/el-registro-italiano-atlas-confirma-la-seguridad-de-atezolizumab-adyuvante-en-c%C3%A1ncer-de-pulm%C3%B3n-operado 2026-04-13 https://www.oncobites.tv/news/la-importancia-del-margen-quir%C3%BArgico-en-radioterapia-en-sarcomas-geri%C3%A1tricos 2026-04-13 https://www.oncobites.tv/news/abaco%3A-cabozantinib-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico-avanzado 2026-04-13 https://www.oncobites.tv/news/nuevas-gu%C3%ADas-de-la-sgo%3A-por-un-seguimiento-menos-intensivo-en-c%C3%A1nceres-ginecol%C3%B3gicos 2026-04-13 https://www.oncobites.tv/news/el-eje-oral-intestinal%3A-la-conexi%C3%B3n-clave-entre-la-microbiota-y-el-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/patina%3A-palbociclib-%2B-terapia-de-mantenimiento-en-c%C3%A1ncer-de-mama-avanzado-hr%2B%2Fher2%2B 2026-04-13 https://www.oncobites.tv/news/la-herramienta-geri%C3%A1trica-g8-predice-la-supervivencia-en-c%C3%A1ncer-urotelial-metast%C3%A1sico-tratado-con-inmunoterapia 2026-04-13 https://www.oncobites.tv/news/d%C3%ADa-mundial-contra-el-c%C3%A1ncer%3A-%E2%80%9Cpor-unos-cuidados-m%C3%A1s-justos%E2%80%9D 2026-04-13 https://www.oncobites.tv/news/d%C3%ADa-mundial-del-c%C3%A1ncer%3A-la-innovaci%C3%B3n-est%C3%A1-transformando-el-abordaje-de-la-enfermedad 2026-04-13 https://www.oncobites.tv/news/el-universo-de-las-ves%C3%ADculas-extracelulares-en-melanoma%3A-un-an%C3%A1lisis-bibliom%C3%A9trico-de-dos-d%C3%A9cadas 2026-04-13 https://www.oncobites.tv/news/captain-1st%3A-supervivencia-a-5-a%C3%B1os-con-camrelizumab-%2B-quimioterapia-en-carcinoma-nasofar%C3%ADngeo-recurrente%2Fmetast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/adherencia-a-las-gu%C3%ADas-de-disecci%C3%B3n-de-ganglios-linf%C3%A1ticos-y-supervivencia-en-pacientes-con-adenocarcinoma-de-pulm%C3%B3n-t1n0m0 2026-04-13 https://www.oncobites.tv/news/fzocus-1%3A-fuzuloparib-con-o-sin-apatinib-en-c%C3%A1ncer-de-ovario-avanzado 2026-04-13 https://www.oncobites.tv/news/panorama%3A-ia-en-la-detecci%C3%B3n-de-c%C3%A1ncer-de-p%C3%A1ncreas 2026-04-13 https://www.oncobites.tv/news/el-tratamiento-agresivo-de-las-met%C3%A1stasis-%C3%B3seas-solitarias-mejora-la-supervivencia-en-sarcomas-de-tejido-blando 2026-04-13 https://www.oncobites.tv/news/an%C3%A1lisis-primario-de-eficacia-de-un-estudio-fase-ii-que-investiga-una-terapia-basada-en-inhibidores-de-la-tirosina-quinasa-e-inotuzumab-ozogamicin-en-la-leucemia-linfobl%C3%A1stica-aguda-ph%2B-de-nuevo-diagn%C3%B3stico 2026-04-13 https://www.oncobites.tv/news/inotuzumab-ozogamicin-consolida-su-papel-terap%C3%A9utico-al-potenciarse-con-venetoclax-en-la-leucemia-linfobl%C3%A1stica-aguda 2026-04-13 https://www.oncobites.tv/news/lencabo%3A-lenvatinib-%2B-everolimus-vs.-cabozantinib-en-carcinoma-renal-de-c%C3%A9lulas-claras-metast%C3%A1sico-progresado-con-icis 2026-04-13 https://www.oncobites.tv/news/el-c%C3%A1ncer-en-espa%C3%B1a-en-2026%3A-los-tumores-se-consolidan-como-la-principal-causa-de-muerte 2026-04-13 https://www.oncobites.tv/news/una-terapia-triple-del-cnio-logra-eliminar-por-completo-tumores-de-p%C3%A1ncreas-en-ratones-y-frena-las-resistencias 2026-04-13 https://www.oncobites.tv/news/la-combinaci%C3%B3n-de-dasatinib-y-blinatumomab-potencia-una-mayor-respuesta-inmunitaria-que-ponatinib-en-la-leucemia-linfobl%C3%A1stica-aguda-ph%2B 2026-04-13 https://www.oncobites.tv/news/biomarcadores-pron%C3%B3sticos-y-diferencias-con-cohortes-occidentales-en-el-sarcoma-de-ewing 2026-04-13 https://www.oncobites.tv/news/discus%3A-3-vs-6-ciclos-de-quimioterapia-%2B-avelumab-en-c%C3%A1ncer-urotelial-avanzado 2026-04-13 https://www.oncobites.tv/news/la-historia-cl%C3%ADnica-que-podr%C3%ADa-adelantar-el-diagn%C3%B3stico-del-c%C3%A1ncer-de-pulm%C3%B3n-en-catalu%C3%B1a 2026-04-13 https://www.oncobites.tv/news/un-estudio-espa%C3%B1ol-revela-c%C3%B3mo-el-impacto-laboral-y-social-tras-el-c%C3%A1ncer-de-mama-condiciona-el-bienestar-emocional-de-las-supervivientes 2026-04-13 https://www.oncobites.tv/news/pembrolizumab-en-c%C3%A1ncer-de-tiroides-medular-recurrente-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/icis-en-personas-con-vih-y-c%C3%A1ncer-de-piel%3A-un-estudio-multic%C3%A9ntrico 2026-04-13 https://www.oncobites.tv/news/skyscraper-08%3A-tiragolumab-%2B-atezolizumab-y-quimioterapia-para-carcinoma-esof%C3%A1gico-de-c%C3%A9lulas-escamosas 2026-04-13 https://www.oncobites.tv/news/ctdna%3A-el-biomarcador-clave-para-personalizar-la-terapia-parpi-en-c%C3%A1ncer-de-ovario 2026-04-13 https://www.oncobites.tv/news/inhibidores-de-sglt2%3A-retraso-en-el-fracaso-de-la-terapia-hormonal-en-c%C3%A1ncer-de-pr%C3%B3stata 2026-04-13 https://www.oncobites.tv/news/kunpeng%3A-vebreltinib-en-nsclc-con-amplificaci%C3%B3n-de-met 2026-04-13 https://www.oncobites.tv/news/eficacia-de-la--terapia-de-rescate-con-cetuximab-tras-inmunoterapia-en-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/morpheus-ec%3A-tiragolumab-%2B-atezolizumab-y-quimioterapia-en-c%C3%A1ncer-de-es%C3%B3fago-avanzado 2026-04-13 https://www.oncobites.tv/news/el-an%C3%A1lisis-reducido-del-lecho-tumoral-mantiene-la-precisi%C3%B3n-en-la-evaluaci%C3%B3n-del-melanoma-tras-la-inmunoterapia 2026-04-13 https://www.oncobites.tv/news/la-sgo-respalda-la-nueva-gu%C3%ADa-de-asco-sobre-quimioterapia-neoadyuvante-en-c%C3%A1ncer-de-ovario-avanzado 2026-04-13 https://www.oncobites.tv/news/nct04200443%3A-cabozantinib-%2B-temozolomida-en-leiomiosarcoma-y-otros-sarcomas-de-tejidos-blandos 2026-04-13 https://www.oncobites.tv/news/avances-en-el-linfoma-perif%C3%A9rico-de-c%C3%A9lulas-t%3A-de-bv-chp-a-nuevas-fronteras-terap%C3%A9uticas 2026-04-13 https://www.oncobites.tv/news/inmind%3A-tafasitamab-%2B-lenalidomida-y-rituximab-en-linfoma-folicular-en-reca%C3%ADda-o-refractario 2026-04-13 https://www.oncobites.tv/news/rm-en-sarcomas-de-tejidos-blandos%3A-estudio-de-la-adherencia-a-las-gu%C3%ADas-alemanas-s3 2026-04-13 https://www.oncobites.tv/news/geltamo-impulsa-la-formaci%C3%B3n-en-linfomas-con-un-completo-programa-acad%C3%A9mico-en-el-primer-semestre-de-2026 2026-04-13 https://www.oncobites.tv/news/checkmate-7dx%3A-nivolumab-%2B-docetaxel-en-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-resistente-a-la-castraci%C3%B3n-pretratado-con-arpi 2026-04-13 https://www.oncobites.tv/news/hn-clear%3A-consenso-internacional-para-el-diagn%C3%B3stico-histopatol%C3%B3gico-de-la-extensi%C3%B3n-extranodal-en-carcinoma-de-c%C3%A9lulas-escamosas-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/el-registro-espa%C3%B1ol-retud-define-la-prevalencia-de-her2-y-el-impacto-de-las-terapias-anti-her2-en-el-c%C3%A1ncer-de-la-v%C3%ADa-biliar 2026-04-13 https://www.oncobites.tv/news/portec-4a%3A-tratamiento-adyuvante-guiado-por-perfil-molecular-en-c%C3%A1ncer-de-endometrio-de-riesgo-alto-intermedio 2026-04-13 https://www.oncobites.tv/news/las-mutaciones-idh1-definen-un-subtipo-molecular-con-tendencia-a-mayor-supervivencia-en-c%C3%A1ncer-de-la-v%C3%ADa-biliar-en-vida-real 2026-04-13 https://www.oncobites.tv/news/biolog%C3%ADa%2C-gen%C3%A9tica-y-abordaje-terap%C3%A9utico-del-melanoma-de-primario-desconocido 2026-04-13 https://www.oncobites.tv/news/torch-c%3A-radioterapia-neoadyuvante-%2B-capox-e-inhibidor-de-pd-1-en-c%C3%A1ncer-de-colon-localmente-avanzado-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/oxaliplatino-adyuvante-combinado-con-s-1-(sox)-frente-a-s-1-en-pacientes-con-adenocarcinoma-g%C3%A1strico-o-de-la-uni%C3%B3n-gastroesof%C3%A1gica-en-estadio-ii%E2%80%93iii 2026-04-13 https://www.oncobites.tv/news/durvalumab-m%C3%A1s-olaparib-ofrece-actividad-antitumoral-duradera-en-c%C3%A1ncer-de-p%C3%A1ncreas-metast%C3%A1sico-con-alteraciones-en-reparaci%C3%B3n-del-adn 2026-04-13 https://www.oncobites.tv/news/el-estudio-rct-paag-demuestra-que-la-combinaci%C3%B3n-con-penpulimab-y-anlotinib-mejora-la-eficacia-frente-a-gemcitabina%E2%80%93nab-paclitaxel-en-primera-l%C3%ADnea-del-c%C3%A1ncer-de-p%C3%A1ncreas-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/el-estudio-calgb-(alliance)%2Fswog-80702-vincula-la-actividad-f%C3%ADsica-con-una-mayor-supervivencia-libre-de-enfermedad-en-pacientes-con-c%C3%A1ncer-de-colon-estadio-iii-sin-enfermedad-residual-molecular 2026-04-13 https://www.oncobites.tv/news/tovecimig-demuestra-actividad-cl%C3%ADnica-y-control-de-enfermedad-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico-refractario-en-el-estudio-fase-ii-companion-003 2026-04-13 https://www.oncobites.tv/news/la-combinaci%C3%B3n-de-tate-y-nivolumab-demuestra-actividad-cl%C3%ADnica-en-carcinoma-hepatocelular-avanzado-refractario-a-inmunoterapia 2026-04-13 https://www.oncobites.tv/news/tiranus%3A-atezolizumab-%2B-tiragolumab-%2B-quimiorradioterapia-en-carcinoma-de-c%C3%A9lulas-escamosas-del-canal-anal-localizado 2026-04-13 https://www.oncobites.tv/news/microbiota-intestinal%3A-un-factor-determinante-en-la-supervivencia-de-pacientes-con-c%C3%A1ncer-frente-al-sars-cov-2 2026-04-13 https://www.oncobites.tv/news/nuevas-estrategias-para-la-mutaci%C3%B3n-braf-en-c%C3%A1ncer-gastrointestinal%3A-de-la-biolog%C3%ADa-a-la-cl%C3%ADnica 2026-04-13 https://www.oncobites.tv/news/diagn%C3%B3stico%2C-pron%C3%B3stico-y-monitoreo-del-carcinoma-hepatocelular%3A-el-papel-de-la-biopsia-l%C3%ADquida 2026-04-13 https://www.oncobites.tv/news/caracterizaci%C3%B3n-epidemiol%C3%B3gica-del-c%C3%A1ncer-de-v%C3%ADa-biliar-en-espa%C3%B1a%3A-hallazgos-del-registro-retud 2026-04-13 https://www.oncobites.tv/news/keynote-937%3A-pembrolizumab-adyuvante-para-carcinoma-hepatocelular%2C-sin-mejoras-en-la-rfs-%5Bia3%5D 2026-04-13 https://www.oncobites.tv/news/matterhorn%3A-durvalumab-%2B-flot-en-adenocarcinoma-g%C3%A1strico-o-de-la-uni%C3%B3n-esofagog%C3%A1strica 2026-04-13 https://www.oncobites.tv/news/disparidades-raciales-en-el-mundo-real%3A-sin-influencia-en-la-eficacia-del-tratamiento-del-carcinoma-hepatocelular-avanzado 2026-04-13 https://www.oncobites.tv/news/neosummit-01%3A-toripalimab-%2B-quimioterapia-vs-quimioterapia-sola-en-c%C3%A1ncer-g%C3%A1strico-localmente-avanzado-o-de-la-uni%C3%B3n-gastroesof%C3%A1gica-%5Bseguimiento-a-3-a%C3%B1os%5D 2026-04-13 https://www.oncobites.tv/news/nuevos-targets-para-el-tratamiento-del-c%C3%A1ncer-de-est%C3%B3mago-%C2%BFredefinen-los-adcs-la-oncolog%C3%ADa-de-precisi%C3%B3n-en-el-c%C3%A1ncer-g%C3%A1strico%3F 2026-04-13 https://www.oncobites.tv/news/el-estudio-rationale-305-demuestra-que-el-ecog-ps-no-refleja-plenamente-la-experiencia-del-paciente-en-c%C3%A1ncer-g%C3%A1strico-avanzado 2026-04-13 https://www.oncobites.tv/news/la-inmunoterapia-y-la-terapia-dirigida-est%C3%A1n-redibujando-la-primera-l%C3%ADnea-y-el-escenario-perioperatorio-del-c%C3%A1ncer-g%C3%A1strico-y-de-la-uni%C3%B3n-gastroesof%C3%A1gica 2026-04-13 https://www.oncobites.tv/news/comienza-el-a%C3%B1o-con-asco-gi 2026-04-13 https://www.oncobites.tv/news/cares-310%3A-camrelizumab-%2B-rivoceranib-vs.-sorafenib-en-primera-l%C3%ADnea-para-carcinoma-hepatocelular 2026-04-13 https://www.oncobites.tv/news/la-cipm-propone-la-financiaci%C3%B3n-de-dos-nuevos-medicamentos-oncol%C3%B3gicos 2026-04-13 https://www.oncobites.tv/news/logran-un-s%C3%B3lido-tres-a%C3%B1os-de-supervivencia-libre-de-eventos-en-estudio-de-c%C3%A1ncer-de-mama-triple-negativo 2026-04-13 https://www.oncobites.tv/news/ascent-07%3A-sacituzumab-govitecan-no-supera-la-quimioterapia-est%C3%A1ndar-en-pfs 2026-04-13 https://www.oncobites.tv/news/la-biolog%C3%ADa-desplaza-la-edad-en-la-decisi%C3%B3n-de-omitir-terapia-adyuvante-en-c%C3%A1ncer-de-mama-hr%2B 2026-04-13 https://www.oncobites.tv/news/resonancia-magn%C3%A9tica-para-predecir-la-supervivencia-en-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/neopanda03%3A-camrelizumab-%2B-apatinib-%2B-quimoterapia-neoadyuvante-en-c%C3%A1ncer-de-mama-triple-negativo- 2026-04-13 https://www.oncobites.tv/news/el-adn-tumoral-circulante-(ctdna)-detectado-en-el-a%C3%B1o-1-define-la-respuesta-prolongada-en-c%C3%A1ncer-de-mama-her2%2B 2026-04-13 https://www.oncobites.tv/news/destiny-breast05%3A-trastuzumab-deruxtecan-(t-dxd)-vs-a-trastuzumab-emtansina-(t-dm1)-en-pacientes-con-c%C3%A1ncer-de-mama-temprano-rh%2B%2C-her2%2B-de-alto-riesgo-con-enfermedad-invasiva-residual-despu%C3%A9s-de-la-terapia-neoadyuvante. 2026-04-13 https://www.oncobites.tv/news/giredestrant-vs-terapia-endocrina-est%C3%A1ndar-como-tratamiento-adyuvante-para-pacientes-con-c%C3%A1ncer-de-mama-temprano-rh%2B-y-her2- 2026-04-13 https://www.oncobites.tv/news/waveline-003%3A-zilovertamab-vedotin-%2B-est%C3%A1ndar-de-cuidado-en-linfoma-difuso-de-c%C3%A9lulas-b-grandes-reca%C3%ADdo-o-refractario 2026-04-13 https://www.oncobites.tv/news/bruin-cll-313%3A-primeros-resultados-de-pirtobrutinib-vs-bendamustina-%2B-rituximab-en-pacientes-con-leucemia-linfoc%C3%ADtica-cr%C3%B3nica-%2F-linfoma-linfoc%C3%ADtico-de-c%C3%A9lulas-peque%C3%B1as-(cll%2Fsll) 2026-04-13 https://www.oncobites.tv/news/revisan-las-alternativas-emergentes-despu%C3%A9s-del-uso-de-cdk4%2F6-en-el-c%C3%A1ncer-de-mama-metast%C3%A1sico-hr%2Bher2- 2026-04-13 https://www.oncobites.tv/news/empower-lung-3%3A-cemiplimab-y-quimioterapia-ofrecen-una-supervivencia-duradera-a-5-a%C3%B1os-en-c%C3%A1ncer-de-pulm%C3%B3n-avanzado-con-pd-l1-%E2%89%A51%25 2026-04-13 https://www.oncobites.tv/news/venetoclax-demuestra-altas-tasas-de-remisi%C3%B3n-en-lma-en-adultos-mayores-aptos-para-quimioterapia-intensiva- 2026-04-13 https://www.oncobites.tv/news/asciminib-desaf%C3%ADa-a-los-tki-tradicionales-y-reconfigura-el-algoritmo-de-tratamiento-de-lmc-en-2025 2026-04-13 https://www.oncobites.tv/news/la-llc-de-nuevo-diagn%C3%B3stico-se-gu%C3%ADa-por-la-gen%C3%A9tica-para-personalizar-la-terapia-de-duraci%C3%B3n-limitada- 2026-04-13 https://www.oncobites.tv/news/pethema-presenta-un-avance-m%C3%ADnimamente-invasivo-para-evaluar-la-enfermedad-residual-perif%C3%A9rica-(prd) 2026-04-13 https://www.oncobites.tv/news/zanubrutinib-en-combinaci%C3%B3n-con-obinutuzumab-mejora-la-respuesta-duradera-en-linfoma-folicular-reca%C3%ADdo%2Frefractario 2026-04-13 https://www.oncobites.tv/news/mosunetuzumab-y-polatuzumab-combinados-con-axicabtagene-ciloleucel-inducen-altas-tasas-de-respuesta-completa-al-d%C3%ADa%2B90-en-el-linfoma-de-c%C3%A9lulas-b-grandes-reca%C3%ADdo%2Frefractario 2026-04-13 https://www.oncobites.tv/news/benefit%3A-sostenibilidad-de-la-mdr-con-isatuximab-%2B-lenalidomida-%2B-dexametasona-con-bortezomib-(isa-vrd)-frente-a-isard-en-mieloma-m%C3%BAltiple-reci%C3%A9n-diagnosticado-no-elegible-para-trasplante- 2026-04-13 https://www.oncobites.tv/news/inmunoterapias-reescriben-el-est%C3%A1ndar-de-cuidado-en-la-leucemia-linfobl%C3%A1stica-aguda-de-c%C3%A9lulas-b-adulta- 2026-04-13 https://www.oncobites.tv/news/sunrise-4%3A-cetrelimab-con-o-sin-gemcitabina-neoadyuvante-en-mibc 2026-04-13 https://www.oncobites.tv/news/persisten-las-disparidades-en-supervivencia-del-melanoma-avanzado 2026-04-13 https://www.oncobites.tv/news/sarcoma-card%C3%ADaco%3A-factores-pron%C3%B3sticos-y-resultados-del-tratamiento-en-una-cohorte-nacional 2026-04-13 https://www.oncobites.tv/news/mars1%3A-un-biomarcador-dual-para-el-carcinoma-papilar-de-tiroides 2026-04-13 https://www.oncobites.tv/news/pirfenidona-para-la-lesi%C3%B3n-pulmonar-de-grado-2-y-3-inducida-por-radiaci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/el-impacto-del-equipo-multidisciplinar-en-la-supervivencia-de-pacientes-con-carcinoma-hepatocelular 2026-04-13 https://www.oncobites.tv/news/16%C2%AA-reuni%C3%B3n-anual-del-gellc%3A-innovaci%C3%B3n-en-leucemia-linfoc%C3%ADtica-cr%C3%B3nica 2026-04-13 https://www.oncobites.tv/news/pr%C3%B3ximo-simposio-internacional-ttd-en-oviedo 2026-04-13 https://www.oncobites.tv/news/nct03612154%3A-lorlatinib-para-nsclc-ros1-positivo- 2026-04-13 https://www.oncobites.tv/news/transcript%C3%B3mica-en-c%C3%A1ncer-de-piel%3A-heterogeneidad%2C-microambiente-y-resistencia 2026-04-13 https://www.oncobites.tv/news/ascent-03%3A-sacituzumab-govitecan-en-c%C3%A1ncer-de-mama-triple-negativo-sin-tratamiento-previo 2026-04-13 https://www.oncobites.tv/news/consenso-de-expertos-de-la-csco%3A-anticuerpos-anti-egfr-%2B-inhibidores-de-checkpoints-en-carcinoma-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/rendimiento-pron%C3%B3stico-de-sarculator-en-sarcoma-de-tejidos-blandos-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/fuzuloparib-con-o-sin-apatinib-en-c%C3%A1ncer-de-ovario-avanzado%3A-resultados-del-ensayo-fase-3-fzocus-1 2026-04-13 https://www.oncobites.tv/news/eficacia-y-seguridad-de-avelumab-%2B-axitinib-en-primera-l%C3%ADnea-de-carcinoma-de-c%C3%A9lulas-renales-avanzado 2026-04-13 https://www.oncobites.tv/news/un-metaan%C3%A1lisis-revela-que-la-edad-modula-el-beneficio-de-intensificaci%C3%B3n-terap%C3%A9utica-en-mhspc 2026-04-13 https://www.oncobites.tv/news/elevate-tn%3A-resultados-a-6-a%C3%B1os-acalabrutinib-%2B-obinutuzumab-en-pacientes-con-llc-no-tratados-previamente- 2026-04-13 https://www.oncobites.tv/news/la-combinaci%C3%B3n-de-ianalumab-e-ibrutinib-logra-respuestas-profundas-y-sostenidas-en-pacientes-con-llc 2026-04-13 https://www.oncobites.tv/news/la-fda-aprueba-la-terapia-con-durvalumab-%2B-flot-para-c%C3%A1ncer-esofagog%C3%A1strico 2026-04-13 https://www.oncobites.tv/news/nivolumab-%2B-radioterapia-en-c%C3%A1ncer-cervical-avanzado-en-pacientes-mayores 2026-04-13 https://www.oncobites.tv/news/imiquimod-t%C3%B3pico-para-m%C3%A1rgenes-positivos-en-melanoma 2026-04-13 https://www.oncobites.tv/news/impacto-de-la-histolog%C3%ADa-en-el-pron%C3%B3stico-de-carcinomas-de-c%C3%A9lulas-basales-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/nuevo-marcador-histopatol%C3%B3gico-en-sarcoma-de-tejidos-blandos 2026-04-13 https://www.oncobites.tv/news/radi%C3%B3mica-y-datos-del-mundo-real-para-predecir-la-eficacia-de-la-inmunoterapia-en-cpnm-avanzado 2026-04-13 https://www.oncobites.tv/news/herizon-gea-01%3A-zanidatamab-%2B-quimioterapia-con%2Fsin-tislelizumab-en-c%C3%A1ncer-esofagog%C3%A1strico-avanzado-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/javier-castro-toma-la-presidencia-de-seom 2026-04-13 https://www.oncobites.tv/news/d%C3%ADa-mundial-del-c%C3%A1ncer-de-p%C3%A1ncreas%3A-llamada-a-la-acci%C3%B3n-con-la-carrera-de-las-ciudades 2026-04-13 https://www.oncobites.tv/news/alpaca%3A-avelumab-en-c%C3%A1ncer-de-pene-con-progresi%C3%B3n-despu%C3%A9s-de-quimioterapia 2026-04-13 https://www.oncobites.tv/news/consenso-de-expertos%3A-la-ngs-no-es-un-est%C3%A1ndar-de-rutina-para-el-sarcoma 2026-04-13 https://www.oncobites.tv/news/segundo-a%C3%B1o-consecutivo-en-la-cobertura-del-congreso-ash 2026-04-13 https://www.oncobites.tv/news/sabcs-nuestro-%C3%BAltimo-congreso-del-a%C3%B1o 2026-04-13 https://www.oncobites.tv/news/la-voz-de-las-expertas-en-c%C3%A1ncer-de-p%C3%A1ncreas 2026-04-13 https://www.oncobites.tv/news/nivolumab-en-dosis-bajas-y-lenalidomida-en-linfoma-de-hodgkin-en-reca%C3%ADda-o-refractario 2026-04-16 https://www.oncobites.tv/news/recuento-de-linfocitos%3A-marcador-de-eficacia-de-inmunoterapia-en-c%C3%A1ncer-de-c%C3%A9rvix 2026-04-13 https://www.oncobites.tv/news/oncolog%C3%ADa-de-precisi%C3%B3n-en-c%C3%A1ncer-g%C3%A1strico%3A-hacia-el-tratamiento-personalizado 2026-04-13 https://www.oncobites.tv/news/hacia-una-mejor-supervivencia-en-el-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/seguimiento-activo-con-enfermer%C3%ADa-de-pr%C3%A1ctica-avanzada-en-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/bi%C3%B3psia-l%C3%ADquida-en-c%C3%A1ncer-de-orofaringe%3A-detecci%C3%B3n-de-adn-de-vph-16 2026-04-13 https://www.oncobites.tv/news/an%C3%A1lisis-con-datos-del-gecp-sobre-nsclc%3A-caracter%C3%ADsticas-cl%C3%ADnicas-y-evoluci%C3%B3n-de-pacientes 2026-04-13 https://www.oncobites.tv/news/existen-casos-genuinos-de-linfoma-difuso-de-c%C3%A9lulas-b-grandes-con-reordenamiento-ccnd1 2026-04-13 https://www.oncobites.tv/news/llega-%E2%80%9Cpsmaddition%3A-sumando-eficacia%E2%80%9D%2C-el-programa-que-analiza-el-estudio-que-podr%C3%ADa-cambiar-el-manejo-del-mhspc 2026-04-13 https://www.oncobites.tv/news/la-voz-de-los-expertos 2026-04-13 https://www.oncobites.tv/news/terapia-dirigida-e-inmunoterapia-en-excluidos-de-ensayos-de-melanoma-metast%C3%A1sico- 2026-04-13 https://www.oncobites.tv/news/m%C3%A1s-del-80%25-de-adjuntos-de-oncolog%C3%ADa-con-riesgo-o-presencia-de-burnout 2026-04-13 https://www.oncobites.tv/news/geltamo-trae-las-novedades-de-car-t-en-linfomas 2026-04-13 https://www.oncobites.tv/news/trybeca-1%3A-eriaspasa-%2B-quimioterapia-de-segunda-l%C3%ADnea-para-adenocarcinoma-pancre%C3%A1tico 2026-04-13 https://www.oncobites.tv/news/%C2%BFadyuvancia-o-neoadyuvancia%3F-el-debate-en-estadio-iii-de-melanoma 2026-04-13 https://www.oncobites.tv/news/%C2%BFadyuvancia-o-neoadyuvancia%3F-el-debate-en-estadio-iii-de-melanoma 2026-04-13 https://www.oncobites.tv/news/la-inmunoterapia-neoadyuvante-desplaza-a-la-quimioterapia-en-hnscc 2026-04-13 https://www.oncobites.tv/news/carcinoma-seroso-de-ovario-de-bajo-grado%3A-avances-en-el-tratamiento 2026-04-13 https://www.oncobites.tv/news/atezolizumab-adyuvante-guiado-por-ctdna-en-c%C3%A1ncer-de-vejiga-m%C3%BAsculo-invasivo 2026-04-13 https://www.oncobites.tv/news/osimertinib-%2B-quimioterapia-mejora-la-supervivencia-en-cpnm-avanzado-con-mutaci%C3%B3n-del-egfr 2026-04-13 https://www.oncobites.tv/news/erspc%3A-cribado-de-c%C3%A1ncer-de-pr%C3%B3stata-con-psa-%5Bresultados-a-23-a%C3%B1os%5D 2026-04-13 https://www.oncobites.tv/news/raludotatug-deruxtecan-(r-dxd)-ofrece-respuestas-significativas-en-c%C3%A1ncer-de-ovario-resistente-al-platino 2026-04-13 https://www.oncobites.tv/news/evolution%3A-inmunoterapia-sin-radioterapia-para-el-cpnm-localmente-avanzado-con-alta-expresi%C3%B3n-de-pd-l1 2026-04-13 https://www.oncobites.tv/news/pazopanib-revoluciona-el-pron%C3%B3stico-en-el-sarcoma-de-ewing-multi-metast%C3%A1sico-pedi%C3%A1trico 2026-04-13 https://www.oncobites.tv/news/sonidegib%3A-an%C3%A1lisis-de-seguridad-en-el-mundo-real 2026-04-13 https://www.oncobites.tv/news/izalontamab-brengitecan-redefine-el-tratamiento-del-carcinoma-nasofar%C3%ADngeo-avanzado%3A-resultados-de-un-estudio-fase-3 2026-04-13 https://www.oncobites.tv/news/optimizar-la-selecci%C3%B3n-de-pacientes-para-terapia-con-radioligandos-en-etapas-avanzadas%3A-una-visi%C3%B3n-estrat%C3%A9gica 2026-04-13 https://www.oncobites.tv/news/gem-12%3A-busulf%C3%A1n-melfal%C3%A1n-en-dosis-altas-frente-a-melfal%C3%A1n-y-vrd-reforzado-en-mieloma-m%C3%BAltiple-de-nuevo-diagn%C3%B3stico 2026-04-13 https://www.oncobites.tv/news/excelencia-oncol%C3%B3gica-europea-en-bellvitge 2026-04-13 https://www.oncobites.tv/news/la-fda-aprueba-blenrep-para-mieloma-m%C3%BAltiple-en-reca%C3%ADda 2026-04-13 https://www.oncobites.tv/news/monarche%3A-terapia-endocrina-%2B-avemaciclib-en-c%C3%A1ncer-de-mama-temprano-de-alto-riesgo-hr%2B%2C-her2- 2026-04-13 https://www.oncobites.tv/news/el-grupo-europeo-de-mieloma-impulsa-la-incorporaci%C3%B3n-del-ngs-en-el-diagn%C3%B3stico-cl%C3%ADnico-del-mieloma-m%C3%BAltiple 2026-04-13 https://www.oncobites.tv/news/psmafore%3A%C2%B9%E2%81%B7%E2%81%B7lu-psma-617-frente-a-un-cambio-de-terapia-con-inhibidor-de-la-v%C3%ADa-del-receptor-androg%C3%A9nico-en-pacientes-con-mcrpc-progresivo-y-sin-exposici%C3%B3n-previa-a-taxanos 2026-04-13 https://www.oncobites.tv/news/optitrop-lung04%3A-sac-tmt-vs-quimioterapia-basada-en-platino-en-nsclc 2026-04-13 https://www.oncobites.tv/news/keynote-717%3A-la-radioterapia-hipofraccionada-potencia-la-respuesta-sist%C3%A9mica-a-pembrolizumab-en-c%C3%A1ncer-de-cabeza-y-cuello-recurrente-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/tactive-n%3A-el-degradador-oral-de-receptores-de-estr%C3%B3geno-vepdegestrant-logra-fuerte-actividad-biol%C3%B3gica-en-c%C3%A1ncer-de-mama-localizado-hr%2B%2Fher2%E2%80%93 2026-04-13 https://www.oncobites.tv/news/eftisarc-neo%3A-la-combinaci%C3%B3n-de-eftilagimod-alfa%2C-pembrolizumab-y-radioterapia-mejora-la-respuesta-patol%C3%B3gica-en-sarcoma-de-tejidos-blandos-resecable 2026-04-13 https://www.oncobites.tv/news/zsab-neogolp-demuestra-una-mejora-significativa-en-supervivencia-libre-de-eventos-en-colangiocarcinoma-intrahep%C3%A1tico-resecable-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/javelin-bladder-medley%3A-avelumab-m%C3%A1s-sacituzumab-govitec%C3%A1n-muestra-control-de-la-enfermedad-en-carcinoma-urotelial-avanzado-seg%C3%BAn-el-sitio-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/checkmate-238%3A-nivolumab-adyuvante-vs-ipilimumab-para-melanoma-%5Bresultados-a-9-a%C3%B1os%5D 2026-04-13 https://www.oncobites.tv/news/ribolaris%3A-ribociclib-neoadyuvante-%2B-terapia-endocrina-en-c%C3%A1ncer-de-mama-er%2B%2Fher2--de-alto-riesgo-%5Bprimer-an%C3%A1lisis-provisional%5D- 2026-04-13 https://www.oncobites.tv/news/el-tratamiento-con-lutecio-lu-177-dotatate-mejora-la-supervivencia-frente-a-everolimus-en-tumores-neuroendocrinos-gastrointestinales-avanzados.-estudio-de-evidencia-real 2026-04-13 https://www.oncobites.tv/news/analizan-la-toxicidad-inmunorrelacionada-y-la-respuesta-patol%C3%B3gica-al-pembrolizumab-neoadyuvante-en-c%C3%A1ncer-de-mama-triple-negativo 2026-04-13 https://www.oncobites.tv/news/la-presencia-de-stas-predice-reca%C3%ADda-tras-la-resecci%C3%B3n-curativa-del-adenocarcinoma-pulmonar-localizado-(luad) 2026-04-13 https://www.oncobites.tv/news/mapean-la-atenci%C3%B3n-multidisciplinar-en-c%C3%A1ncer-de-cabeza-y-cuello-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/fortitude-101%3A-bemarituzumab-%2B-mfolfox6-en-c%C3%A1ncer-g%C3%A1strico-o-de-la-uni%C3%B3n-gastroesof%C3%A1gica 2026-04-13 https://www.oncobites.tv/news/zuma-3-an%C3%A1lisis-a-tres-a%C3%B1os-en-pacientes-adultos-con-leucemia-linfobl%C3%A1stica-aguda-de-c%C3%A9lulas-b-en-reca%C3%ADda-o-refractaria-tratados-con-brexucabtagene-autoleucel 2026-04-13 https://www.oncobites.tv/news/%F0%9F%A4%96-un-modelo-multimodal-basado-en-inteligencia-artificial-predice-reca%C3%ADda-temprana-en-osteosarcoma-tras-quimioterapia-neoadyuvante 2026-04-13 https://www.oncobites.tv/news/her2dx-predice-respuesta-patol%C3%B3gica-y-supervivencia-en-c%C3%A1ncer-de-mama-her2-positivo-tratado-con-hp%3A-experiencia-del-hospital-universitario-de-a-coru%C3%B1a 2026-04-13 https://www.oncobites.tv/news/belzutifan-mejora-la-supervivencia-libre-de-progresi%C3%B3n-y-la-calidad-de-vida-frente-a-everolimus-en-carcinoma-renal-avanzado%3A-resultados-del-estudio-litespark-005 2026-04-13 https://www.oncobites.tv/news/talapro-2-muestra-tiempos-de-respuesta-r%C3%A1pidos-con-talazoparib-m%C3%A1s-enzalutamida-en-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-resistente-a-la-castraci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/psmaddition%3A-ensayo-fase-iii-de-%5B%C2%B9%E2%81%B7%E2%81%B7lu%5Dlu-psma-617-combinado-con-adt-%2B-arpi-en-pacientes-con-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-hormonosensible-y-psma-positivo 2026-04-13 https://www.oncobites.tv/news/c-post%3A-an%C3%A1lisis-de-segundos-tumores-primarios-de-carcinoma-cut%C3%A1neo-de-c%C3%A9lulas-escamosas-(cscc)-con-cemiplimab-adyuvante-vs.-placebo-en-pacientes-con-cscc-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/engot-cx11%3A-pembrolizumab-%2B-quimiorradioterapia-concurrente-en-lacc 2026-04-13 https://www.oncobites.tv/news/el-mecanismo-clave-de-resistencia-a-los-icb-en-nsclc 2026-04-13 https://www.oncobites.tv/news/natalee%3A-%5Bresultados-a-5-a%C3%B1os%5D-ribociclib-%2B-terapia-endocrina-en-pacientes-hr%2B%2Fher2--temprano 2026-04-13 https://www.oncobites.tv/news/terapia-dirigida-en-primera-l%C3%ADnea-para-all%3A-inotuzumab-ozogamicina 2026-04-13 https://www.oncobites.tv/news/parere%3A-retratamiento-con-panitumumab-seguido-de-regorafenib-vs.-secuencia-inversa-en-pacientes-con-c%C3%A1ncer-colorrectal-metast%C3%A1sico-quimiorresistente-y-adn-tumoral-circulante-(ctdna)-wild-type-para-ras-y-braf 2026-04-13 https://www.oncobites.tv/news/citric%3A-nuevos-datos-sobre-la-selecci%C3%B3n-por-ctdna-en-la-reinducci%C3%B3n-anti-egfr-con-cetuximab-%2B-irinotec%C3%A1n 2026-04-13 https://www.oncobites.tv/news/duncan%3A-eficacia-y-seguridad-de-la-terapia-intralesional-l19il2%2Fl19tnf-(daromun)-en-pacientes-con-carcinoma-cut%C3%A1neo-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/regn4018%3A-ubamatamab-%C2%B1-cemiplimab-en-pacientes-con-c%C3%A1ncer-de-ovario-resistente-a-platino 2026-04-13 https://www.oncobites.tv/news/el-grupo-espa%C3%B1ol-getne-presenta-nuevos-datos-sobre-terapias-dirigidas-e-inmunoterapia-en-carcinoma-anapl%C3%A1sico-de-tiroides 2026-04-13 https://www.oncobites.tv/news/la-voz-de-la-experta-en-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/el-grupo-espa%C3%B1ol-geico-presenta-en-esmo-2025-el-estudio-geico137-e%2Fnadia-sobre-dostarlimab-neoadyuvante-en-c%C3%A1ncer-de-endometrio-mmrd-estadio-ii%E2%80%93iii 2026-04-13 https://www.oncobites.tv/news/el-estudio-europa-demuestra-resultados-favorables-con-niraparib-como-mantenimiento-de-1l-en-c%C3%A1ncer-de-ovario-avanzado-estadio-iii-sin-enfermedad-residual-visible 2026-04-13 https://www.oncobites.tv/news/edge-gastric-demuestra-resultados-prometedores-con-domvanalimab%2C-zimberelimab-y-folfox-en-c%C3%A1ncer-g%C3%A1strico-avanzado 2026-04-13 https://www.oncobites.tv/news/nuevos-abordajes-transforman-el-manejo-del-melanoma-con-met%C3%A1stasis-cerebrales-y-leptomen%C3%ADngeas 2026-04-13 https://www.oncobites.tv/news/solidaridad-y-prevenci%C3%B3n-del-c%C3%A1ncer-de-mama-este-19-de-octubre 2026-04-13 https://www.oncobites.tv/news/nct04076579%3A-trabectedina-%2B-olaparib-en-sarcoma-avanzado-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/%226-superhalfs-en-1-a%C3%B1o%22-recauda-m%C3%A1s-de-3.500-%E2%82%AC-contra-el-c%C3%A1ncer-de-v%C3%ADas-biliares 2026-04-13 https://www.oncobites.tv/news/retos-y-oportunidades-para-optimizar-el-tratamiento-de-la-leucemia-linfobl%C3%A1stica-aguda-en-adultos 2026-04-13 https://www.oncobites.tv/news/c%C3%A1ncer-de-tiroides%3A-un-nuevo-sistema-de-clasificaci%C3%B3n-gen%C3%A9tica-mejora-la-predicci%C3%B3n-del-pron%C3%B3stico 2026-04-13 https://www.oncobites.tv/news/2%C2%BA-consenso-de-la-gecp-sobre-el-manejo-del-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico 2026-04-13 https://www.oncobites.tv/news/terapia-fotodin%C3%A1mica-para-el-melanoma-con-microagujas-3d 2026-04-13 https://www.oncobites.tv/news/portec-3%3A-datos-a-10-a%C3%B1os-de-tumores-endometriales-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/romper-las-barreras-de-la-medicina-nuclear 2026-04-13 https://www.oncobites.tv/news/evaluaci%C3%B3n-del-riesgo-de-fracturas-en-peace-3 2026-04-13 https://www.oncobites.tv/news/siguientes-pasos-en-medicina-nuclear%3A-c%C3%A1ncer-renal-y-de-mama 2026-04-13 https://www.oncobites.tv/news/a-un-d%C3%ADa-de-empezar-esmo 2026-04-13 https://www.oncobites.tv/news/bullseye%3A-%5B%C2%B9%E2%81%B7%E2%81%B7lu%5Dlu-psma-617-en-c%C3%A1ncer-de-pr%C3%B3stata-oligometast%C3%A1sico-sensible-a-hormonas 2026-04-13 https://www.oncobites.tv/news/icis-y-utilidad-de-la-pet%2Frm-con-18f-fdopa-para-detectar-reca%C3%ADdas-tumorales-cerebrales 2026-04-13 https://www.oncobites.tv/news/eficacia-de-la-terapia-de-radioligandos-lutecio-177-%5B177lu%5Dlu-psma-en-el-retratamiento-de-pacientes-con-mcrpc-m%C3%A1s-all%C3%A1-de-seis-ciclos 2026-04-13 https://www.oncobites.tv/news/scandare%3A-correlaci%C3%B3n-de-la-pcr-y-el-valor-pron%C3%B3stico-con-%5B18f%5Dfdg-pet%2Fct-en-tnbc 2026-04-13 https://www.oncobites.tv/news/tratamiento-con-resina-de-188-renio-para-c%C3%A1ncer-de-piel-no-melanoma%3A-primeros-tratamientos-realizados-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/el-pet%2Fct-mejora-la-selecci%C3%B3n-de-pacientes-para-citorreducci%C3%B3n-secundaria-en-c%C3%A1ncer-de-ovario-recurrente 2026-04-13 https://www.oncobites.tv/news/avances-teran%C3%B3sticos-en-c%C3%A1ncer-de-pr%C3%B3stata%3A-177lu-psma-617 2026-04-13 https://www.oncobites.tv/news/radiof%C3%A1rmacos-en-el-mcrpc 2026-04-13 https://www.oncobites.tv/news/enza-p-trial-(anzup-1901)%3A-spect%2Fct-con-%5B177lu%5Dlu-psma-617-como-un-biomarcador-de-respuesta-temprana-para-la-predicci%C3%B3n-de-la-pfs-y-la-os-en-pacientes-con-c%C3%A1ncer-de-pr%C3%B3stata-resistente-a-la-castraci%C3%B3n-metast%C3%A1sico-tratados-con-enzalutamida-y-%5B177lu%5Dlu-psma-61 2026-04-13 https://www.oncobites.tv/news/la-combinaci%C3%B3n-de-%C2%B9%E2%81%B8f-fdg-y-%C2%B9%E2%81%B8f-psma-pet%2Fct-podr%C3%ADa-optimizar-la-evaluaci%C3%B3n-del-carcinoma-escamoso-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/un-%C3%ADndice-de-masa-corporal-elevado-mejora-la-supervivencia-en-pacientes-con-c%C3%A1ncer-de-pr%C3%B3stata-resistente-a-la-castraci%C3%B3n-tratados-con-lupsma 2026-04-13 https://www.oncobites.tv/news/la-inteligencia-artificial-mejora-la-evaluaci%C3%B3n-metab%C3%B3lica-del-melanoma-uveal-metast%C3%A1sico-tratado-con-tebentafusp-mediante-pet%2Fct-de-campo-largo 2026-04-13 https://www.oncobites.tv/news/el-%5B18f%5Dfdg-pet%2Fct-mejora-la-detecci%C3%B3n-de-reca%C3%ADdas-frente-al-ct-en-pacientes-con-melanoma-cut%C3%A1neo-en-inmunoterapia-adyuvante 2026-04-13 https://www.oncobites.tv/news/prisma-revela-potencial-del-pet-dirigido-a-psma-en-c%C3%A1ncer-de-mama-triple-negativo-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/el-pet%2Fct-con-%E2%81%B6%E2%81%B8ga-ny104-mejora-la-detecci%C3%B3n-del-carcinoma-de-c%C3%A9lulas-renales-claras-en-pacientes-prequir%C3%BArgicos 2026-04-13 https://www.oncobites.tv/news/aprendiendo-con-evidencia-sobre-el-papel-cl%C3%ADnico-emergente-con-terapia-teratogn%C3%B3stica-dirigida-a-sstr 2026-04-13 https://www.oncobites.tv/news/un-estudio-gen%C3%B3mico-abre-la-puerta-a-terapias-personalizadas-para-sarcomas 2026-04-13 https://www.oncobites.tv/news/el-impacto-de-la-fibrosis-mamaria-en-la-calidad-de-vida-de-las-pacientes-tras-la-terapia-conservadora 2026-04-13 https://www.oncobites.tv/news/eficacia-de-mirvetuximab-soravtansine-en-c%C3%A1ncer-de-ovario-platino-resistente 2026-04-13 https://www.oncobites.tv/news/%C2%BFcu%C3%A1l-es-la-mejor-opci%C3%B3n-para-el-c%C3%A1ncer-de-pulm%C3%B3n-con-mutaci%C3%B3n-brafv600e%3F 2026-04-13 https://www.oncobites.tv/news/zsab-transgolp%3A-terapia-de-conversi%C3%B3n-con-tislelizumab-%2B-gemox-%2B-levatinib 2026-04-13 https://www.oncobites.tv/news/vision%3A-lutetium-177%E2%80%93psma-617-para-c%C3%A1ncer-de-pr%C3%B3stata-resistente-a-la-castraci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/c%C3%A9lulas-tils-vs.-ipilimumab-en-melanoma%3A-impacto-del-tratamiento-en-la-qol 2026-04-13 https://www.oncobites.tv/news/superando-la-resistencia-con-terapias-dirigidas-para-la-leucemia-mieloide-aguda 2026-04-13 https://www.oncobites.tv/news/actualizaci%C3%B3n-de-medicamentos-financiados-por-la-cipm 2026-04-13 https://www.oncobites.tv/news/augment-101%3A-inhibici%C3%B3n-de-menina-con-revumenib-para-leucemia-mieloide-aguda-recidivante-o-resistente-con-mutaci%C3%B3n-en-npm1 2026-04-13 https://www.oncobites.tv/news/la-edad-act%C3%BAa-como-un-continuo-de-riesgo-en-leucemia-mieloide-aguda-(lma) 2026-04-13 https://www.oncobites.tv/news/terapia-con-haz-de-protones-vs.-radioterapia-con-fotones-en-sarcoma 2026-04-13 https://www.oncobites.tv/news/efectos-de-la-deprivaci%C3%B3n-de-estr%C3%B3geno-en-la-terapia-endocrina-para-el-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/trilynx%3A-xevinapant-%2B-quimiorradioterapia-para-c%C3%A1ncer-de-laringe 2026-04-13 https://www.oncobites.tv/news/oncobites-se-suma-a-la-cobertura-del-eanm25 2026-04-13 https://www.oncobites.tv/news/pembrolizumab-%2B-quimioterapia-para-c%C3%A1ncer-de-pene-avanzado 2026-04-13 https://www.oncobites.tv/news/actinomicina-d-como-tratamiento-de-primera-l%C3%ADnea-en-neoplasia-trofobl%C3%A1stica-gestacional-de-bajo-riesgo 2026-04-13 https://www.oncobites.tv/news/tratamientos-locales-para-la-enfermedad-oligoprogresiva-en-el-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico 2026-04-13 https://www.oncobites.tv/news/pivotal%3A-daromun-neoadyuvante-en-melanoma-estadio-iii 2026-04-13 https://www.oncobites.tv/news/oncobites-estar%C3%A1-en-esmo2025-(berl%C3%ADn%2C-alemania)-trabajando-al-servicio-del-conocimiento-en-oncolog%C3%ADa 2026-04-13 https://www.oncobites.tv/news/mc1675%3A-desecalaci%C3%B3n-de-radioterapia-adyuvante-en-carcinoma-de-c%C3%A9lulas-escamosas-orofar%C3%ADngeo-asociado-a-hpv 2026-04-13 https://www.oncobites.tv/news/an%C3%A1lisis-con-datos-del-mundo-real%3A-levatinib-%2B-pembrolizumab-en-carcinoma-endometrial-avanzado 2026-04-13 https://www.oncobites.tv/news/mejora-en-la-qol-con-sotorasib-%2B-panitumumab-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/afamitresgene-autoleucel-mejora-la-calidad-de-vida-en-pacientes-con-sarcoma-sinovial-o-liposarcoma-mixoide 2026-04-13 https://www.oncobites.tv/news/un-biomarcador-simple-y-accesible-predice-el-riesgo-de-melanoma 2026-04-13 https://www.oncobites.tv/news/lenvatinib-y-pembrolizumab-muestran-actividad-prometedora-en-timoma-b3-y-carcinoma-t%C3%ADmico-refractarios-al-platino 2026-04-13 https://www.oncobites.tv/news/biomarcadores-redefinen-la-selecci%C3%B3n-de-pacientes-para-terapia-con-radioligandos-en-c%C3%A1ncer-de-pr%C3%B3stata-resistente-a-la-castraci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/sunrise-1%3A-tar-200-muestra-alta-tasa-de-respuesta-en-c%C3%A1ncer-de-vejiga-no-invasivo 2026-04-13 https://www.oncobites.tv/news/ascembl%3A-se-mantiene-superioridad-de-asciminib-vs-bosutinib-tras-4-a%C3%B1os-de-seguimiento 2026-04-13 https://www.oncobites.tv/news/diamond%3A-toripalimab-sin-cisplatino-concurrente-en-carcinoma-nasofar%C3%ADngeo 2026-04-13 https://www.oncobites.tv/news/linfocitos-y-carga-tumoral-como-predictores-en-el-pron%C3%B3stico-de-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/la-cardio-oncolog%C3%ADa-alerta-y-propone%3A-la-enfermedad-cardiovascular-condiciona-el-manejo-moderno-de-la-leucemia-mieloide-cr%C3%B3nica 2026-04-13 https://www.oncobites.tv/news/la-european-leukemianet-actualiza-recomendaciones-y-redefine-el-manejo-de-la-leucemia-mieloide-cr%C3%B3nica 2026-04-13 https://www.oncobites.tv/news/supervivencia-a-20-a%C3%B1os-con-imatinib-en-gist 2026-04-13 https://www.oncobites.tv/news/la-neutropenia%2C-%C2%BFun-marcador-de-eficacia-en-el-c%C3%A1ncer-colorrectal-metast%C3%A1sico%3F 2026-04-13 https://www.oncobites.tv/news/caracter%C3%ADsticas-del-melanoma-en-chile 2026-04-13 https://www.oncobites.tv/news/paloma-2%3A-amivantamab-%2B-lazertinib-para-nsclc-%5Bcohorte-5%5D 2026-04-13 https://www.oncobites.tv/news/rucaparib-como-terapia-de-mantenimiento-en-c%C3%A1ncer-de-endometrio-metast%C3%A1sico-y-recurrente 2026-04-13 https://www.oncobites.tv/news/actividades-en-el-d%C3%ADa-mundial-del-linfoma 2026-04-13 https://www.oncobites.tv/news/la-voz-de-los-expertos-en-linfoma 2026-04-13 https://www.oncobites.tv/news/rastrear-la-evoluci%C3%B3n-del-c%C3%A1ncer-a-escala-cl%C3%ADnica-con-an%C3%A1lisis-epigen%C3%A9ticos 2026-04-13 https://www.oncobites.tv/news/impacto-de-la-radioterapia-%2B-icis-en-nsclc-avanzado.-datos-del-mundo-real. 2026-04-13 https://www.oncobites.tv/news/entre-radioterapia-y-cirug%C3%ADa%3A-el-papel-de-las-comorbilidades-en-c%C3%A1ncer-de-pulm%C3%B3n-temprano 2026-04-13 https://www.oncobites.tv/news/rationale-315%3A-tislelizumab-neoadyuvante-%2B-quimioterapia-con-tislelizumab-adyuvante-en-cpnm-resecable 2026-04-13 https://www.oncobites.tv/news/relativity-104%3A-nivolumab-%2B-relatlimab-%2B-quimioterapia-muestra-resultados-prometedores-en-c%C3%A1ncer-de-pulm%C3%B3n-avanzado 2026-04-13 https://www.oncobites.tv/news/mscin002%3A-la-inyecci%C3%B3n-subcut%C3%A1nea-de-atezolizumab-gana-la-preferencia-de-los-pacientes-con-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/revelan-datos-a-5-a%C3%B1os-del-empower-lung-3- 2026-04-13 https://www.oncobites.tv/news/impacto-de-la-quimioinmunoterapia-neoadyuvante-en-nsclc-avanzado.-an%C3%A1lisis-con-datos-del-mundo-real.- 2026-04-13 https://www.oncobites.tv/news/el-ctdna-basado-en-genoma-completo-predice-la-recurrencia-en-cpnm-resecable-en-estadio-temprano 2026-04-13 https://www.oncobites.tv/news/radioterapia-hipofraccionada-para-reducir-toxicidad-en-ls-sclc 2026-04-13 https://www.oncobites.tv/news/%C2%BFes-necesario-la-reestadificaci%C3%B3n-invasiva-tras-la-quimioinmunoterapia-neoadyuvante-en-cpnm-estadio-iii%3F 2026-04-13 https://www.oncobites.tv/news/un-nuevo-algoritmo-de-segmentaci%C3%B3n-de-im%C3%A1genes-mejora-la-precisi%C3%B3n-en-el-diagn%C3%B3stico-del-c%C3%A1ncer-de-piel 2026-04-13 https://www.oncobites.tv/news/panda-1%3A-tislelizumab-m%C3%A1s-quimioterapia-demuestra-altas-tasas-de-respuesta-tumoral-y-conversi%C3%B3n-quir%C3%BArgica-en-cpnm-estadio-iii-inicialmente-irresecable 2026-04-13 https://www.oncobites.tv/news/el-an%C3%A1lisis-metabol%C3%B3mico-del-nadim-ii-revela-a-la-histamina-como-biomarcador-predictivo-en-la-quimioinmunoterapia-perioperatoria 2026-04-13 https://www.oncobites.tv/news/across-2%3A-aumolertinib-m%C3%A1s-quimioterapia-mejora-la-supervivencia-libre-de-progresi%C3%B3n-en-nsclc-con-mutaciones-egfr-y-genes-supresores-de-tumor 2026-04-13 https://www.oncobites.tv/news/tarlatamab-combinado-con-anti-pd-l1-prolonga-la-supervivencia-en-es-sclc-(dellphi-303) 2026-04-13 https://www.oncobites.tv/news/un-nuevo-test-para-c%C3%A1ncer-de-mama-que-transforma-el-tratamiento-de-las-pacientes 2026-04-13 https://www.oncobites.tv/news/nuevas-directrices-internacionales-para-la-radioterapia-en-el-carcinoma-nasofar%C3%ADngeo%3A-un-consenso-para-una-delineaci%C3%B3n-m%C3%A1s-precisa 2026-04-13 https://www.oncobites.tv/news/pcpro%3A-biomarcadores-lip%C3%ADdicos-para-predecir-el-beneficio-de-enzalutamida 2026-04-13 https://www.oncobites.tv/news/nueva-variante-de-mesotelioma-descubierta 2026-04-13 https://www.oncobites.tv/news/la-voz-del-experto-en-leucemia 2026-04-13 https://www.oncobites.tv/news/la-voz-de-la-experta-en-mieloma-m%C3%BAltiple 2026-04-13 https://www.oncobites.tv/news/mifamurtida-%2B-quimioterapia%3A-resultados-de-geis-33-y-isg%2Fos-2 2026-04-13 https://www.oncobites.tv/news/terapias-dirigidas-y-combinaciones-transforman-el-manejo-de-la-leucemia-linfobl%C3%A1stica-aguda-en-adultos 2026-04-13 https://www.oncobites.tv/news/lenvatinib-%2B-toripalimab-a-dosis-bajas-para-c%C3%A1ncer-de-ovario-resistente-al-platino 2026-04-13 https://www.oncobites.tv/news/venetoclax-m%C3%A1s-quimioterapia-de-baja-intensidad-para-adultos-con-leucemia-linfobl%C3%A1stica-aguda 2026-04-13 https://www.oncobites.tv/news/eortc-1333%2Fpeace-3%3A-enzatulamida-%2B-ra223-para-mcrpc 2026-04-13 https://www.oncobites.tv/news/alta-carga-mutacional-y-braf-v600-mejoran-la-inmunoterapia-adyuvante-en-melanoma-avanzado 2026-04-13 https://www.oncobites.tv/news/terapia-dirigida-a-vegf%3A-una-opci%C3%B3n-para-el-tratamiento-paliativo-del-sft-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/an%C3%A1logos-de-cannabinoides-con-potente-actividad-antitumoral-en-c%C3%A1ncer-de-p%C3%A1ncreas 2026-04-13 https://www.oncobites.tv/news/pemetrexed-no-beneficia-la-terapia-de-mantenimiento-con-pembrolizumab-para-el-cpnm 2026-04-13 https://www.oncobites.tv/news/anlotinib-%2B-yodo-131%3A-una-terapia-combinada-para-el-c%C3%A1ncer-de-tiroides-diferenciado-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/el-factor-de-la-edad-en-el-c%C3%A1ncer-de-mama%3A-estudio-de-cohorte-del-institut-catal%C3%A0-d%E2%80%99oncologia 2026-04-13 https://www.oncobites.tv/news/nuevas-directrices-europeas-para-el-carcinoma-de-endometrio%3A-la-era-de-la-clasificaci%C3%B3n-molecular 2026-04-13 https://www.oncobites.tv/news/redefiniendo-el-pron%C3%B3stico-de-leucemia-linfobl%C3%A1stica-aguda-siguiendo-la-enfermedad-residual-m%C3%ADnima 2026-04-13 https://www.oncobites.tv/news/%C2%A1cubriremos-el-wclc-desde-barcelona! 2026-04-13 https://www.oncobites.tv/news/esmo-actualiza-recomendaciones-de-tratamiento-sist%C3%A9mico-en-c%C3%A1ncer-de-mama-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/modelo-predictivo-para-predecir-la-rfs-en-c%C3%A1ncer-de-pr%C3%B3stata 2026-04-13 https://www.oncobites.tv/news/trasplante-hep%C3%A1tico-en-c%C3%A1ncer-colorrectal-irresecable-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/calla%3A-an%C3%A1lisis-del-ctdna-en-c%C3%A1ncer-cervical-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/la-terapia-celular-adoptiva-transforma-el-tratamiento-del-melanoma-avanzado 2026-04-13 https://www.oncobites.tv/news/el-instituto-catal%C3%A1n-de-oncolog%C3%ADa-(ico)-analiza-resultados-reales-de-cinco-cohortes-en-tumores-de-cabeza-y-cuello-avanzados 2026-04-13 https://www.oncobites.tv/news/enfoque-multidisciplinar-de-los-tumores-urol%C3%B3gicos-en-un-solo-d%C3%ADa 2026-04-13 https://www.oncobites.tv/news/lacog-1018%3A-palbociclib-%2B-letrozol-de-segunda-l%C3%ADnea-en-tumores-serosos-ginecol%C3%B3gicos 2026-04-13 https://www.oncobites.tv/news/pevosq%3A-pembrolizumab-%2B-vorinostat-en-carcinomas-de-c%C3%A9lulas-escamosas-recurrentes%2Fmetast%C3%A1sicos 2026-04-13 https://www.oncobites.tv/news/imatinib-y-erupciones-cut%C3%A1neas-en-gist 2026-04-13 https://www.oncobites.tv/news/terapia-hormonal-y-c%C3%A1ncer-de-mama-de-inicio-temprano 2026-04-13 https://www.oncobites.tv/news/convivir%3A-el-simposio-de-vida-y-tumores-digestivos-pionero-en-madrid 2026-04-13 https://www.oncobites.tv/news/triple-combinaci%C3%B3n-prometedora-en-cpnm-avanzado 2026-04-13 https://www.oncobites.tv/news/nuevo-marcador-predictivo-para-quimioterapia-en-carcinoma-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/la-biopsia-l%C3%ADquida-revoluciona-el-manejo-de-los-sarcomas 2026-04-13 https://www.oncobites.tv/news/la-voz-de-la-experta-en-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/tp53-multi-hit-confiere-mayor-complejidad-gen%C3%A9tica-pero-no-peor-supervivencia-en-llc-en-la-era-de-terapias-dirigidas 2026-04-13 https://www.oncobites.tv/news/cartoon-informa-sobre-la-cardiotoxicidad-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/accord%3A-quimiorradiaci%C3%B3n-para-colangiocarcinoma-y-c%C3%A1ncer-de-ves%C3%ADcula-biliar 2026-04-13 https://www.oncobites.tv/news/las-resistencias-desaf%C3%ADan-y-revolucionan-el-tratamiento-de-la-llc%3A-nuevos-agentes-y-terapias-inmunes-emergen 2026-04-13 https://www.oncobites.tv/news/t%C3%ADtulo%3A-flair%3A-terapia-guiada-por-enfermedad-m%C3%ADnima-residual-en-leucemia-linfoc%C3%ADtica-cr%C3%B3nica-(llc) 2026-04-13 https://www.oncobites.tv/news/melt79-y-su-papel-en-la-resistencia-del-melanoma-cut%C3%A1neo-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/modelo-csoarg-para-el-pron%C3%B3stico-y-la-respuesta-al-tratamiento-del-c%C3%A1ncer-de-ovario 2026-04-13 https://www.oncobites.tv/news/disparidades-raciales-y-%C3%A9tnicas-en-terapias-celulares-para-sarcoma-sinovial 2026-04-13 https://www.oncobites.tv/news/eficacia-y-seguridad-de-olanzapina-en-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/recientemente-se-ha-propuesto-un-nuevo-medicamento-oncol%C3%B3gico-a-financiar-por-parte-del-ministerio-de-sanidad-espa%C3%B1ol-y-nuevas-indicaciones-a-la-hora-de-administrar-otros-dos-tratamientos-para-el-c%C3%A1ncer.-te-hacemos-un-breve-repaso-desde-oncobites%3A- 2026-04-13 https://www.oncobites.tv/news/pace-c-eval%C3%BAa-la-toxicidad-temprana-de-sbrt-en-c%C3%A1ncer-de-pr%C3%B3stata 2026-04-13 https://www.oncobites.tv/news/savannah%3A-savolitinib-%2B-osimertinib-en-nsclc-avanzado 2026-04-13 https://www.oncobites.tv/news/patrones-de-expresi%C3%B3n-distintos-de-adcs-en-c%C3%A1ncer-de-ovario 2026-04-13 https://www.oncobites.tv/news/pexidartinib-en-tumor-de-c%C3%A9lulas-gigantes-tenosinoviales 2026-04-13 https://www.oncobites.tv/news/cirug%C3%ADa-tras-terapia-dirigida-neoadyuvante-en-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/contact-02%3A-cabozantinib-%2B-atezolizumab-en-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/eficacia-card%C3%ADaca-y-seguridad-en-c%C3%A1ncer-de-mama-temprano-tratado-con-pld-(nct03949634) 2026-04-13 https://www.oncobites.tv/news/nuevos-horizontes-terap%C3%A9uticos-transforman-el-pron%C3%B3stico-del-mieloma-m%C3%BAltiple 2026-04-13 https://www.oncobites.tv/news/terapia-con-linfocitos-infiltrantes-de-tumor-para-melanoma-acral 2026-04-13 https://www.oncobites.tv/news/car-t-y-cardiotoxicidades-en-la-era-de-la-inmunoterapia 2026-04-13 https://www.oncobites.tv/news/tripletes-mejoran-la-supervivencia-en-mieloma-m%C3%BAltiple-pero-aumentan-los-efectos-adversos%3A-resultados-del-mayor-metaan%C3%A1lisis-publicado 2026-04-13 https://www.oncobites.tv/news/entre-inducci%C3%B3n-y-adyuvancia-para-carcinoma-nasofar%C3%ADngeo-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/concienciaci%C3%B3n-e-investigaci%C3%B3n-como-protagonistas-del-d%C3%ADa-mundial-del-sarcoma 2026-04-13 https://www.oncobites.tv/news/la-voz-de-las-expertas-en-sarcoma 2026-04-13 https://www.oncobites.tv/news/midas%3A-terapia-guiada-por-enfermedad-m%C3%ADnima-residual-en-el-mieloma-reci%C3%A9n-diagnosticado 2026-04-13 https://www.oncobites.tv/news/resultados-de-intrigue%2C-el-ensayo-en-fase-3-para-gist-avanzado 2026-04-13 https://www.oncobites.tv/news/bo-112-%2B-pembrolizumab-para-melanoma-avanzado-resistente-a-anti-pd-1 2026-04-13 https://www.oncobites.tv/news/descodificando-asco%3A-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-resistente-a-la-castraci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/c%C3%A1ncer-de-orofaringe-asociado-a-vph%3A-cirug%C3%ADa-transoral-y-tratamiento-adyuvante 2026-04-13 https://www.oncobites.tv/news/detectar-el-c%C3%A1ncer-de-pulm%C3%B3n-exhalando 2026-04-13 https://www.oncobites.tv/news/sox-%2B-tisleizumab-en-c%C3%A1ncer-g%C3%A1strico-metast%C3%A1sico-(nct-05325528) 2026-04-13 https://www.oncobites.tv/news/start-001%3A-invikafusp-alfa-demuestra-eficacia-en-c%C3%A1ncer-gastrointestinal-resistente-a-inmunoterapia 2026-04-13 https://www.oncobites.tv/news/panirinox%3A-panitumumab-(p)-%2B-folfirinox-o-mfolfox6-en-pacientes-(pts)-con-c%C3%A1ncer-colorrectal-metast%C3%A1sico-(mcrc)-irresecable-y-estado-tumoral-ras%2Fbraf-wild-type-(wt)-seg%C3%BAn-adn-circulante-(cirdna) 2026-04-13 https://www.oncobites.tv/news/retos-del-tratamiento-de-adenocarcinoma-g%C3%A1strico-en-pacientes-latinoamericanos 2026-04-13 https://www.oncobites.tv/news/medicamentos-para-el-tratamiento-de-c%C3%A1ncer-de-v%C3%ADas-biliares-marcan-el-futuro-de-la-terapia-dirigida 2026-04-13 https://www.oncobites.tv/news/bsk-011-201%3A-irpagratinib-(absk-011)-%2B-atezolizumab-en-1l-y-en-pacientes-tratados-previamente-con-inhibidores-de-puntos-de-control-inmunitario-en-carcinoma-hepatocelular-avanzado-(hcc)-con-sobreexpresi%C3%B3n-de-fgf19-(%2B) 2026-04-13 https://www.oncobites.tv/news/estrategia-global-en-el-tratamiento-del-carcinoma-hepatocelular%3A-primeras-y-sucesivas-l%C3%ADneas 2026-04-13 https://www.oncobites.tv/news/encorafenib-y-cetuximab-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico-braf-v600em- 2026-04-13 https://www.oncobites.tv/news/origami-1%3A-amivantamab-muestra-actividad-antitumoral-al-reintroducirse-tras-progresi%C3%B3n-a-anti-egfr-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico-ras%2Fbraf-wild-type- 2026-04-13 https://www.oncobites.tv/news/quimioterapia-neoadyuvante-muestra-respuestas-similares-en-adenocarcinoma-g%C3%A1strico-avanzado-en-poblaci%C3%B3n-latinoamericana%3A-retos-a-superar 2026-04-13 https://www.oncobites.tv/news/estudio-de-real-world-evidente-de--trifluridina%2Ftipiracil-%2B-bevacizumab-demuestra-superioridad-en-supervivencia-global-frente-a-regorafenib-en-c%C3%A1ncer-colorrectal-avanzado-refractario 2026-04-13 https://www.oncobites.tv/news/combinar-camrelizumab-y-famitinib-para-tratar-el-c%C3%A1ncer-de-cuello-uterino 2026-04-13 https://www.oncobites.tv/news/bevacizumab-%2B-erlotinib-en-c%C3%A1ncer-de-ri%C3%B1%C3%B3n-papilar-(nct01130519) 2026-04-13 https://www.oncobites.tv/news/antraciclina-adyuvante-en-sarcoma-de-tejido-blando-(isg-sts-1001) 2026-04-13 https://www.oncobites.tv/news/regtas%3A-regorafenib-%2B-trifluridina%2Ftipiracilo-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico-refractario 2026-04-13 https://www.oncobites.tv/news/batiraxcept-%2B-cabozantinib-para-c%C3%A1ncer-renal-de-c%C3%A9lulas-claras 2026-04-13 https://www.oncobites.tv/news/c%C3%A1ncer-endometrial-lynch-like-y-respuesta-a-pembrolizumab 2026-04-13 https://www.oncobites.tv/news/denosumab-e-inmunoterapia-en-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/investigadores-en-china-analizan-los-desaf%C3%ADos-y-promesas-terap%C3%A9uticas-del-linfoma-t-perif%C3%A9rico 2026-04-13 https://www.oncobites.tv/news/zongertinib-para-nsclc-her2-previamente-tratado 2026-04-13 https://www.oncobites.tv/news/los-tratamientos-emergentes-transforman-el-abordaje-del-linfoma-folicular-refractario-o-en-reca%C3%ADda 2026-04-13 https://www.oncobites.tv/news/pembrolizumab-neoadyuvante-y-adyuvante-en-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/terapia-car-t-mejorada-para-linfoma-tras-un-fracaso-previo 2026-04-13 https://www.oncobites.tv/news/p-verify 2026-04-13 https://www.oncobites.tv/news/nuevos-medicamentos-financiados-por-el-ministerio-de-sanidad-espa%C3%B1ol 2026-04-13 https://www.oncobites.tv/news/ipilimumab-%2B-nivolumab-en-melanoma-uveal-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/estado-de-la-inmunoterapia-en-carcinoma-escamoso-de-cabeza-y-cuello-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/eremiss-estudia-la-terapia-de-mantenimiento-en-sarcomas-de-tejido-blando 2026-04-13 https://www.oncobites.tv/news/palmares-2%2C-an%C3%A1lisis-de-icdk4%2F6-en-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/siendo%3A-seguimiento-a-largo-plazo-de-mantenimiento-con-selinexor-(sel)-en-pacientes-con-c%C3%A1ncer-de-endometrio-(ce)-avanzado%2Frecurrente-(a%2Fr)-con-tp53-tipo-salvaje-(wt)%2C-resultados-seg%C3%BAn-el-estado-de-reparaci%C3%B3n-de-desajustes-(mmr) 2026-04-13 https://www.oncobites.tv/news/zanidatamab-%2B-quimioterapia-en-adenocarcinoma-gastroesof%C3%A1gico-her2-positivo-avanzado 2026-04-13 https://www.oncobites.tv/news/piccolo%3A-an%C3%A1lisis-finales-de-mirvetuximab-soravtansine-gynx-(mirv)-en-pacientes-con-c%C3%A1ncer-de-ovario-seroso-de-alto-grado-platino-sensible-de-tercera-l%C3%ADnea-o-m%C3%A1s-(3l%2B-psoc) 2026-04-13 https://www.oncobites.tv/news/el-recorrido-del-tratamiento-para-c%C3%A1ncer-endometrial 2026-04-13 https://www.oncobites.tv/news/la-integraci%C3%B3n-de-ngs-e-ihq-mejora-la-estratificaci%C3%B3n-de-riesgo-y-el-tratamiento-en-c%C3%A1ncer-de-endometrio 2026-04-13 https://www.oncobites.tv/news/mutaciones-brca-y-respuesta-a-parpi-en-c%C3%A1ncer-de-ovario-avanzado%2C-valor-de-la-localizaci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/expertos-comparten-adelantos-de-novedades-destacadas-del-congreso 2026-04-13 https://www.oncobites.tv/news/tratamiento-adyuvante-%C3%B3ptimo-en-c%C3%A1ncer-de-cuello-uterino-inicial 2026-04-13 https://www.oncobites.tv/news/sugemalimab-%2B-quimioterapia-basada-en-platino-(gemstone-302) 2026-04-13 https://www.oncobites.tv/news/beatcc-(engot-cx10%2Fgeico-68-c%2Fjgog1084%2Fgog-3030)--an%C3%A1lisis-finales-de-atezolizumab-%2B-qt-%2B-bevacizumab-en-1l-para-c%C3%A1ncer-de-c%C3%A9rvix-metast%C3%A1sico-recurrente-o-persistente 2026-04-13 https://www.oncobites.tv/news/s%C3%AD%2C-estaremos-en-esmo-gynae-2025 2026-04-13 https://www.oncobites.tv/news/pron%C3%B3stico-del-c%C3%A1ncer-de-pr%C3%B3stata-m%C3%A1s-all%C3%A1-del-volumen-de-met%C3%A1stasis 2026-04-13 https://www.oncobites.tv/news/bellwave-003%3A-nemtabrutinib-en-linfoma-de-zona-marginal 2026-04-13 https://www.oncobites.tv/news/dreamm-8%3A-belantamab-mafodotin-%2B-pomalidomida-y-dexametasona- 2026-04-13 https://www.oncobites.tv/news/keynote-b68%3A-nuevos-datos-de-pembrolizumab-actividad-y-seguridad-en-linfomas-hodgkin-y-b-de-mediastino 2026-04-13 https://www.oncobites.tv/news/asc4start%3A-asciminib-demuestra-mejor-tolerabilidad-que-nilotinib-en-leucemia-mieloide-cr%C3%B3nica 2026-04-13 https://www.oncobites.tv/news/actividades-en-el-d%C3%ADa-mundial-del-c%C3%A1ncer-renal 2026-04-13 https://www.oncobites.tv/news/validaci%C3%B3n-de-instrumentos-de-calidad-de-vida-en-leucemia-mieloide-cr%C3%B3nica%3A-un-paso-clave-para-la-atenci%C3%B3n-centrada-en-el-paciente 2026-04-13 https://www.oncobites.tv/news/opinion%3A-monoterapia-de-mantenimiento-con-olaparib-en-pacientes-con-c%C3%A1ncer-de-ovario 2026-04-13 https://www.oncobites.tv/news/optimize%3A-orelabrutinib-%2B-bendamustina-rituximab-u-obinutuzumab-seguido-de-mantenimiento-con-orelabrutinib-en-linfoma-de-zona-marginal-no-tratado 2026-04-13 https://www.oncobites.tv/news/asc2escalate%3A-asciminib-(asc)-tratamiento-en-leucemia-mieloide-cr%C3%B3nica-en-fase-cr%C3%B3nica-(lmc-fc)-despu%C3%A9s-de-un-inhibidor-de-tirosina-quinasa-(itk) 2026-04-13 https://www.oncobites.tv/news/reveng%3A-resultados-preliminares-sobre-el-retratamiento-con-venetoclax-%2B-obinutuzumab-(reveng)-en-pacientes-con-leucemia-linfoc%C3%ADtica-cr%C3%B3nica-(llc)-recurrente 2026-04-13 https://www.oncobites.tv/news/picaros%3A-acalabrutinib-demuestra-eficacia-y-seguridad-como-tratamiento-de-primera-l%C3%ADnea-en-llc-en-pr%C3%A1ctica-cl%C3%ADnica-espa%C3%B1ola 2026-04-13 https://www.oncobites.tv/news/dominando-las-nuevas-terapias-para-desbloquear-el-control-del-mieloma%3A-perfiles-de-seguridad 2026-04-13 https://www.oncobites.tv/news/batalla-contra-el-mieloma%3A-se-superan-los-l%C3%ADmites-y-se-eleva-el-est%C3%A1ndar-terap%C3%A9utico 2026-04-13 https://www.oncobites.tv/news/las-voces-de-las-expertas-en-c%C3%A1ncer-renal 2026-04-13 https://www.oncobites.tv/news/%C2%BFqu%C3%A9-mutaciones-hay-en-los-liposarcomas-mixoides%3F 2026-04-13 https://www.oncobites.tv/news/reducci%C3%B3n-de-la-quimioterapia-en-carcinoma-nasofar%C3%ADngeo-(nct04384627) 2026-04-13 https://www.oncobites.tv/news/inmunoterapia-en-pacientes-inmunosuprimidos-de-carcinoma-de-c%C3%A9lulas-de-merkel 2026-04-13 https://www.oncobites.tv/news/estrategias-innovadoras-en-lmc%3A-balanceando-eficacia%2C-tolerabilidad-y-calidad-de-vida-del-paciente 2026-04-13 https://www.oncobites.tv/news/desentra%C3%B1ando-la-resistencia-al-tratamiento-en-c%C3%A1ncer-de-p%C3%A1ncreas%3A-el-papel-del-microambiente-tumoral 2026-04-13 https://www.oncobites.tv/news/enlighted%3A-terapia-fotodin%C3%A1mica-con-padeliporfin-(vtp)-en-carcinoma-urotelial-de-tracto-superior 2026-04-13 https://www.oncobites.tv/news/la-voz-de-las-expertas-en-c%C3%A1ncer-de-pr%C3%B3stata 2026-04-13 https://www.oncobites.tv/news/morpheus-bc%3A-estudio-de-combinaciones-farmacol%C3%B3gicas-para-c%C3%A1ncer-de-mama- 2026-04-13 https://www.oncobites.tv/news/evolution%3B-anzup2001%3A-77lu-psma-617-%2B-ipilimumab-(ipi)-y-nivolumab-(nivo)-en-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-resistente-a-la-castraci%C3%B3n-(mcrpc) 2026-04-13 https://www.oncobites.tv/news/d%C3%ADa-mundial-del-c%C3%A1ncer-de-pr%C3%B3stata%3A-actividades-conmemorativas-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/c-post%3A-cemiplimab-como-terapia-adyuvante-para-pacientes-con-cscc-con-alto-riesgo-de-recurrencia-tras-cirug%C3%ADa-y-radioterapia 2026-04-13 https://www.oncobites.tv/news/cemiplimab-%2B-quimioterapia-%2B-egfrxcd28-(regn7075)-en-carcinoma-pulmonar-no-microc%C3%ADtico-resecable 2026-04-13 https://www.oncobites.tv/news/immunosarc-2%3A-inmunoterapia-y-antiangiog%C3%A9nicos-en-condrosarcoma-mixoide-extraesquel%C3%A9tico 2026-04-13 https://www.oncobites.tv/news/checkmate-77t%3A-beneficios-en-c%C3%A1ncer-de-pulm%C3%B3n-temprano 2026-04-13 https://www.oncobites.tv/news/paola-1%3A-refinando-la-estratificaci%C3%B3n-en-c%C3%A1ncer-de-ovario-con-olaparib-%2B-bevacizumab 2026-04-13 https://www.oncobites.tv/news/predecir-la-respuesta-patol%C3%B3gica-en-c%C3%A1ncer-de-mama-her2%2B 2026-04-13 https://www.oncobites.tv/news/ringside%3A-respuestas-tumorales-homog%C3%A9neas-con-varegacestat-en-tumores-desmoides 2026-04-13 https://www.oncobites.tv/news/c-post%3A-cemiplimab-adyuvante-despu%C3%A9s-de-cirug%C3%ADa-y-radioterapia-en-cscc-de-alto-riesgo.-resultados-sobre-la-hrqol 2026-04-13 https://www.oncobites.tv/news/biomarcadores-predictivos-para-c%C3%A1ncer-de-cabeza-y-cuello- 2026-04-13 https://www.oncobites.tv/news/optimizaci%C3%B3n-de-dosis-con-e7386-%2B-levatinib-para-carcinoma-endometrial 2026-04-13 https://www.oncobites.tv/news/crest%3A-mejora-de-efs-en-pacientes-de-nmibc- 2026-04-13 https://www.oncobites.tv/news/imforte%3A-un-nuevo-est%C3%A1ndar-en-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/sobreexpresi%C3%B3n-de-trop2-y-predicci%C3%B3n-de-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/alliance%3Alas-sinergias-entre-avelumab-y-cetuximab 2026-04-13 https://www.oncobites.tv/news/dipcan%3A-un-enfoque-multidimensional-para-personalizar-el-tratamiento-del-c%C3%A1ncer-metast%C3%A1sico-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/brentuximab-vedotina-%2B-pembrolizumab-en-c%C3%A1ncer-de-cabeza-y-cuello-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/immunosarc2%3A-terapia-de-primera-l%C3%ADnea-para-sarcoma-pleom%C3%B3rfico-indiferenciado- 2026-04-13 https://www.oncobites.tv/news/secombit%3A-timidina-quinasa-como-biomarcador-para-melanoma 2026-04-13 https://www.oncobites.tv/news/neostar-a2%3A-sacituzumab-govitec%C3%A1n-%2B-pembrolizumab-en-c%C3%A1ncer-de-mama-triple-negativo-temprano-(early-stage-tnbc) 2026-04-13 https://www.oncobites.tv/news/un-test-detecta-inestabilidad-gen%C3%B3mica-en-c%C3%A1ncer-de-ovario-seroso-de-alto-grado-con-alta-precisi%C3%B3n 2026-04-13 https://www.oncobites.tv/news/belzutifan-y-casdatifan-reafirman-su-rol-como-inhibidores-de-hif-2%CE%B1-en-c%C3%A1ncer-renal-avanzado-y-asociado-a-vhl 2026-04-13 https://www.oncobites.tv/news/estudio-sachi%3A-savolitinib-m%C3%A1s-osimertinib-duplica-la-supervivencia-libre-de-progresi%C3%B3n-frente-a-quimioterapia-en-cpnm-avanzado-con-amplificaci%C3%B3n-de-met-tras-egfr-tki 2026-04-13 https://www.oncobites.tv/news/nrg-br003%3A-a%C3%B1adir-carboplatino-no-mejora-la-supervivencia-libre-de-enfermedad-invasiva-en-tnbc-temprano 2026-04-13 https://www.oncobites.tv/news/el-perfil-mutacional-del-c%C3%A1ncer-colorrectal-mss%2Fbrafwt-predice-patrones-metast%C3%A1sicos-distintos-seg%C3%BAn-estudio-en-vall-d%E2%80%99hebron 2026-04-13 https://www.oncobites.tv/news/betas%3A-datos-de-evidencia-real-de-investigaci%C3%B3n-espa%C3%B1ola-confirman-eficacia-del-estudio-sunlight-de-ftd%2Ftpi-m%C3%A1s-bevacizumab-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/pembrolizumab-mejora-el-tiempo-de-vida-ajustado-por-calidad-frente-a-quimioterapia-en-el-estudio-keynote-177 2026-04-13 https://www.oncobites.tv/news/el-futuro-de-la-detecci%C3%B3n-del-c%C3%A1ncer-est%C3%A1-en-camino 2026-04-13 https://www.oncobites.tv/news/relaci%C3%B3n-entre-trauma-y-pron%C3%B3stico-del-melanoma-acral- 2026-04-13 https://www.oncobites.tv/news/avarwe%3A-evaluaci%C3%B3n-de-avapritinib-para-tumores-del-estroma-gastrointestinal 2026-04-13 https://www.oncobites.tv/news/manejo-de-factores-complejos-en-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/manejo-de-factores-complejos-en-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/riesgo-pulmonar-con-icis-tras-pleurodesis-con-talco- 2026-04-13 https://www.oncobites.tv/news/riesgo-pulmonar-con-icis-tras-pleurodesis-con-talco- 2026-04-13 https://www.oncobites.tv/news/ventajas-de-la-quimioterapia-neoadyuvante-en-c%C3%A1ncer-de-mama-triple-negativo 2026-04-13 https://www.oncobites.tv/news/tropics-04%3A-sacituzumab-govitecan-no-mejora-la-supervivencia-global-en-c%C3%A1ncer-urotelial-avanzado-pretratado 2026-04-13 https://www.oncobites.tv/news/esmo-mcbs-v2.0%3A-evaluaci%C3%B3n-del-beneficio-de-nuevas-terapias-contra-el-c%C3%A1ncer 2026-04-13 https://www.oncobites.tv/news/cemiplimab-y-peltopemiut-s-en-c%C3%A1ncer-de-c%C3%A9rvix-recurrente-hpv16%2B 2026-04-13 https://www.oncobites.tv/news/portos%3A-predicci%C3%B3n-de-la-respuesta-a-radioterapia-en-c%C3%A1ncer-de-pr%C3%B3stata 2026-04-13 https://www.oncobites.tv/news/la-cirug%C3%ADa-guiada-por-fluorescencia-mejora-la-precisi%C3%B3n-en-c%C3%A1ncer-de-cabeza-y-cuello%3A-una-revisi%C3%B3n-evidencia-su-potencial-en-evaluaci%C3%B3n-de-m%C3%A1rgenes 2026-04-13 https://www.oncobites.tv/news/beat-meso%3A-cambio-de-enfoque-para-tratar-el-mesotelioma-pleural 2026-04-13 https://www.oncobites.tv/news/nos-vamos-a-chicago-a-cubrir-asco-2025 2026-04-13 https://www.oncobites.tv/news/olaparib-y-radioterapia-en-sarcomas%3A-una-combinaci%C3%B3n-prometedora 2026-04-13 https://www.oncobites.tv/news/las-voces-de-las-expertas-en-melanoma 2026-04-13 https://www.oncobites.tv/news/espa%C3%B1a-conmemora-el-d%C3%ADa-mundial-del-melanoma-poniendo-el-foco-en-la-prevenci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/ascolt%3A-aspirina-de-tratamiento-adyuvante-para-c%C3%A1ncer-colorrectal-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/%C2%BFcompromete-la-radioterapia-adyuvante-la-eficacia-de-la-inmunoterapia-en-c%C3%A1ncer-de-endometrio-recurrente%3F 2026-04-13 https://www.oncobites.tv/news/t-dm1-y-palbociclib-en-c%C3%A1ncer-de-mama-her2-positivo-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/imlunestrant-%2B-abemaciclib-duplica-la-pfs-en-pacientes-er%2B%2Fher2--tras-cdk4%2F6i 2026-04-13 https://www.oncobites.tv/news/rosaline%3A-terapia-endocrina-(et)-y-entrectinib-neoadyuvante-en-el-carcinoma-lobulillar-invasivo-de-mama-(ilbc) 2026-04-13 https://www.oncobites.tv/news/el-embarazo-tras-un-c%C3%A1ncer-de-mama-durante-la-gestaci%C3%B3n-es-seguro-en-portadoras-brca 2026-04-13 https://www.oncobites.tv/news/supervivencia-libre-de-reca%C3%ADda-en-c%C3%A1ncer-de-mama-hr%2B%2Fher2--con-grupo-de-riesgo-intermedio-pam50 2026-04-13 https://www.oncobites.tv/news/expertos-conversan-c%C3%B3mo-la-inmunoterapia-y-los-adcs-transforman-el-abordaje-del-c%C3%A1ncer-de-mama-temprano-y-avanzado 2026-04-13 https://www.oncobites.tv/news/tropspain%3A-an%C3%A1lisis-retrospectivo-observacional-para-evaluar-la-efectividad-de-sacituzumab-govitecan-en-mtnbc 2026-04-13 https://www.oncobites.tv/news/procure%3A-variantes-hla-se-asocian-con-mayor-riesgo-de-neumonitis-en-pacientes-tratadas-con-t-dxd 2026-04-13 https://www.oncobites.tv/news/abemaciclib-demuestra-beneficio-sostenido-en-pacientes-j%C3%B3venes-con-c%C3%A1ncer-de-mama-temprano-hr%2B%2Fher2%E2%80%93%2C-seg%C3%BAn-el-estudio-monarche 2026-04-13 https://www.oncobites.tv/news/el-talento-espa%C3%B1ol-se-escribe-en-femenino-en-esmo-breast 2026-04-13 https://www.oncobites.tv/news/el-estudio-neoletexe-muestra-beneficios-cl%C3%ADnicos-y-de-biomarcadores-con-letrozol-y-exemestano-secuenciales-en-c%C3%A1ncer-de-mama-hr%2B%2Fher2%E2%80%93 2026-04-13 https://www.oncobites.tv/news/tumores-her2%2B-con-mutaciones-en-erbb2-evolucionan-bajo-tratamiento-neoadyuvante-y-seleccionan-mutaciones-patog%C3%A9nicas 2026-04-13 https://www.oncobites.tv/news/nuevas-estrategias-terap%C3%A9uticas-redefinen-el-abordaje-del-c%C3%A1ncer-de-mama-her2%2B-avanzado-tras-la-era-de-los-adcs 2026-04-13 https://www.oncobites.tv/news/integral%3A-docetaxel-y-pembrolizumab-m%C3%A1s-terapia-g%C3%A9nica-con-interleucina-12-en-c%C3%A1ncer-de-mama-triple-negativo-no-metast%C3%A1sico%2C-refractario-a-antraciclinas 2026-04-13 https://www.oncobites.tv/news/%C2%BFc%C3%B3mo-responde-a-la-inmunoterapia-el-carcinoma-escamoso-en-%C3%BAlceras-cr%C3%B3nicas%3F 2026-04-13 https://www.oncobites.tv/news/biopsia-l%C3%ADquida-en-sarcoma-para-detectar-erm 2026-04-13 https://www.oncobites.tv/news/las-estatinas-mejoran-la-supervivencia-en-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/nanomedicinas-basadas-en-fagos-para-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/harmoni-2%3A-invonescimab-vs.-pembrolizumab-en-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-pd-l1-positivo 2026-04-13 https://www.oncobites.tv/news/an%C3%A1lisis-molecular-del-carcinoma-anapl%C3%A1sico-de-ovario 2026-04-13 https://www.oncobites.tv/news/estudio-de-gata6-como-marcador-pron%C3%B3stico-en-c%C3%A1ncer-pancre%C3%A1tico-resecado 2026-04-13 https://www.oncobites.tv/news/esmo-breast%3A-buena-ciencia%2C-mejor-medicina%2C-mejores-pr%C3%A1cticas 2026-04-13 https://www.oncobites.tv/news/shewanella-como-posible-factor-de-riesgo-microbiano-en-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/diagn%C3%B3stico-en-la-primera-mamograf%C3%ADa%3A-una-alerta-sobre-la-supervivencia-de-las-pacientes 2026-04-13 https://www.oncobites.tv/news/ratones-hut%3A-una-herramienta-para-estudiar-la-telomerasa-y-tel%C3%B3meros-en-melanoma-acral- 2026-04-13 https://www.oncobites.tv/news/localizaci%C3%B3n-tumoral-y-pron%C3%B3stico-en-c%C3%A1ncer-de-colon 2026-04-13 https://www.oncobites.tv/news/detecci%C3%B3n-de-ctdna-en-biopsia-l%C3%ADquida-en-sarcoma-%C3%B3seo-y-de-ewing 2026-04-13 https://www.oncobites.tv/news/-predicci%C3%B3n-de-la-p%C3%A9rdida-de-gusto-en-radioterapia-para-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/la-voz-de-las-expertas-en-c%C3%A1ncer-de-ovario 2026-04-13 https://www.oncobites.tv/news/bonenza%3A-adici%C3%B3n-de-%C3%A1cido-zoledr%C3%B3nico-a-enzalutamida-y-terapia-de-privaci%C3%B3n-androg%C3%A9nica-en-el-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-sensible-a-hormonas 2026-04-13 https://www.oncobites.tv/news/las-voces-de-los-expertos-en-c%C3%A1ncer-urotelial 2026-04-13 https://www.oncobites.tv/news/las-gu%C3%ADas-aua-2025-redefinen-el-manejo-del-c%C3%A1ncer-renal-localizado-con-foco-en-individualizaci%C3%B3n%2C-funci%C3%B3n-renal-y-seguimiento-inteligente 2026-04-13 https://www.oncobites.tv/news/atad3a-se-posiciona-como-biomarcador-pron%C3%B3stico-y-posible-diana-terap%C3%A9utica-en-carcinoma-renal-de-c%C3%A9lulas-claras 2026-04-13 https://www.oncobites.tv/news/cirug%C3%ADa%2C-quimioterapia-e-inmunoterapia-transforman-el-abordaje-de-los-timomas-avanzados 2026-04-13 https://www.oncobites.tv/news/desarrollan-una-herramienta-predictiva-para-pacientes-con-sarcoma-de-partes-blandas-tratados-con-quimioterapia-neoadyuvante 2026-04-13 https://www.oncobites.tv/news/la-fda-aprueba-penpulimab-kcqx-en-combinaci%C3%B3n-con-quimioterapia-para-carcinoma-nasofar%C3%ADngeo-recurrente-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/revisi%C3%B3n-sobre-el-papel-del-adn-circulante-tumoral-en-la-detecci%C3%B3n-precoz-y-monitoreo-del-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/investigadores-identifican-el-valor-pron%C3%B3stico-de-la-amplificaci%C3%B3n-de-erbb2-en-carcinoma-urotelial-vesical-t1-de-alto-grado 2026-04-13 https://www.oncobites.tv/news/crest%3A-sasanlimab-en-combinaci%C3%B3n-con-bacillus-calmette-gu%C3%A9rin-mejora-la-supervivencia-libre-de-eventos-en-comparaci%C3%B3n-con-bacillus-calmette-gu%C3%A9rin-como-tratamiento-est%C3%A1ndar-en-c%C3%A1ncer-de-vejiga-no-m%C3%BAsculo-invasivo-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/en-espa%C3%B1a-desarrollan-herramienta-urinaria-multimodal-para-predecir-la-respuesta-a-inmunoterapia-en-c%C3%A1ncer-de-vejiga 2026-04-13 https://www.oncobites.tv/news/investigadores-detectan-mutaciones-impulsoras-en-adn-libre-urinario-de-pacientes-con-c%C3%A1ncer-urotelial-sin-evidencia-patol%C3%B3gica-de-enfermedad 2026-04-13 https://www.oncobites.tv/news/redefiniendo-el-manejo-de-la-recurrencia-bioqu%C3%ADmica-en-c%C3%A1ncer-de-pr%C3%B3stata-tras-prostatectom%C3%ADa-radical 2026-04-13 https://www.oncobites.tv/news/apalutamide-mejora-la-respuesta-de-psa-en-pacientes-afroamericanos-con-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-sensible-a-castraci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/investigadores-analizan-la-expresi%C3%B3n-de-nectin4-y-trop2-en-c%C3%A1ncer-urotelial-de-tracto-superior-tras-quimioterapia-preoperatoria 2026-04-13 https://www.oncobites.tv/news/resultados-basados-en-alteraciones-de-genes-supresores-de-tumor-en-el-c%C3%A1ncer-de-pr%C3%B3stata-hormonosensible-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/el-papel-emergente-de-los-inhibidores-de-akt-en-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-hormonosensible 2026-04-13 https://www.oncobites.tv/news/actualizan-la-herramienta-gpa-(graded-prognostic-assessment)-de-melanoma--y-revela-una-mejora-significativa-en-la-supervivencia-con-terapias-modernas 2026-04-13 https://www.oncobites.tv/news/el-uso-de-diferentes-ensayos-de-pd-l1-revela-variaciones-en-la-inmunobiolog%C3%ADa-y-resultados-cl%C3%ADnicos-en-c%C3%A1ncer-urotelial 2026-04-13 https://www.oncobites.tv/news/nrg-gy018%3A-pembrolizumab-m%C3%A1s-quimioterapia-en-c%C3%A1ncer-de-endometrio-avanzado-o-recurrente%3A-supervivencia-global-y-an%C3%A1lisis-exploratorios 2026-04-13 https://www.oncobites.tv/news/el-consenso-de-manejo-de-eventos-adversos-con-lorlatinib-hecho-programa 2026-04-13 https://www.oncobites.tv/news/eventos-inmunomediados-bajo-inmunoterapia-en-c%C3%A1ncer-de-mama-triple-negativo%3A-frecuentes%2C-manejables-y-potencialmente-asociados-a-mejor-respuesta 2026-04-13 https://www.oncobites.tv/news/estudio-nectar%3A-amivantamab-con-quimioterapia-demuestra-superioridad-en-comparaci%C3%B3n-con-tratamientos-reales-en-c%C3%A1ncer-de-pulm%C3%B3n-con-mutaciones-egfr-exon-20 2026-04-13 https://www.oncobites.tv/news/estudio-combi-ad%3A-la-medici%C3%B3n-de-ctdna-predice-reca%C3%ADdas-en-melanoma-estadio-iii-tras-cirug%C3%ADa 2026-04-13 https://www.oncobites.tv/news/reducir-la-dosis-electiva-en-radioterapia-para-c%C3%A1ncer-de-cabeza-y-cuello-es-seguro%3A-evidencia-del-ensayo-upgrade-rt 2026-04-13 https://www.oncobites.tv/news/estudio-nrg-gy006%3A-triapina-no-mejora-la-supervivencia-en-c%C3%A1ncer-cervicovaginal-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/desaf%C3%ADos-y-oportunidades-en-la-b%C3%BAsqueda-de-biomarcadores-en-el-c%C3%A1ncer-de-renal-de-c%C3%A9lulas-claras 2026-04-13 https://www.oncobites.tv/news/codebreak-300-resultados-de-supervivencia-global-de-sotorasib-%2B-panitumumab-vs-quimiorradioterapia-en-pacientes-con-c%C3%A1ncer-de-colon-kras-g12c 2026-04-13 https://www.oncobites.tv/news/nos-vamos-a-las-vegas-para-cubrir-el-congreso-americano-de-urolog%C3%ADa-(aua) 2026-04-13 https://www.oncobites.tv/news/%C2%BFvolver-al-platino-o-cambiar-a-inmunoterapia%3F-nuevo-estudio-rompe-mitos-en-c%C3%A1ncer-de-endometrio 2026-04-13 https://www.oncobites.tv/news/regorafenib-mejora-la-supervivencia-libre-de-progresi%C3%B3n-tras-doxorrubicina-en-sarcoma-avanzado-no-adipoc%C3%ADtico 2026-04-13 https://www.oncobites.tv/news/la-terapia-dirigida-adyuvante-muestra-mayor-eficacia-que-la-inmunoterapia-en-melanoma-estadio-iiia 2026-04-13 https://www.oncobites.tv/news/el-estudio-palmares-2-demuestra-que-abemaciclib-y-ribociclib-superan-a-palbociclib-en-eficacia-en-c%C3%A1ncer-de-mama-hr%2B%2Fher2- 2026-04-13 https://www.oncobites.tv/news/el-an%C3%A1lisis-de-cerumen-con-sers-y-machine-learning-detecta-c%C3%A1ncer-de-cabeza-y-cuello-con-alta-precisi%C3%B3n 2026-04-13 https://www.oncobites.tv/news/rationale-302%3A-mutaci%C3%B3n-de-notch1-y-an%C3%A1lisis-de-supervivencia-con-tislelizumab-en-el-carcinoma-escamoso-de-es%C3%B3fago-avanzado-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/desentra%C3%B1ando-las-claves-moleculares-del-c%C3%A1ncer-de-ovario-metast%C3%A1sico-y-opciones-de-terapias-combinadas 2026-04-13 https://www.oncobites.tv/news/la-combinaci%C3%B3n-de-inmunoterapias-reprograma-linfocitos-cd8%2B-y-mejora-respuestas-en-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/efectos-tard%C3%ADos-f%C3%ADsicos-y-psicol%C3%B3gicos-tras-el-tratamiento-del-sarcoma-%C3%B3seo 2026-04-13 https://www.oncobites.tv/news/la-inteligencia-artificial-mejora-la-predicci%C3%B3n-de-pron%C3%B3stico-y-beneficio-de-terapia-adyuvante-en-c%C3%A1nceres-gastrointestinales 2026-04-13 https://www.oncobites.tv/news/cambiar-el-payload-mejora-la-eficacia-del-tratamiento-secuencial-con-adcs-en-c%C3%A1ncer-de-mama-metast%C3%A1sico-her2%2B 2026-04-13 https://www.oncobites.tv/news/encuesta-nacional-revela-c%C3%B3mo-se-toman-decisiones-en-melanoma-metast%C3%A1sico-en-la-era-de-relatlimab-y-nivolumab-en-el-reino-unido 2026-04-13 https://www.oncobites.tv/news/talapro-2%3A-talazoparib-m%C3%A1s-enzalutamida-en-primera-l%C3%ADnea-versus-placebo-m%C3%A1s-enzalutamida-para-el-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-resistente-a-la-castraci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/ipilimumab-en-baja-dosis-en-combinaci%C3%B3n-con-pembrolizumab-en-pacientes-con-met%C3%A1stasis-cerebrales-de-melanoma 2026-04-13 https://www.oncobites.tv/news/el-futuro-del-tratamiento-del-carcinoma-cut%C3%A1neo%2C-no-melanoma 2026-04-13 https://www.oncobites.tv/news/-terapia-neoadyuvante%3A-nuevo-est%C3%A1ndar-en-melanoma-seg%C3%BAn-experta-internacional 2026-04-13 https://www.oncobites.tv/news/merlin-assay%3A-el-modelo-cp-gep-identifica-pacientes-con-melanoma-en-estadio-temprano-que-podr%C3%ADan-evitar-la-biopsia-del-ganglio-centinela 2026-04-13 https://www.oncobites.tv/news/dermat%C3%B3logos-espa%C3%B1oles-eval%C3%BAa-la-inteligencia-artificial-para-detectar-cambios-en-lesiones-mediante-fotograf%C3%ADa-corporal-total-en-2d-y-3d 2026-04-13 https://www.oncobites.tv/news/nuevas-estrategias-terap%C3%A9uticas-remodelan-el-tratamiento-del-carcinoma-cut%C3%A1neo-de-c%C3%A9lulas-escamosas 2026-04-13 https://www.oncobites.tv/news/seguimiento-a-2-a%C3%B1os-y-an%C3%A1lisis-de-biomarcadores-de-cemiplimab-neoadyuvante-para-el-carcinoma-cut%C3%A1neo-de-c%C3%A9lulas-escamosas-en-estadio-ii%E2%80%93iv 2026-04-13 https://www.oncobites.tv/news/overview-del-abordaje-del-carcinoma-cut%C3%A1neo-escamocelular-(cscc) 2026-04-13 https://www.oncobites.tv/news/el-ctdna-predice-respuesta%2C-toxicidad-e-identifica-reca%C3%ADda-antes-que-la-imagen-en-melanoma 2026-04-13 https://www.oncobites.tv/news/potencial-del-ctdna-tumor-informado-para-personalizar-la-inmunoterapia-en-melanoma 2026-04-13 https://www.oncobites.tv/news/el-subtipo-luminal-like-predice-el-beneficio-de-la-terapia-endocrina-extendida-en-c%C3%A1ncer-de-mama-con-receptores-hormonales-positivos 2026-04-13 https://www.oncobites.tv/news/nuevas-terapias-dirigidas-contra-her2-transforman-el-abordaje-de-los-tumores-ginecol%C3%B3gicos-her2-positivos 2026-04-13 https://www.oncobites.tv/news/el-suban%C3%A1lisis-del-estudio-hilus-muestra-control-local-con-sbrt-en-c%C3%A1ncer-de-pulm%C3%B3n-central%2C-pero-con-alta-toxicidad 2026-04-13 https://www.oncobites.tv/news/estudio-revela-que-la-quimioterapia-de-rescate-mejora-la-supervivencia-tras-fracaso-de-platino-y-nivolumab-en-c%C3%A1ncer-de-cabeza-y-cuello-(rm-hnscc) 2026-04-13 https://www.oncobites.tv/news/la-combinaci%C3%B3n-de-enzalutamida-y-%5B%C2%B9%E2%81%B7%E2%81%B7lu%5Dlu-psma-617-mejora-la-supervivencia-global-en-el-estudio-enza-p%2C-resultados-finales-de--supervivencia 2026-04-13 https://www.oncobites.tv/news/jcog0905%3A-metotrexato%2C-doxorrubicina-y-cisplatino-vs.-metotrexato%2C-doxorrubicina%2C-cisplatino-m%C3%A1s-ifosfamida-en-pacientes-con-mala-respuesta-a-la-qt-preoperatoria-para-el-osteosarcoma-de-alto-grado-reci%C3%A9n-diagnosticado 2026-04-13 https://www.oncobites.tv/news/el-estudio-euproms-pone-sobre-la-mesa-el-impacto-real-del-c%C3%A1ncer-de-pr%C3%B3stata-en-la-vida-sexual-de-los-pacientes-y-sus-parejas- 2026-04-13 https://www.oncobites.tv/news/gagome-score-predice-recurrencia-en-c%C3%A1ncer-renal-con-alta-sensibilidad%3A-datos-del-estudio-aurorax-0087a- 2026-04-13 https://www.oncobites.tv/news/oncobites-presente-en-el-congreso-de-la-asociaci%C3%B3n-europea-de-urolog%C3%ADa-(eau) 2026-04-13 https://www.oncobites.tv/news/bond-003--cohort-p%3A-cretostimogene-grenadenorepvec-intravesical-para-c%C3%A1ncer-de-vejiga-no-m%C3%BAsculo-invasivo-de-alto-riesgo%2C-solo-papilar-que-no-responde-al-bcg-(actualizaci%C3%B3n-de-resultados-cl%C3%ADnicos-y-traslacionales) 2026-04-13 https://www.oncobites.tv/news/dos-noticias-importantes-sobre-tumores-cut%C3%A1neos 2026-04-13 https://www.oncobites.tv/news/reflexiones-de-expertas-sobre-c%C3%A1ncer-de-es%C3%B3fago 2026-04-13 https://www.oncobites.tv/news/en-el-d%C3%ADa-mundial-del-c%C3%A1ncer-de-colon%2C-actividades-y-mensajes-desde-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/las-voces-de-las-expertas-en-c%C3%A1ncer-de-colon 2026-04-13 https://www.oncobites.tv/news/terapia-dirigida-por-biomarcadores-revoluciona-el-tratamiento-del-c%C3%A1ncer-de-pulm%C3%B3n-localizado-con-mutaciones-oncog%C3%A9nicas 2026-04-13 https://www.oncobites.tv/news/actualizaci%C3%B3n-sobre-tratamiento-de-primera-l%C3%ADnea-en-c%C3%A1ncer-de-pulm%C3%B3n-egfrm-avanzado 2026-04-13 https://www.oncobites.tv/news/an%C3%A1lisis-de-resultados-en-un-subgrupo-de-pacientes-con-nsclc-tratados-con-cemiplimab-en-monoterapia-de-1l-y-que%2C-tras-la-progresi%C3%B3n%2C-continuaron-cemiplimab-con-qt-a%C3%B1adida%2C-junto-con-una-visi%C3%B3n-general-de-los-beneficios-cl%C3%ADnicos--al-a%C3%B1o%2C-3-y-5-a%C3%B1os-del-estudio-empower-lung-1- 2026-04-13 https://www.oncobites.tv/news/rationale-304%3A-an%C3%A1lisis-de-subgrupo-con-expresi%C3%B3n-de-pd-l1-%E2%89%A550%25.-tislelizumab-%2B-qt-como-terapia-de-1l-para-c%C3%A1ncer-de-pulm%C3%B3n-de-c%C3%A9lulas-no-peque%C3%B1as-no-escamoso-(cpcnp-no-escamoso)-localmente-avanzado-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/osimertinib%2C-amivantamab-y-aumolertinib-redefinen-el-tratamiento-del-cpnm-estadio-iii-irresecable-con-mutaci%C3%B3n-egfr 2026-04-13 https://www.oncobites.tv/news/el-enfoque-sist%C3%A9mico-en-estadio-iii-de-c%C3%A1ncer-de-pulm%C3%B3n-transforma-el-paradigma-quir%C3%BArgico-y-de-supervivencia 2026-04-13 https://www.oncobites.tv/news/el-estudio-nadim-ii-demuestra-que-la-enfermedad-m%C3%ADnima-residual-(mdr)-predice-reca%C3%ADda-y-supervivencia-en-c%C3%A1ncer-de-pulm%C3%B3n-resecable 2026-04-13 https://www.oncobites.tv/news/larotrectinib-ofrece-beneficios-cl%C3%ADnicos-sostenidos-en-c%C3%A1ncer-de-pulm%C3%B3n-con-fusi%C3%B3n-trk%2C-independientemente-de-terapias-previas 2026-04-13 https://www.oncobites.tv/news/mirada-de-los-expertos-en-c%C3%A1ncer-cervicouterino 2026-04-13 https://www.oncobites.tv/news/d%C3%ADa-mundial-de-la-prevenci%C3%B3n-en-c%C3%A1ncer-de-cuello-uterino%2C-acciones-ejecutadas-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/el-d%C3%ADa-de-la-ciencia-con-la-fundaci%C3%B3n-cris-contra-el-c%C3%A1ncer 2026-04-13 https://www.oncobites.tv/news/por-primera-vez%2C-oncobites-cubrir%C3%A1-el-congreso-mundial-de-melanoma-y-el-eado 2026-04-13 https://www.oncobites.tv/news/la-cin%C3%A9tica-del-ctdna-predice-la-respuesta-a-terapia-sist%C3%A9mica-en-c%C3%A1ncer-de-pulm%C3%B3n-avanzado 2026-04-13 https://www.oncobites.tv/news/el-estudio-infinity-demuestra-la-eficacia-de-tremelimumab-y-durvalumab-como-estrategia-neoadyuvante-en-el-c%C3%A1ncer-gastroesof%C3%A1gico 2026-04-13 https://www.oncobites.tv/news/el-melanoma-asociado-a-nevus-mejora-el-pron%C3%B3stico-en-comparaci%C3%B3n-con-el-melanoma-de-novo 2026-04-13 https://www.oncobites.tv/news/el-psa-persistente-tras-prostatectom%C3%ADa-radical-aumenta-el-riesgo-de-mortalidad-en-c%C3%A1ncer-de-pr%C3%B3stata 2026-04-13 https://www.oncobites.tv/news/edici%C3%B3n-gen%C3%A9tica-del-gen-ewsr1%3A%3Afli1-bloquea-la-proliferaci%C3%B3n-celular-en-el-sarcoma-de-ewing 2026-04-13 https://www.oncobites.tv/news/rumbo-a-elcc-2025%2C-traeremos-los-adelantos-claves-de-c%C3%A1ncer-de-pulm%C3%B3n-presentadas-desde-par%C3%ADs 2026-04-13 https://www.oncobites.tv/news/inmunoterapia-en-c%C3%A1ncer-cervical%3A-una-revisi%C3%B3n-de-avances-y-nuevas-estrategias-terap%C3%A9uticas 2026-04-13 https://www.oncobites.tv/news/dipper%3A-bloqueo-adyuvante-de-pd-1-con-camrelizumab-para-el-carcinoma-nasofar%C3%ADngeo 2026-04-13 https://www.oncobites.tv/news/la-microbiota-intestinal%2C-un-factor-clave-en-el-tratamiento-del-carcinoma-renal 2026-04-13 https://www.oncobites.tv/news/pembrolizumab-en-combinaci%C3%B3n-con-bevacizumab-para-met%C3%A1stasis-cerebrales-no-tratadas-de-melanoma 2026-04-13 https://www.oncobites.tv/news/la-separaci%C3%B3n-de-fase-l%C3%ADquida-en-sarcoma%3A-un-nuevo-enfoque-para-la-patog%C3%A9nesis-y-el-tratamiento 2026-04-13 https://www.oncobites.tv/news/asco-actualiza-gu%C3%ADas-de-tratamiento-en-c%C3%A1ncer-de-pulm%C3%B3n-metast%C3%A1sico-sin-alteraciones-gen%C3%A9ticas 2026-04-13 https://www.oncobites.tv/news/exosomas-y-su-impacto-en-la-resistencia-a-la-quimioterapia-en-c%C3%A1ncer-de-ovario 2026-04-13 https://www.oncobites.tv/news/%C2%BFc%C3%B3mo-influye-la-interacci%C3%B3n-entre-el-metabolismo-de-los-%C3%A1cidos-grasos-y-la-microbiota-intestinal-en-el-c%C3%A1ncer-colorrectal%3F 2026-04-13 https://www.oncobites.tv/news/her2dx-mejora-la-toma-de-decisiones-en-c%C3%A1ncer-de-mama-her2%2B-en-estadios-tempranos 2026-04-13 https://www.oncobites.tv/news/oncobites-lanza-un-programa-especial-sobre-terapia-con-radioligandos-en-c%C3%A1ncer-de-pr%C3%B3stata 2026-04-13 https://www.oncobites.tv/news/el-melanoma-acral-en-poblaci%C3%B3n-cauc%C3%A1sica-muestra-un-pron%C3%B3stico-desfavorable%2C-seg%C3%BAn-un-amplio-estudio-de-cohortes 2026-04-13 https://www.oncobites.tv/news/a-coru%C3%B1a-ser%C3%A1-el-epicentro-del-debate-oncol%C3%B3gico-en-el-xi-congreso-ttcc 2026-04-13 https://www.oncobites.tv/news/la-combinaci%C3%B3n-de-inhibidores-de-parp-y-radioterapia-muestra-potencial-en-sarcomas-de-tejido-blando 2026-04-13 https://www.oncobites.tv/news/metaan%C3%A1lisis-confirma-la-superioridad-de-inhibidores-de-aromatasa-frente-a-tamoxifeno-en-c%C3%A1ncer-de-mama-temprano-hr%2B%2Fher2%E2%88%92 2026-04-13 https://www.oncobites.tv/news/participa-en-el-curso-de-competencias-en-c%C3%A1ncer-de-pulm%C3%B3n-2025 2026-04-13 https://www.oncobites.tv/news/eventos-adversos-asociados-a-la-combinaci%C3%B3n-parpi-%2B-terapia-hormonal-novedosa-y-su-manejo-recomendado 2026-04-13 https://www.oncobites.tv/news/rlt-talks-un-programa-sobre-los-radioligandos-en-primera-l%C3%ADnea-para-tumores-neuroendocrinos 2026-04-13 https://www.oncobites.tv/news/keynote-158%3A-pembrolizumab-en-pacientes-con-pacientes-con-c%C3%A1ncer-de-endometrio-avanzado-con-y-sin-inestabilidad-de-microsat%C3%A9lites-alta%2Fdeficiencia-en-la-reparaci%C3%B3n-de-desajustes-(msi-h%2Fdmmr) 2026-04-13 https://www.oncobites.tv/news/el-estudio-sarcoma-ring-trial-revela-discrepancias-en-el-manejo-cl%C3%ADnico-de-los-sarcomas-en-centros-especializados 2026-04-13 https://www.oncobites.tv/news/%C2%BFenfortumab-vedotin-terapia-prometedora-para-el-c%C3%A1ncer-de-cabeza-y-cuello-con-posible-v%C3%ADnculo-con-el-vph%3F 2026-04-13 https://www.oncobites.tv/news/gog-0258%3A-clasificaci%C3%B3n-molecular-del-c%C3%A1ncer-de-endometrio-y-su-impacto-en-la-supervivencia 2026-04-13 https://www.oncobites.tv/news/cambios-claves-en-la-gu%C3%ADa-de-manejo-de-carcinoma-hepatocelular-de-esmo 2026-04-13 https://www.oncobites.tv/news/enza-p%3A-resultados-2rios-de-os-y-calidad-de-vida-con-%5B%C2%B9%E2%81%B7%E2%81%B7lu%5Dlu-psma-617-%2B-enzalutamida-vs.-enzalutamida-en-monoterapia-en-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-resistente-a-la-castraci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/young-pearl%3A-palbociclib-con-terapia-endocrina-vs.-capecitabina-en-c%C3%A1ncer-de-mama-metast%C3%A1sico%2C-%C2%BFuna-estrategia-diferencial-en-supervivencia%3F 2026-04-13 https://www.oncobites.tv/news/ipilimumab-y-nivolumab-mejoran-la-supervivencia-en-melanoma-con-met%C3%A1stasis-cerebral-a-7-a%C3%B1os 2026-04-13 https://www.oncobites.tv/news/cabinet%3A-cabozantinib-para-el-tratamiento-de-tumores-neuroendocrinos-avanzados 2026-04-13 https://www.oncobites.tv/news/el-uso-de-modelos-de-predicci%C3%B3n-de-riesgo-en-sarcoma%3A-herramienta-clave-pero-con-desaf%C3%ADos-en-la-pr%C3%A1ctica-cl%C3%ADnica 2026-04-13 https://www.oncobites.tv/news/desarrollan-un-nomograma-para-predecir-el-riesgo-de-hiperplasia-y-c%C3%A1ncer-endometrial-en-mujeres-premenop%C3%A1usicas 2026-04-13 https://www.oncobites.tv/news/la-detecci%C3%B3n-de-mirnas-en-sangre-mejora-el-diagn%C3%B3stico-y-seguimiento-del-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/innovaci%C3%B3n-en-la-investigaci%C3%B3n-del-melanoma%3A-%C3%BAnete-al-encuentro-anual-del-grupo-gem-en-san-sebasti%C3%A1n 2026-04-13 https://www.oncobites.tv/news/el-registro-retud-revela-el-manejo-y-resultados-en-c%C3%A1ncer-de-p%C3%A1ncreas-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/amivantamab%3A-un-enfoque-dual-para-nsclc-con-mutaciones-egfr-exon20ins 2026-04-13 https://www.oncobites.tv/news/primer-an%C3%A1lisis-de-datos-del-estudio-m%C3%A1s-grande-en-c%C3%A1ncer-de-vejiga-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/tendance%3A-seguridad-y-eficacia-de-trastuzumab-deruxtecan-%2B-rt-concurrente-en--breast-cancer 2026-04-13 https://www.oncobites.tv/news/urotelial 2026-04-13 https://www.oncobites.tv/news/lenvatinib-perioperatorio-y-pembrolizumab-en-pacientes-con-carcinoma-renal-localmente-avanzado-no-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/resultados-finales-del-checkmate-9er%3A-nivolumab-%2B-cabozantinib-reafirma-su-eficacia-en-carcinoma-renal-avanzado 2026-04-13 https://www.oncobites.tv/news/keymaker-u03-substudy-03b%3A-pembrolizumab-y-nuevos-agentes-de-inmunoterapia-en-carcinoma-de-c%C3%A9lulas-renales-avanzadas 2026-04-13 https://www.oncobites.tv/news/superando-los-desaf%C3%ADos-de-los-conjugados-anticuerpo-f%C3%A1rmaco-en-c%C3%A1ncer-de-vejiga 2026-04-13 https://www.oncobites.tv/news/el-mundo-cambiante-del-c%C3%A1ncer-de-vejiga-no-invasivo-muscular 2026-04-13 https://www.oncobites.tv/news/libertas%3A-apalutamida-con-terapia-de-privaci%C3%B3n-androg%C3%A9nica-intermitente-en-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico-sensible-a-la-castraci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/metan%C3%A1lisis-wolverine-confirma-el-beneficio-de-la-terapia-dirigida-a-met%C3%A1stasis-en-c%C3%A1ncer-de-pr%C3%B3stata-oligometast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/terapia-basada-en-psma-en-enfermedad-avanzada.-abordando-combinaciones-y-secuenciaci%C3%B3n-en-c%C3%A1ncer-de-pr%C3%B3stata 2026-04-13 https://www.oncobites.tv/news/regorafenib-mejora-la-supervivencia-en-hepatocarcinoma-irresecable%2C-en-combinaci%C3%B3n-con-inmunoterapia 2026-04-13 https://www.oncobites.tv/news/un-estudio-de-vida-real-confirma-la-seguridad-y-beneficio-econ%C3%B3mico-de-la-terapia-de-mantenimiento-con-niraparib-en-pacientes-con-c%C3%A1ncer-de-ovario-recurrente 2026-04-13 https://www.oncobites.tv/news/un-caso-cl%C3%ADnico-destaca-los-desaf%C3%ADos-y-avances-en-el-tratamiento-del-melanoma-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/estado-del-arte-y-nuevas-estrategias-terap%C3%A9uticas-para-el-manejo-del-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/eurocare-6-revela-tendencias-en-incidencia-y-supervivencia-de-sarcomas-en-j%C3%B3venes-europeos 2026-04-13 https://www.oncobites.tv/news/secuenciaci%C3%B3n-de-ctdna-mediante-wgs-permite-la-detecci%C3%B3n-temprana-del-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/gfpc-08%E2%80%932015-energy%3A-nivolumab-%2B-ipilimumab-vs.-doblete-basado-en-carboplatino-como-tratamiento-de-1l-para-pacientes-con-c%C3%A1ncer-de-pulm%C3%B3n-de-c%C3%A9lulas-no-peque%C3%B1as-avanzado%2C-de-%E2%89%A570-a%C3%B1os-o-con-un-estado-funcional-ecog-de-2- 2026-04-13 https://www.oncobites.tv/news/espa%C3%B1a-conmemora-el-d%C3%ADa-mundial-del-colangiocarcinoma-y-los-tumores-de-las-v%C3%ADas-biliares-con-eventos-de-concienciaci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/reflexiones-de-expertos-sobre-los-avances-en-el-tratamiento-de-los-tumores-de-las-v%C3%ADas-biliares-(colangiocarcinoma) 2026-04-13 https://www.oncobites.tv/news/el-estudio-oprah-eval%C3%BAa-la-dosis-%C3%B3ptima-de-radioterapia-paliativa-en-carcinoma-escamoso-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/pacientes-con-enfermedad-metast%C3%A1sica-de-novo-tienen-mejor-pron%C3%B3stico-en-c%C3%A1ncer-de-mama-avanzado-hr%2B%2Fher2- 2026-04-13 https://www.oncobites.tv/news/madrid-ser%C3%A1-la-sede-del-10%C2%BA-curso-multidisciplinario-de-tumores-%C3%B3seos-y-de-tejidos-blandos-(bstt) 2026-04-13 https://www.oncobites.tv/news/pembrolizumab-con-quimioterapia-demuestra-factibilidad-y-modulaci%C3%B3n-inmunol%C3%B3gica-en-c%C3%A1ncer-de-ovario-avanzado 2026-04-13 https://www.oncobites.tv/news/amivantamab-mejora-la-eficacia-de-alectinib-en-c%C3%A1ncer-de-pulm%C3%B3n-alk-positivo 2026-04-13 https://www.oncobites.tv/news/el-test-de-metilaci%C3%B3n-del-adn-urinario-muestra-alta-sensibilidad-para-el-diagn%C3%B3stico-de-c%C3%A1ncer-de-vejiga 2026-04-13 https://www.oncobites.tv/news/estaremos-en-asco-gu25%3A-el-congreso-de-referencia-en-oncolog%C3%ADa-genitourinaria 2026-04-13 https://www.oncobites.tv/news/aprueban-fruquintinib-en-espa%C3%B1a-para-el-tratamiento-del-c%C3%A1ncer-colorrectal-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/checkmate-8hw%3A-nivolumab-m%C3%A1s-ipilimumab-versus-nivolumab-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico-con-alta-inestabilidad-de-microsat%C3%A9lites 2026-04-13 https://www.oncobites.tv/news/elacestrant-en-la-pr%C3%A1ctica.-la-fda-aprob%C3%B3-este-medicamento-para-tratar-el-c%C3%A1ncer-de-mama-her2--rh%2B%2C-mutado-esr1 2026-04-13 https://www.oncobites.tv/news/inhibidores-de-tirosin-quinasa-en-el-tratamiento-de-c%C3%A1ncer-de-mama-her2%2B-avanzado 2026-04-13 https://www.oncobites.tv/news/ocho-expertos-oncologia 2026-04-13 https://www.oncobites.tv/news/cemiplimab-revoluciona-el-tratamiento-del-carcinoma-escamoso-cut%C3%A1neo-avanzado%3A-resultados-finales-del-estudio-empower-cscc-1 2026-04-13 https://www.oncobites.tv/news/olaparib-demuestra-beneficios-consistentes-en-c%C3%A1ncer-de-ovario%3A-an%C3%A1lisis-final-del-estudio-light 2026-04-13 https://www.oncobites.tv/news/la-secuenciaci%C3%B3n-gen%C3%A9tica-revela-diferencias-clave-en-c%C3%A1ncer-de-pulm%C3%B3n-escamoso-seg%C3%BAn-el-historial-de-tabaquismo 2026-04-13 https://www.oncobites.tv/news/estudio-eval%C3%BAa-la-viabilidad-de-una-intervenci%C3%B3n-basada-en-la-aplicaci%C3%B3n-de-atenci%C3%B3n-plena-en-pacientes-con-carcinoma-de-c%C3%A9lulas-renales-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/resultados-finales-del-estudio-falcon%3A-fulvestrant-muestra-resultados-consistentes-en-la-supervivencia-global-frente-a-anastrozol 2026-04-13 https://www.oncobites.tv/news/eagles%3A-avelumab-en-combinaci%C3%B3n-con-gemcitabina-en-leiomiosarcoma-avanzado-como-tratamiento-de-2l 2026-04-13 https://www.oncobites.tv/news/pembrolizumab-con-o-sin-bevacizumab-en-carcinoma-nasofar%C3%ADngeo-recurrente-o-metast%C3%A1sico-resistente-al-platino 2026-04-13 https://www.oncobites.tv/news/unidos-por-lo-%C3%BAnico%3A-oncobites-destaca-las-actividades-del-d%C3%ADa-mundial-del-c%C3%A1ncer-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/eficacia-y-seguridad-de-fruquintinib-alternando-con-bevacizumab-m%C3%A1s-capecitabina-como-terapia-de-mantenimiento-despu%C3%A9s-del-tratamiento-de-1l-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico-(mcrc) 2026-04-13 https://www.oncobites.tv/news/deeper%3A-an%C3%A1lisis-final-de-supervivencia-confirma-beneficio-de-m-folfoxiri-m%C3%A1s-cetuximab-en-mcrc-ras%2Fbraf-wild-type-del-lado-izquierdo 2026-04-13 https://www.oncobites.tv/news/calgb%2Fswog-80702%3A-ctdna-identifica-pacientes-con-c%C3%A1ncer-de-colon-que-podr%C3%ADan-beneficiarse-de-celecoxib 2026-04-13 https://www.oncobites.tv/news/tinegotinib-en-pacientes-con-colangiocarcinoma-avanzado-y-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/la-positividad-de-her2-impacta-el-pron%C3%B3stico-y-la-eficacia-de-terapias-dirigidas-en-c%C3%A1ncer-de-v%C3%ADas-biliares-avanzado 2026-04-13 https://www.oncobites.tv/news/resultados-del-estudio-racb-demuestran-que-la-resecci%C3%B3n-hep%C3%A1tica-despu%C3%A9s-de-atezolizumab-y-bevacizumab-tiene--resultados-prometedores-en-carcinoma-hepatocelular 2026-04-13 https://www.oncobites.tv/news/con-el--estudio-artemis-pc-analizan-si-el-ctdna-mejora-el-monitoreo-del-tratamiento-en-c%C3%A1ncer-de-p%C3%A1ncreas-avanzado 2026-04-13 https://www.oncobites.tv/news/fruquintinib-combinado-con-camrelizumab%2C-paclitaxel-liposoma-y-nedaplatino-muestra-resultados-prometedores-en-el-tratamiento-de-escc-avanzado 2026-04-13 https://www.oncobites.tv/news/anlotinib-combinado-con-radioterapia-muestra-eficacia-prometedora-en-carcinoma-escamoso-de-es%C3%B3fago-avanzado 2026-04-13 https://www.oncobites.tv/news/meta-an%C3%A1lisis-destaca-el-beneficio-de-los-inhibidores-de-pd-1%2Fpd-l1-combinados-con-quimioterapia-en-tumores-gastroesof%C3%A1gicos-avanzados 2026-04-13 https://www.oncobites.tv/news/alta-prevalencia-de-deficiencia-en-la-reparaci%C3%B3n-de-desajustes-(dmmr)-en-c%C3%A1nceres-gastrointestinales-en-m%C3%A9xico 2026-04-13 https://www.oncobites.tv/news/avances-en-terapias-sist%C3%A9micas-dirigidas%3A-m%C3%A1s-all%C3%A1-de-pd-1-en-el-tratamiento-del-c%C3%A1ncer-esofagog%C3%A1strico 2026-04-13 https://www.oncobites.tv/news/hb1801-reduce-el-riesgo-de-muerte-en-c%C3%A1ncer-g%C3%A1strico-avanzado-frente-a-taxotere%C2%AE 2026-04-13 https://www.oncobites.tv/news/factores-del-exposoma-en-melanoma%3A-radiaci%C3%B3n-uv-y-nuevos-hallazgos-en-prevenci%C3%B3n 2026-04-13 https://www.oncobites.tv/news/onc%C3%B3logos-italianos-avalan-la-flexibilidad-en-el-uso-de-inhibidores-cdk4%2F6-para-pacientes-con-hr%2B%2Fher2- 2026-04-13 https://www.oncobites.tv/news/calidad-de-vida-en-pacientes-con-sarcoma-sometidos-a-terapia-multimodal 2026-04-13 https://www.oncobites.tv/news/decisiones-de-manejo-en-c%C3%A1ncer-de-pr%C3%B3stata-avanzado-seg%C3%BAn-el-consenso-apccc-2024 2026-04-13 https://www.oncobites.tv/news/la-abundancia-de-c%C3%A9lulas-b-como-biomarcador-clave-en-la-respuesta-a-inhibidores-de-puntos-de-control-en-c%C3%A1nceres-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/greko-iii%3A-eficacia-de-enzalutamida-en-tumores-ov%C3%A1ricos-de-c%C3%A9lulas-de-la-granulosa-avanzados-no-resecables 2026-04-13 https://www.oncobites.tv/news/etop-13-18-beat-meso%3A-qt-(bevacizumab-y-carboplatino-pemetrexed)-con-o-sin-atezolizumab-como-tratamiento-de-1l--para-el-mesotelioma-pleural-avanzado 2026-04-13 https://www.oncobites.tv/news/asco-gi25-el-primer-congreso-del-a%C3%B1o 2026-04-13 https://www.oncobites.tv/news/cisplatino-semanal-vs.-cada-tres-semanas%3A-nuevos-hallazgos-tras-tres-a%C3%B1os-en-el-c%C3%A1ncer-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/hipofraccionamiento-moderado-en-radioterapia-preoperatoria%3A-resultados-prometedores-en-sarcoma-de-tejidos-blandos 2026-04-13 https://www.oncobites.tv/news/osimertinib-en-primera-l%C3%ADnea%3A-%C2%BFun-cambio-paradigm%C3%A1tico-en-el-c%C3%A1ncer-de-pulm%C3%B3n-avanzado%3F 2026-04-13 https://www.oncobites.tv/news/durvalumab-y-pembrolizumab-en-quimio-inmunoterapia%3A-una-nueva-era-para-los-tumores-de-la-v%C3%ADa-biliar 2026-04-13 https://www.oncobites.tv/news/quimioterapia-combinada-con-radioterapia-mejora-la-supervivencia-en-c%C3%A1ncer-de-cuello-uterino-en-mujeres-mayores 2026-04-13 https://www.oncobites.tv/news/litespark-003%3A-belzutifan-m%C3%A1s-cabozantinib-como-tratamiento-de-1l-para-pacientes-con-carcinoma-de-c%C3%A9lulas-renales-de-tipo-claro-avanzado 2026-04-13 https://www.oncobites.tv/news/el-estudio-checkmate-204-eval%C3%BAa-criterios-intracraneales-en-melanoma-con-met%C3%A1stasis-cerebrales-tratados-con-nivolumab-e-ipilimumab 2026-04-13 https://www.oncobites.tv/news/la-inmunoterapia-y-la-cirug%C3%ADa-redefinen-el-manejo-locorregional-del-melanoma 2026-04-13 https://www.oncobites.tv/news/helen-006%3A-nab-paclitaxel-semanal-neoadyuvante-en-dosis-reducida-con-trastuzumab-y-pertuzumab-versus-docetaxel%2C-carboplatino%2C-trastuzumab-y-pertuzumab-en-pacientes-con-c%C3%A1ncer-de-mama-temprano-her2%2B 2026-04-13 https://www.oncobites.tv/news/c-brain%3A-radioterapia-cerebral-combinada-con-camrelizumab-y-quimioterapia-con-doblete-de-platino-para-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-avanzado-previamente-no-tratado-con-met%C3%A1stasis-cerebrales 2026-04-13 https://www.oncobites.tv/news/el-estudio-checkmate-067-revela-beneficios-de-supervivencia-a-10-a%C3%B1os-en-melanoma-avanzado 2026-04-13 https://www.oncobites.tv/news/revisi%C3%B3n-del-tratamiento-y-prevenci%C3%B3n-del-c%C3%A1ncer-cervical 2026-04-13 https://www.oncobites.tv/news/desaf%C3%ADos-moleculares-y-terap%C3%A9uticos-de-las-neoplasias-neuroendocrinas-pulmonares 2026-04-13 https://www.oncobites.tv/news/presencia-de-m-chip-en-pacientes-con-leucemia-linfoc%C3%ADtica-cr%C3%B3nica%3A-impacto-en-el-pron%C3%B3stico-y-la-supervivencia 2026-04-13 https://www.oncobites.tv/news/sarcomas-fibromixoides-y-fibrosarcomas-epitelioides-esclerosantes%3A-un-an%C3%A1lisis-internacional-revela-diferencias-en-el-pron%C3%B3stico-y-la-recurrencia 2026-04-13 https://www.oncobites.tv/news/recql4-potencia-la-progresi%C3%B3n-del-c%C3%A1ncer-cervical-a-trav%C3%A9s-de-la-v%C3%ADa-pi3k%2Fakt 2026-04-13 https://www.oncobites.tv/news/test-urinario-de-18-genes-mejora-significativamente-la-detecci%C3%B3n-de-c%C3%A1ncer-de-pr%C3%B3stata-de-alto-grado 2026-04-13 https://www.oncobites.tv/news/factores-cardiovasculares-y-quimioterapia-con-t-p-influyen-en-la-cardiotoxicidad-en-pacientes-con-her2%2B-ebc 2026-04-13 https://www.oncobites.tv/news/toripalimab-en-neoadyuvancia-y-adyuvancia-para-el-carcinoma-nasofar%C3%ADngeo-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/chipor%3A-quimioterapia-intraperitoneal-hipert%C3%A9rmica-para-c%C3%A1ncer-de-ovario-recurrente 2026-04-13 https://www.oncobites.tv/news/starglo%3A-glofitamab-m%C3%A1s-gemcitabina-y-oxaliplatino-(gemox)-frente-a-rituximab-gemox-para-el-linfoma-difuso-de-c%C3%A9lulas-b-grandes-recidivante-o-refractario 2026-04-13 https://www.oncobites.tv/news/secuenciaci%C3%B3n-de-arn-de-c%C3%A9lula-%C3%BAnica-con-biopsia-por-aspiraci%C3%B3n-encuentra-subclon-agresivo-en-tumores-pancre%C3%A1ticos 2026-04-13 https://www.oncobites.tv/news/el-estudio-comet-demuestra-que-la-monitorizaci%C3%B3n-activa-mantiene-la-calidad-de-vida-en-pacientes-con-carcinoma-ductal-in-situ-de-bajo-riesgo 2026-04-13 https://www.oncobites.tv/news/atezolizumab-mejora-la-supervivencia-a-largo-plazo-en-c%C3%A1ncer-de-pulm%C3%B3n-de-c%C3%A9lulas-peque%C3%B1as-en-estadio-extenso 2026-04-13 https://www.oncobites.tv/news/sunvozertinib-demuestra-eficacia-en-pacientes-con-c%C3%A1ncer-de-pulm%C3%B3n-resistente-a-inhibidores-de-tirosina-quinasa-egfr 2026-04-13 https://www.oncobites.tv/news/estrategias-tumor-informadas-superan-enfoques-tumor-agn%C3%B3sticos-en-la-detecci%C3%B3n-de-enfermedad-residual-m%C3%ADnima-en-c%C3%A1ncer-colorrectal 2026-04-13 https://www.oncobites.tv/news/3-perspectivas-sobre-estrategias-terap%C3%A9uticas-de-neoadyuvancia-en-melanoma-en-estadio-iii-con-mutaci%C3%B3n-braf-desde-australia 2026-04-13 https://www.oncobites.tv/news/la-combinaci%C3%B3n-de-inhibidores-egfr-y-alk%3A-una-estrategia-prometedora-ante-resistencia-en-nsclc-avanzado 2026-04-13 https://www.oncobites.tv/news/asco-publica-nuevas-gu%C3%ADas-de-manejo-de-quimioterapia-sist%C3%A9mica-para-carcinoma-escamoso-anal-en-estadios-i-iii 2026-04-13 https://www.oncobites.tv/news/nrg-hn004%3A-radioterapia-con-durvalumab-comparado-con-cetuximab-en-c%C3%A1ncer-de-cabeza-y-cuello-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/exploran-del-estudio-clear-biomarcadores-clave-para-evaluar-la-eficacia-de-lenvatinib-m%C3%A1s-pembrolizumab-frente-a-sunitinib-en-carcinoma-renal-avanzado 2026-04-13 https://www.oncobites.tv/news/el-estudio-relativity-047-confirma-la-eficacia-sostenida-de-nivolumab-m%C3%A1s-relatlimab-en-melanoma-avanzado 2026-04-13 https://www.oncobites.tv/news/el-estudio-swog-s1815-desaf%C3%ADa-la-quimioterapia-est%C3%A1ndar-en-c%C3%A1nceres-avanzados-de-la-v%C3%ADa-biliar-con-el-r%C3%A9gimen-gap 2026-04-13 https://www.oncobites.tv/news/estudio-ebano-revela-brechas-en-el-tratamiento-del-carcinoma-urotelial-avanzado-en-el-norte-de-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/marcadores-gen%C3%B3micos-predictivos-para-optimizar-las-decisiones-terap%C3%A9uticas-con-trastuzumab-deruxtecan-y-trastuzumab-emtansina 2026-04-13 https://www.oncobites.tv/news/preserve-2%3A-trilaciclib-no-mejora-la-supervivencia-en-c%C3%A1ncer-de-mama-triple-negativo 2026-04-13 https://www.oncobites.tv/news/la-expresi%C3%B3n-de-nectin-4-predice-la-respuesta-patol%C3%B3gica-completa-en-c%C3%A1ncer-de-mama-triple-negativo-temprano 2026-04-13 https://www.oncobites.tv/news/atropina-profil%C3%A1ctica-para-prevenir-la-diarrea-producida-por-sacituzumab-govitec%C3%A1n--en-pacientes-con-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/resultados-de-datos-del-mundo-real-de-eribulina-en-la-mejora-de-la-supervivencia-en-pacientes-con-c%C3%A1ncer-de-mama-her2-negativo 2026-04-13 https://www.oncobites.tv/news/avances-en-terap%C3%A9uticas-her2 2026-04-13 https://www.oncobites.tv/news/touch%3A-palbociclib-y-letrozol-muestran-promesa-como-tratamiento-neoadyuvante-en-c%C3%A1ncer-de-mama-hr%2B%2Fher2%2B 2026-04-13 https://www.oncobites.tv/news/sigue-en-marcha-la-investigaci%C3%B3n-sobre-ctdna-para-el-c%C3%A1ncer-de-mama-avanzado-y-temprano 2026-04-13 https://www.oncobites.tv/news/la-detecci%C3%B3n-de-ctdna-revoluciona-el-monitoreo-del-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/el-poder-de-la-imagenolog%C3%ADa-multiplexada%3A-avances-en-oncolog%C3%ADa-de-precisi%C3%B3n-contra-el-c%C3%A1ncer-de-mama-triple-negativo 2026-04-13 https://www.oncobites.tv/news/aprueban-inavolisib-para-el-tratamiento-del-c%C3%A1ncer-de-mama-luminal-pik3ca 2026-04-13 https://www.oncobites.tv/news/%C2%BFpor-qu%C3%A9-aprobaron-ribociclib-para-el-tratamiento-del-c%C3%A1ncer-de-mama-luminal%3F 2026-04-13 https://www.oncobites.tv/news/elacestrant-nuevos-datos-y-giredestrant-en-investigaci%C3%B3n-para-el-tratamiento-del-c%C3%A1ncer-de-mama-luminal-(rh%2B%2C-her2-) 2026-04-13 https://www.oncobites.tv/news/datos-de-evidencia-en-el-mundo-real-refuerzan-opciones-terap%C3%A9uticas-para-el-c%C3%A1ncer-de-mama-triple-negativo 2026-04-13 https://www.oncobites.tv/news/biomarcadores-en-adn-tumoral-circulante-y-modelos-de-ia-para-el-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/inhibidores-de-tirosin-quinasa-en-el-tratamiento-de-c%C3%A1ncer-de-mama-her2%2B-avanzado 2026-04-13 https://www.oncobites.tv/news/3-p%C3%B3steres-de-lmc 2026-04-13 https://www.oncobites.tv/news/tgrx-678-demuestra-eficacia-y-seguridad-en-leucemia-mieloide-cr%C3%B3nica-resistente-o-intolerante-a-inhibidores-de-tirosina-quinasa 2026-04-13 https://www.oncobites.tv/news/eradic-eval%C3%BAa-la-combinaci%C3%B3n-guiada-por-mrd-de-ibrutinib-y-venetoclax-frente-a-fcr-en-pacientes-con-llc-de-riesgo-intermedio 2026-04-13 https://www.oncobites.tv/news/la-leucemia-linfoc%C3%ADtica-cr%C3%B3nica-se-adapta-al-ibrutinib-mediante-plasticidad-epigen%C3%A9tica-y-la-activaci%C3%B3n-de-la-v%C3%ADa-mapk 2026-04-13 https://www.oncobites.tv/news/secuenciar-car-t-y-bsab-en-linfoma-folicular%3A-%C2%BFc%C3%B3mo-decidir-la-estrategia-%C3%B3ptima%3F 2026-04-13 https://www.oncobites.tv/news/transformando-la-evaluaci%C3%B3n-del-mieloma-m%C3%BAltiple%3A-nuevas-perspectivas-con-la-espectrometr%C3%ADa-de-masas 2026-04-13 https://www.oncobites.tv/news/teclistamab-induce-una-respuesta-inmunol%C3%B3gica-diferencial-en-mieloma-m%C3%BAltiple 2026-04-13 https://www.oncobites.tv/news/estudio-perseus%3A-analizando-el-rol-de-las-c%C3%A9lulas-tumorales-circulantes-en-el-tratamiento-del-mieloma-m%C3%BAltiple 2026-04-13 https://www.oncobites.tv/news/explorando-las-estrategias-terap%C3%A9uticas-actuales-del-tratamiento-del-linfoma-cl%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/pacientes-con-adenocarcinoma-pulmonar-mucinoso-muestran-menor-respuesta-a-inmunoterapia 2026-04-13 https://www.oncobites.tv/news/nuevas-herramientas-in-vitro%3A-modelo-de-piel-humana-para-pruebas-de-c%C3%A9lulas-t-vg9vd2-contra-el-melanoma 2026-04-13 https://www.oncobites.tv/news/sigue-a-oncobites-mientras-desglosamos-los-destacados-clave-de-sabcs-2024 2026-04-13 https://www.oncobites.tv/news/oncobites-debuta-con-el-primer-cubrimiento-del-ash 2026-04-13 https://www.oncobites.tv/news/resultados-negativos-en-colonoscop%C3%ADa%3A-claves-para-entender-el-riesgo-futuro-de-c%C3%A1ncer-colorrectal 2026-04-13 https://www.oncobites.tv/news/extentorch-toripalimab-m%C3%A1s-quimioterapia-como-1l-de-c%C3%A1ncer-de-pulm%C3%B3n-de-c%C3%A9lula-peque%C3%B1a-extendido 2026-04-13 https://www.oncobites.tv/news/el-ii-congreso-de-tumores-de-cabeza-y-cuello-a-la-vuelta-de-la-esquina 2026-04-13 https://www.oncobites.tv/news/seom-seap-actualiza-el-consenso-de-biomarcadores-en-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/keynote-a18-posiciona-a-pembrolizumab-como-nuevo-est%C3%A1ndar-de-tratamiento-del-c%C3%A1ncer-de-cuello-uterino 2026-04-13 https://www.oncobites.tv/news/se-adicionan-durvalumab-y-tarlatamab%2C-como-terapias-en-la-gu%C3%ADa-para-el-tratamiento-del-c%C3%A1ncer-de-pulm%C3%B3n-microc%C3%ADtico 2026-04-13 https://www.oncobites.tv/news/estudios-preecl%C3%ADnicos-positivos-de-car-t-para-c%C3%A1ncer-de-mama-en-estudios-her2%2B 2026-04-13 https://www.oncobites.tv/news/gate2brain-revoluciona-el-tratamiento-de-c%C3%A1ncer-infantil- 2026-04-13 https://www.oncobites.tv/news/fruquinitinib-combinado-con-nab-paclitaxel-y-gemcitabina-(ag)-como-tratamiento-de-primera-l%C3%ADnea-para-el-adenocarcinoma-ductal-pancre%C3%A1tico-(pdac)-con-met%C3%A1stasis-hep%C3%A1ticas 2026-04-13 https://www.oncobites.tv/news/actividades-para-concienciar-sobre-el-c%C3%A1ncer-de-p%C3%A1ncreas-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/las-voces-de-los-expertos 2026-04-13 https://www.oncobites.tv/news/ev-202-hnc%3A-enfortumab-vedotin-en-pacientes-con-c%C3%A1ncer-de-cabeza-y-cuello-avanzado-previamente-tratado 2026-04-13 https://www.oncobites.tv/news/checkmate-274%3A-nivolumab-adyuvante-en-carcinoma-urotelial-invasivo-de-m%C3%BAsculo-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/fertiss%3A-evaluando-el-impacto-de-las-cirug%C3%ADas-en-c%C3%A1ncer-cervical-sobre-la-fertilidad 2026-04-13 https://www.oncobites.tv/news/investigan-beneficio-de-cart-cell-en-el-tratamiento-para-el-c%C3%A1ncer-de-mama-triple-negativo 2026-04-13 https://www.oncobites.tv/news/estrategias-de-respuesta-y-biomarcadores-en-estudio-para-c%C3%A1ncer-colorrectal-dmmr-(deficient-mismatch-repair)-y-pmmr-(proficient-mismatch-repair) 2026-04-13 https://www.oncobites.tv/news/investigan-las-diferencias-en-estructuras-linfoides-de-melanomas-primarios-y-metast%C3%A1sicos 2026-04-13 https://www.oncobites.tv/news/actualizan-directrices-para-nsclc-estadio-iv%3A-osimertinib-y-nuevas-mutaciones-en-foco 2026-04-13 https://www.oncobites.tv/news/recomendaciones-de-expertos-para-escenarios-cl%C3%ADnicos-desafiantes-y-secuenciaci%C3%B3n-de-terapias-en-c%C3%A1ncer-de-mama-her2%2B 2026-04-13 https://www.oncobites.tv/news/las-voces-de-los-expertos-en-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/espa%C3%B1a-se-mueve-para-combatir-el-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/serena-2%3A-camizestrant-vs-fulvestrant-en-mujeres-posmenop%C3%A1usicas-con-c%C3%A1ncer-de-mama-avanzado-con-receptor-de-estr%C3%B3geno-positivo-y-her2-negativo 2026-04-13 https://www.oncobites.tv/news/descubren-el-potencial-del-biomarcador-mtap-en-diagn%C3%B3stico-de-c%C3%A1ncer-tor%C3%A1cico 2026-04-13 https://www.oncobites.tv/news/se-complet%C3%B3-el-estudio-geico-105-o%3A-combinaci%C3%B3n-de-trabectedina-y-doxorubicina-liposomal-pegilada-(pld)-para-el-tratamiento-de-pacientes-mayores-con-c%C3%A1ncer-de-ovario-recurrente 2026-04-13 https://www.oncobites.tv/news/te-descubrimos-c%C3%B3mo-espa%C3%B1a-se-involucra-en-la-batalla-contra-el-c%C3%A1ncer-g%C3%A1strico 2026-04-13 https://www.oncobites.tv/news/las-voces-de-los-expertos-en-c%C3%A1ncer-g%C3%A1strico 2026-04-13 https://www.oncobites.tv/news/keynote-811-an%C3%A1lisis-final-de-supervivencia-global-de-pembrolizumab-m%C3%A1s-trastuzumab-y-quimioterapia-en-adenocarcinoma-g%C3%A1strico-o-de-la-uni%C3%B3n-gastroesof%C3%A1gica-her2%2B-irresecable-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/investigaci%C3%B3n-destaca-factores-clave-en-la-eficacia-y-seguridad-de-trastuzumab-deruxtecan-en-c%C3%A1ncer-g%C3%A1strico-her2-positivo 2026-04-13 https://www.oncobites.tv/news/curso-gem-en-madrid%3A-actualizaci%C3%B3n-en-el-abordaje-del-melanoma-y-tumores-cut%C3%A1neos 2026-04-13 https://www.oncobites.tv/news/desentra%C3%B1ando-el-rol-de-recql4-en-el-c%C3%A1ncer-de-cuello-uterino 2026-04-13 https://www.oncobites.tv/news/estudiando-el-slc2a1-como-mecanismo-de-resistencia-en-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/a-puertas-del-simposio-anual-del-sogug 2026-04-13 https://www.oncobites.tv/news/tulip%3A-trastuzumab-duocarmazina-en-el-c%C3%A1ncer-de-mama-avanzado-o-metast%C3%A1sico-positivo-para-el-her2-en-pacientes-pretratados 2026-04-13 https://www.oncobites.tv/news/dragon-iv%2Fcap-05%3A-respuesta-patol%C3%B3gica-del-camrelizumab-perioperatorio-%2B-rivoceranib-y-quimioterapia-vs.-quimioterapia-para-c%C3%A1ncer-g%C3%A1strico-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/nuevos-avances-en-oncolog%C3%ADa-digestiva%3A-pamplona 2026-04-13 https://www.oncobites.tv/news/%C2%BFhay-beneficio-cl%C3%ADnico-en-c%C3%A1ncer-de-pulm%C3%B3n-y-deficiencia-hla-con-quimioinmunotetapia%3F 2026-04-13 https://www.oncobites.tv/news/acceso-a-biomarcadores-impulsa-la-medicina-personalizada-en-c%C3%A1ncer-de-pulm%C3%B3n-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/destiny-breast06%3A-trastuzumab-deruxtecan-despu%C3%A9s-de-la-terapia-endocrina-en-c%C3%A1ncer-de-mama-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/la-terapia-endocrina-extendida-mejora-la-supervivencia-en-pacientes-con-c%C3%A1ncer-de-mama-er%2B-y-her2-en-riesgo-de-recurrencia-tard%C3%ADa 2026-04-13 https://www.oncobites.tv/news/flipbooks-digitales%3A-una-herramienta-avanzada-para-la-evaluaci%C3%B3n-de-tumores-cerebrales-en-neuro-oncolog%C3%ADa 2026-04-13 https://www.oncobites.tv/news/engot-en11%2Fgog-3053%2Fkeynote-b21%3A-pembrolizumab-o-placebo-m%C3%A1s-quimioterapia-adyuvante-con-o-sin-radioterapia-para-c%C3%A1ncer-de-endometrio-de-alto-riesgo-con-mismatch-repair 2026-04-13 https://www.oncobites.tv/news/pace-b%3A-radioterapia-corporal-estereot%C3%A1ctica-en-c%C3%A1ncer-de-pr%C3%B3stata-localizado 2026-04-13 https://www.oncobites.tv/news/presentan-los-resultados-a-largo-plazo-del-estudio-ejecutado-en-espa%C3%B1a-nadim%2C-tratamiento-con-nivolumab-en-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/personaliza-la-terapia-en-c%C3%A1ncer-de-mama-triple-negativo-con-el-test-tnbc-dx 2026-04-13 https://www.oncobites.tv/news/nuevas-gu%C3%ADas-esgo%2Feuracan%2Fgcig-sobre-sarcomas-uterinos%2C-buscando-mejorar-la-atenci%C3%B3n-de-las-pacientes 2026-04-13 https://www.oncobites.tv/news/%C2%BFpueden-los-marcadores-pron%C3%B3sticos-actualmente-conocidos-para-c%C3%A1ncer-esof%C3%A1gico-y-g%C3%A1strico-guiar-tratamientos-cl%C3%ADnicos%3F 2026-04-13 https://www.oncobites.tv/news/%C2%BFest%C3%A1n-los-biomarcadores-listos-para-su-aplicaci%C3%B3n-en-la-pr%C3%A1ctica-cl%C3%ADnica-en-c%C3%A1ncer-de-pulm%C3%B3n%3F 2026-04-13 https://www.oncobites.tv/news/zircon%3A-innovador-estudio-que-eval%C3%BAa-t%C3%A9cnica-de-imagen-no-invasiva-para-el-c%C3%A1ncer-renal 2026-04-13 https://www.oncobites.tv/news/r%C3%A1pida-revisi%C3%B3n-consorcio-internacional-sobre-meningiomas 2026-04-13 https://www.oncobites.tv/news/investigadores-de-barcelona-desarrolla-una-herramienta-predictiva-para-la-mortalidad-en-pacientes-hospitalizados-con-c%C3%A1ncer 2026-04-13 https://www.oncobites.tv/news/desde-todas-las-latitudes-espa%C3%B1a-trabaja-por-educar-y-orientar-sobre-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/ayudando-a-tus-pacientes-a-entender-el-c%C3%A1ncer-de-mama-y-los-cuidados-post-radioterapia 2026-04-13 https://www.oncobites.tv/news/aceleran-las-pruebas-de-medicamentos-contra-el-c%C3%A1ncer-infantil-con-nuevos-modelos-pdx 2026-04-13 https://www.oncobites.tv/news/%C2%A1todo-listo-para-la-edici%C3%B3n-2024-del-simposio-geico! 2026-04-13 https://www.oncobites.tv/news/resultados-prometedores-de-adicionar-terapia-directa-a-las-met%C3%A1stasis-en-c%C3%A1ncer-pancre%C3%A1tico 2026-04-13 https://www.oncobites.tv/news/%C2%BFes-%C3%BAtil-usar-la-tecnolog%C3%ADa-ctdna-en-la-toma-de-decisiones-cl%C3%ADnicas-en-c%C3%A1ncer-avanzado-de-mama%3F 2026-04-13 https://www.oncobites.tv/news/tumor-supresor-predice-progresi%C3%B3n-temprana-en-c%C3%A1ncer-de-pr%C3%B3stata%3A-resultados-de-un-estudio-multic%C3%A9ntrico 2026-04-13 https://www.oncobites.tv/news/siguen-estudiando-el-valor-de-los-metabolitos-microbianos-en-el-diagn%C3%B3stico-del-c%C3%A1ncer-gastrointestinal 2026-04-13 https://www.oncobites.tv/news/medicina-de-precisi%C3%B3n-con-capmatinib-en-c%C3%A1ncer-de-pulm%C3%B3n%3A-%C2%BFuna-historia-de-%C3%A9xito-parcial%3F 2026-04-13 https://www.oncobites.tv/news/actualizan-gu%C3%ADa-esmo-sobre-neoplasias-neuroendocrinas-para-optimizar-tratamiento-y-diagn%C3%B3stico 2026-04-13 https://www.oncobites.tv/news/resultados-del-mundo-real-con-sacituzumab-govitecan-en-c%C3%A1ncer-de-mama-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/impacto-de-las-mutaciones-egfr-en-los-resultados-del-tratamiento-del-nsclc 2026-04-13 https://www.oncobites.tv/news/un-programa-de-detecci%C3%B3n-basado-en-serolog%C3%ADa-del-virus-de-epstein-barr-reduce-la-mortalidad-por-carcinoma-nasofar%C3%ADngeo-en-china 2026-04-13 https://www.oncobites.tv/news/niagara%3A-durvalumab-perioperatorio-con-quimioterapia-neoadyuvante-en-c%C3%A0ncer-de-vejiga-operable 2026-04-13 https://www.oncobites.tv/news/imatinib-a-largo-plazo%3A-nueva-esperanza-para-pacientes-con-gist-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/nuevas-directrices-para-la-preservaci%C3%B3n-de-la-fertilidad-en-c%C3%A1ncer-ginecol%C3%B3gico 2026-04-13 https://www.oncobites.tv/news/un-nuevo-hito-en-el-tratamiento-de-gliomas%3A-la-extirpaci%C3%B3n-quir%C3%BArgica-en-adultos%2C-seg%C3%BAn-la-clasificaci%C3%B3n-de-la-oms-2021 2026-04-13 https://www.oncobites.tv/news/innovadora-t%C3%A9cnica-para-detectar-mutaciones-de-resistencia-en-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/proyecto-legacy%3A-avanzando-en-la-investigaci%C3%B3n-del-c%C3%A1ncer-g%C3%A1strico-en-europa-y-am%C3%A9rica-latina 2026-04-13 https://www.oncobites.tv/news/keynote-522%3A-supervivencia-global-de-pembrolizumab-en-c%C3%A1ncer-de-mama-triple-negativo-estadio-temprano 2026-04-13 https://www.oncobites.tv/news/cabozantinib-para-el-tratamiento-de-tumores-neuroendocrinos-avanzados 2026-04-13 https://www.oncobites.tv/news/ramunet%3A-ramucirumab-en-combinaci%C3%B3n-con-dacarbazina-para-en-tumores-neuroendocrinos-pancre%C3%A1ticos%2C-resultados-iniciales 2026-04-13 https://www.oncobites.tv/news/immunocobivem%2C-resultados-a-largo-plazo-del-estudio-para-el-melanoma-avanzado-con-brafv600 2026-04-13 https://www.oncobites.tv/news/cosibelimab%3A-nuevos-avances-en-la-eficacia-y-seguridad-a-largo-plazo-en-el-carcinoma-cut%C3%A1neo-de-c%C3%A9lulas-escamosas-avanzado 2026-04-13 https://www.oncobites.tv/news/%C2%BFse-puede-preservar-la-fertilidad-en-mujeres-con-c%C3%A1ncer-cervical-que-son-expuestas-a-quimioterapia-y-tislelizumab%3F 2026-04-13 https://www.oncobites.tv/news/mirasol%2C-resultados-actualizados-de-supervivencia-global 2026-04-13 https://www.oncobites.tv/news/sunniforecast%3A-ensayo-fase-ii-de-ipilimumab%2Fnivolumab-vs.-tratamiento-est%C3%A1ndar-en-c%C3%A1ncer-de-c%C3%A9lulas-renales-no-claras 2026-04-13 https://www.oncobites.tv/news/r%C3%A1pida-vista-del-nuevo-algoritmo-de-tratamiento-en-c%C3%A1ncer-de-mama-metast%C3%A1sico-her2-positivo-2024 2026-04-13 https://www.oncobites.tv/news/ivonescimab-%2B-quimioterapia-como-tratamiento-de-1l-en-c%C3%A1ncer-de-mama-triple-negativo-(tnbc) 2026-04-13 https://www.oncobites.tv/news/esg401%3A-un-nuevo-adc-dirigido-a-trop2-demuestra-eficacia-en-el-c%C3%A1ncer-de-mama-metast%C3%A1sico-her2-con-met%C3%A1stasis-cerebrales 2026-04-13 https://www.oncobites.tv/news/aplicando-a-la-inteligencia-artificial-en-la-oncolog%C3%ADa 2026-04-13 https://www.oncobites.tv/news/el-%22rome-trial%22-revoluciona-la-oncolog%C3%ADa-personalizada-con-nuevas-terapias-dirigidas-e-inmunoterapia 2026-04-13 https://www.oncobites.tv/news/alectinib-adyuvante-vs-quimioterapia%3A-an%C3%A1lisis-de-biomarcadores-en-el-estudio-alina 2026-04-13 https://www.oncobites.tv/news/osimertinib-post-crt-en-nsclc%3A-menor-progresi%C3%B3n-en-snc-y-a-distancia%2C-resultados-del-estudio-laura 2026-04-13 https://www.oncobites.tv/news/keynote-811%3A-an%C3%A1lisis-final-de-la-os-de-pembrolizumab-m%C3%A1s-trastuzumab-y-quimioterapia-(qt)-en-el-adenocarcinoma-g%C3%A1strico%2Fgej-her2%2B-no-resecable-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/resultados-a-5-a%C3%B1os-del-hypog-01-de-unicancer%3A-la-radioterapia-locorregional-puede-reducirse-a-3-semanas-como-nuevo-est%C3%A1ndar. 2026-04-13 https://www.oncobites.tv/news/contact-02%3A-resultados-finales-de-os-con-cabozantinib-(c)-m%C3%A1s-atezolizumab-(a)-frente-a-segunda-terapia-hormonal-novedosa-(nht)-en-pacientes-(pts)-con-c%C3%A1ncer-de-pr%C3%B3stata-resistente-a-la-castraci%C3%B3n-metast%C3%A1sico-(mcrpc) 2026-04-13 https://www.oncobites.tv/news/keynote-006%3A-seguimiento-a-10-a%C3%B1os-de-pembrolizumab-vs-ipilimumab-para-el-melanoma-avanzado 2026-04-13 https://www.oncobites.tv/news/mariposa-2%3A-2do-an%C3%A1lisis-interino-de-supervivencia-global-de-amivantamab-m%C3%A1s-quimioterapia-(qt)-vs-qt-en-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-avanzado-con-mutaci%C3%B3n-egfr-tras-progresi%C3%B3n-con-osimertinib 2026-04-13 https://www.oncobites.tv/news/la-trabectedina-mejora-la-supervivencia-en-pacientes-con-sarcomas-de-tejidos-blandos%3A-datos-de-un-centro-de-alto-volumen 2026-04-13 https://www.oncobites.tv/news/porter-m3%3A-inmunoterapia-combinada-con-radioterapia-muestra-resultados-prometedores-en-melanoma-mucoso-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/utopia%3A-la-detecci%C3%B3n-de-adn-tumoral-circulante-(ctdna)-como-biomarcador-en-el-carcinoma-endometrial-avanzado 2026-04-13 https://www.oncobites.tv/news/resultados-de-supervivencia-global-(os)-del-estudio-arcadia-en-carcinoma-urotelial-avanzado 2026-04-13 https://www.oncobites.tv/news/estudio-breakwater%3A-encorafenib-%2B-cetuximab-(ec)-%2B-folfiri-para-c%C3%A1ncer-colorrectal-metast%C3%A1sico-(mcrc)-con-mutaci%C3%B3n-braf-v600e 2026-04-13 https://www.oncobites.tv/news/estudio-geicam%2F2011-06%3A-prevalencia-del-c%C3%A1ncer-de-mama-her2-bajo-y-precisi%C3%B3n-de-la-inmunohistoqu%C3%ADmica 2026-04-13 https://www.oncobites.tv/news/el-uso-de-los-anticuerpos-conjugado-f%C3%A1rmaco-(adcs)-en-el-tratamiento-del-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-(nsclc)%3A-pasado%2C-presente%2C-futuro 2026-04-13 https://www.oncobites.tv/news/estrategias-de-inmunoterapia-personalizada-para-c%C3%A1nceres-de-cabeza-y-cuello 2026-04-13 https://www.oncobites.tv/news/trastuzumab-deruxtecan-muestra-eficacia-prometedora-en-pacientes-con-c%C3%A1ncer-de-mama-her2-positivo-y-met%C3%A1stasis-cerebrales 2026-04-13 https://www.oncobites.tv/news/doxorrubicina%E2%80%93trabectedina-con-mantenimiento-de-trabectedina-en-leiomiosarcoma 2026-04-13 https://www.oncobites.tv/news/quimiorradioterapia-vs.-radioterapia-corta%3A-%C2%BFcu%C3%A1l-preserva-mejor-el-%C3%B3rgano%3F 2026-04-13 https://www.oncobites.tv/news/nuevo-enfoque-terap%C3%A9utico-para-el-c%C3%A1ncer-colorrectal-metast%C3%A1sico%3A-resultados-preliminares-del-ensayo-prabitas 2026-04-13 https://www.oncobites.tv/news/trophy-u-01-cohort-2%3A-sacituzumab-govitecan-en-pacientes-con-c%C3%A1ncer-urotelial-metast%C3%A1sico-no-elegibles-para-cisplatino-que-han-progresado-despu%C3%A9s-de-la-terapia-con-inhibidores-de-puntos-de-control-(icis) 2026-04-13 https://www.oncobites.tv/news/destiny-crc02-trastuzumab-deruxtecan-en-pacientes-con-c%C3%A1ncer-colorrectal-avanzado-her2-positivo%3A-resultados-primarios-del-estudio-fase-2 2026-04-13 https://www.oncobites.tv/news/consenso-internacional-establece-nuevas-directrices-para-la-investigaci%C3%B3n-cl%C3%ADnica-en-c%C3%A1ncer-endometrial 2026-04-13 https://www.oncobites.tv/news/la-disecci%C3%B3n-axilar-completa-en-la-identificaci%C3%B3n-de-candidatos-para-abemaciclib-en-c%C3%A1ncer-de-mama-luminal%3A-resultados-del-estudio-senomac 2026-04-13 https://www.oncobites.tv/news/litespark-005-belzutifan-vs.-everolimus-para-c%C3%A1ncer-de-c%C3%A9lulas-renales-avanzado 2026-04-13 https://www.oncobites.tv/news/publicaron-los-resultados-extendidos-de-seguimiento-a-8-a%C3%B1os-del-estudio-checkmate-214-para-c%C3%A1ncer-renal-avanzado 2026-04-13 https://www.oncobites.tv/news/prima%2Fengot-ov26%2Fgog-3012%3A-an%C3%A1lisis-post-hoc-de-la-eficacia-y-seguridad-de-niraparib-en-pacientes-de-65-a%C3%B1os-o-m%C3%A1s-con-c%C3%A1ncer-de-ovario-avanzado 2026-04-13 https://www.oncobites.tv/news/nuevo-estudio-demuestra-eficacia-del-tratamiento-quir%C3%BArgico-en-pacientes-con-c%C3%A1ncer-de-pulm%C3%B3n-en-estadio-temprano 2026-04-13 https://www.oncobites.tv/news/estudio-mozart-revela-la-importancia-de-la-secuenciaci%C3%B3n-gen%C3%B3mica-en-tumores-s%C3%B3lidos-metast%C3%A1sicos 2026-04-13 https://www.oncobites.tv/news/ophelia%3A-olaparib-m%C3%A1s-trastuzumab-en-pacientes-con-c%C3%A1ncer-de-mama-avanzado-her2-positivo-con-mutaciones-germinales-en-brca-1-y-2 2026-04-13 https://www.oncobites.tv/news/estudio-revela-la-variabilidad-del-biomarcador-pd-l1-en-el-adenocarcinoma-gastroesof%C3%A1gico-y-su-impacto-en-el-tratamiento-con-inmunoterapia 2026-04-13 https://www.oncobites.tv/news/nuevos-avances-en-la-estratificaci%C3%B3n-del-c%C3%A1ncer-de-pr%C3%B3stata-con-psma-pet-y-promise 2026-04-13 https://www.oncobites.tv/news/esmo-2024%3A-la-cumbre-mundial-de-la-oncolog%C3%ADa-en-su-edici%C3%B3n-49. 2026-04-13 https://www.oncobites.tv/news/nuevas-recomendaciones-para-el-manejo-del-nsclc-en-estadio-iii 2026-04-13 https://www.oncobites.tv/news/atezolizumab-antes-y-despu%C3%A9s-de-la-quimiorradiaci%C3%B3n-(crt)-para-el-c%C3%A1ncer-de-pulm%C3%B3n-de-c%C3%A9lulas-no-peque%C3%B1as-en-estadio-iii-no-resecable 2026-04-13 https://www.oncobites.tv/news/monarch-3%3A-resultados-finales-de-supervivencia-global-del-estudio-de-abemaciclib-%2B-un-inhibidor-de-aromatasa-no-esteroidal-para-c%C3%A1ncer-de-mama-avanzado-hr%2B%2C-her2%E2%88%92. 2026-04-13 https://www.oncobites.tv/news/la-presencia-de-escherichia-intratumoral-mejora-la-supervivencia-en-c%C3%A1ncer-de-pulm%C3%B3n-de-c%C3%A9lulas-no-peque%C3%B1as 2026-04-13 https://www.oncobites.tv/news/beneficios-de-los-nuevos-serd-orales-en-el-tratamiento-del-c%C3%A1ncer-de-mama-avanzado-resistente-a-la-endocrinoterapia 2026-04-13 https://www.oncobites.tv/news/el-ejercicio-neoadyuvante-muestra-resultados-prometedores-en-el-c%C3%A1ncer-de-pr%C3%B3stata-localizado 2026-04-13 https://www.oncobites.tv/news/analizando-caracter%C3%ADsticas-de-ensayos-sobre-inhibidores-de-cdk4%2F6-y-su-papel-en-la-supervivencia-en-c%C3%A1ncer-de-mama-avanzado 2026-04-13 https://www.oncobites.tv/news/keynote-b10%3A-pembrolizumab-%2B-carboplatino-y-paclitaxel-como-1ra-l%C3%ADnea-de-tratamiento-para-carcinoma-de-c%C3%A9lulas-escamosas-de-cabeza-y-cuello-recurrente%2Fmetast%C3%A1sico-(hnscc-r%2Fm) 2026-04-13 https://www.oncobites.tv/news/efectividad-de-la-terapia-con-linfocitos-infiltrantes-de-tumor-(til-act)-en-melanoma-avanzado%3A-metaan%C3%A1lisis-actualizado 2026-04-13 https://www.oncobites.tv/news/lo-que-se-viene-en-asco-breakthrough-2024-acerca-de-inteligencia-artificial-(ia)-en-oncolog%C3%ADa 2026-04-13 https://www.oncobites.tv/news/la-comunicaci%C3%B3n-familiar-y-las-pruebas-gen%C3%A9ticas-en-supervivientes-de-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/resultados-prometedores-en-el-tratamiento-del-carcinoma-escamoso-de-cabeza-y-cuello-recurrente-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/tratamientos-adyuvantes-en-c%C3%A1ncer-de-ves%C3%ADcula-biliar%3A-nuevas-esperanzas-para-la-supervivencia 2026-04-13 https://www.oncobites.tv/news/peak-e-immunosarc-dos-ensayos-cl%C3%ADnicos-para-el-tratamiento-del-gist-metast%C3%A1sico-y-los-sarcomas%2C-respectivamente%2C-ejecutados-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/%C2%BFqu%C3%A9-se-est%C3%A1-investigando-en-espa%C3%B1a-para-carcinoma-urotelial-y-c%C3%A1ncer-de-pr%C3%B3stata-metast%C3%A1sico%3F 2026-04-13 https://www.oncobites.tv/news/los-ensayos-cl%C3%ADnicos-del-momento-en-espa%C3%B1a-para-c%C3%A1ncer-de-mama-her2%2B-y-her2-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/dos-importantes-ensayos-cl%C3%ADnicos-en-espa%C3%B1a-para-c%C3%A1ncer-de-pulm%C3%B3n-en-la-actualidad 2026-04-13 https://www.oncobites.tv/news/investigaciones-top-en-c%C3%A1ncer-colorrectal-y-pancre%C3%A1tico-metast%C3%A1sico-en-espa%C3%B1a 2026-04-13 https://www.oncobites.tv/news/atempt%3A-trastuzumab-emtansina-adyuvante-vs.-paclitaxel-m%C3%A1s-trastuzumab-para-el-c%C3%A1ncer-de-mama-estadio-i-her2%2B%2C-resultados-a-5-a%C3%B1os-y-an%C3%A1lisis-correlativos. 2026-04-13 https://www.oncobites.tv/news/innovatv-301%3A-tisotumab-vedotin-como-terapia-de-segunda-o-tercera-l%C3%ADnea-para-el-c%C3%A1ncer-cervical-recurrente 2026-04-13 https://www.oncobites.tv/news/relevant%3A-eficacia-y-seguridad-de-ramucirumab-m%C3%A1s-carboplatino-y-paclitaxel-en-carcinoma-t%C3%ADmico-metast%C3%A1sico-no-tratado 2026-04-13 https://www.oncobites.tv/news/mariposa%3A-amivantamab-m%C3%A1s-lazertinib-en-nsclc-avanzado-con-mutaci%C3%B3n-egfr-previamente-no-tratado 2026-04-13 https://www.oncobites.tv/news/pet%2Fct-con-fluorina-18-vs-rm%3A-%C2%BFcu%C3%A1l-es-la-mejor-para-la-estadificaci%C3%B3n-del-c%C3%A1ncer-de-pr%C3%B3stata%3F 2026-04-13 https://www.oncobites.tv/news/estudios-que-modifican-la-pr%C3%A1ctica-en-tumores-ginecol%C3%B3gicos 2026-04-13 https://www.oncobites.tv/news/ruby-el-estudio-del-congreso 2026-04-13 https://www.oncobites.tv/news/nuevos-targets-y-nuevos-medicamentos-en-tumores-colorrectales 2026-04-13 https://www.oncobites.tv/news/modular-el-microbioma-ayudar-a-mejorar-los-resultados-del-tratamiento-del-c%C3%A1ncer-de-colon 2026-04-13 https://www.oncobites.tv/news/aio-ikf-038%2Fpolestar%3A-iparp-%2B-inhibidor-de-pd-1-como-opci%C3%B3n-de-tratamiento-de-adenocarcinomas-esofagog%C3%A1stricos-her2- 2026-04-13 https://www.oncobites.tv/news/bevacizumab-o-anticuerpos-monoclonales-anti-egfr-para-las-met%C3%A1stasis-hep%C3%A1ticas-de-c%C3%A1ncer-colorrectal-no-resecable-en-el-lado-izquierdo 2026-04-13 https://www.oncobites.tv/news/adyuvancia-o-neoadyuvancia-en-el-tratamiento-del-c%C3%A1ncer-de-colon-estadio-iii 2026-04-13 https://www.oncobites.tv/news/revisi%C3%B3n-y-manejo-de-lesiones-precancerosa-en-p%C3%A1ncreas 2026-04-13 https://www.oncobites.tv/news/comienza-la-primera-edici%C3%B3n-de-esmo-gastrointestinal-cancer-congress 2026-04-13 https://www.oncobites.tv/news/los-receptores-target-para-anticuerpos-conjugado-f%C3%A1rmaco-en-el-c%C3%A1ncer-cervical 2026-04-13 https://www.oncobites.tv/news/nueva-clasificaci%C3%B3n-del-c%C3%A1ncer-endometrial-por-la-figo 2026-04-13 https://www.oncobites.tv/news/eficacia-y-seguridad-de-tislelizumab-combinado-con-quimiorradioterapia-(qrt)-concurrente-para-el-c%C3%A1ncer-de-cuello-uterino-localmente-avanzado-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/tratamiento-de-primera-l%C3%ADnea-en-el-c%C3%A1ncer-de-endometrio-(ce)-seg%C3%BAn-la-clasificaci%C3%B3n-molecular 2026-04-13 https://www.oncobites.tv/news/nuevos-agentes-y-combinaciones-en-c%C3%A1ncer-de-ovario 2026-04-13 https://www.oncobites.tv/news/una-herramienta-para-los-onc%C3%B3logos-con-informaci%C3%B3n-sobre-diagn%C3%B3stico-y-tratamiento-a-revelar-a-los-pacientes-con-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/resultados-de-la-actividad-de-la-red-euracan%2C-que-apoya-a-las-pacientes-con-tumores-ginecol%C3%B3gicos-raros 2026-04-13 https://www.oncobites.tv/news/personalizaci%C3%B3n-del-tratamiento-en-c%C3%A1ncer-de-pulm%C3%B3n-con-adn-tumoral-circulante-(ctdna) 2026-04-13 https://www.oncobites.tv/news/asco2024-dos-estudios-cuyos-resultados-cambian-el-est%C3%A1ndar-de-tratamiento 2026-04-13 https://www.oncobites.tv/news/checkmate-9dw-el-estudio-esperado-para-c%C3%A1ncer-hepatocelular-en-asco2024 2026-04-13 https://www.oncobites.tv/news/el-crown-resultados-a-5-a%C3%B1os%2C-el-estudio-de-asco2024 2026-04-13 https://www.oncobites.tv/news/el-destiny-breast06-(db-06)-el-estudio-top-de-asco2024 2026-04-13 https://www.oncobites.tv/news/la-terapia-neoadyuvante-con-nivolumab-%2B-ipilimumab-en-el-melanoma-estadio-iii-resecable-del-nadina%2C-el-estudio-estrella-de-otros-tumores-en-asco2024 2026-04-13 https://www.oncobites.tv/news/esmo-gineco%2C-es-nuestro-siguiente-congreso 2026-04-13 https://www.oncobites.tv/news/armani%3A-ramucirumab-m%C3%A1s-paclitaxel-como-terapia-de-mantenimiento-vs.-continuaci%C3%B3n-de-quimioterapia-de-oxaliplatino-en-pacientes-con-c%C3%A1ncer-gastroesof%C3%A1gico-(gej)-o-g%C3%A1strico-her2-negativo-avanzado 2026-04-13 https://www.oncobites.tv/news/adriatic%3A-primero-resultados-de-durvalumab-como-tratamiento-de-consolidaci%C3%B3n-para-pacientes-con-c%C3%A1ncer-de-c%C3%A9lula-peque%C3%B1a-localizado-(ls-sclc) 2026-04-13 https://www.oncobites.tv/news/asco2024-un-pincelazo-de-estudios-uroteliales 2026-04-13 https://www.oncobites.tv/news/asco2024-melanoma-y-c%C3%A1ncer-de-piel-protagonistas-en-el-congreso 2026-04-13 https://www.oncobites.tv/news/asco2024-resultados-innovadores-en-el-tratamiento-del-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/explorando-la-evidencia-cient%C3%ADfica-de-esmo-breast2-con-el-abanico-de-posibilidades-de-tratamiento-para-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/a-d%C3%ADas-de-asco-2024 2026-04-13 https://www.oncobites.tv/news/el-estudio-relevante-de-esmo-breast24 2026-04-13 https://www.oncobites.tv/news/esmo-breast24-navegando-las-complejidades-del-tratamiento-del-c%C3%A1ncer-de-mama-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/federica%3A-combinaci%C3%B3n-de-dosis-fija-de-pertuzumab-y-trastuzumab-para-inyecci%C3%B3n-subcut%C3%A1nea-m%C3%A1s-quimioterapia-en-c%C3%A1ncer-de-mama-temprano-her2-positivo-(neo)adjuvante 2026-04-13 https://www.oncobites.tv/news/estrategias-de-tratamiento-actuales-y-futuras-despu%C3%A9s-de-los-inhibidores-cdk4%2F6-para-pacientes-con-c%C3%A1ncer-de-mama-avanzado-er%2B%2Fher2-. 2026-04-13 https://www.oncobites.tv/news/seguridad-de-las-t%C3%A9cnicas-de-reproducci%C3%B3n-asistida-en-mujeres-j%C3%B3venes-portadoras-de-brca-con-un-embarazo-despu%C3%A9s-de-c%C3%A1ncer-de-mama%3A-resultados-de-un-estudio-de-cohorte-internacional 2026-04-13 https://www.oncobites.tv/news/elacestrant-en-la-pr%C3%A1ctica.-la-fda-aprob%C3%B3-este-medicamento-para-tratar-el-c%C3%A1ncer-de-mama-her2-rh%2B%2C-mutado-esr1 2026-04-13 https://www.oncobites.tv/news/resultados-de-supervivencia-global-del-estudio-monarch3 2026-04-13 https://www.oncobites.tv/news/tide-a%3A-avelumab-m%C3%A1s-axitinib-intermitente-en-pacientes-previamente-no-tratados-con-carcinoma-de-c%C3%A9lulas-renales-metast%C3%A1sico-(ccrm) 2026-04-13 https://www.oncobites.tv/news/perspectivas-actuales-en-terapia%3A-encorafenib-y-binimetinib-en-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-braf-v600e 2026-04-13 https://www.oncobites.tv/news/cabozantinib-como-monoterapia-para-el-carcinoma-adrenocortical-avanzado 2026-04-13 https://www.oncobites.tv/news/etop-(european-thoracic-oncology-platform)-y-ibcsg-(international-breast-cancer-study-group)-dan-una-perspectiva-del-auge-de-los-conjugados-anticuerpo-f%C3%A1rmaco-(adcs) 2026-04-13 https://www.oncobites.tv/news/desarrollo-y-validaci%C3%B3n-de-un-nuevo-modelo-para-predecir-supervivencia-de-melanoma-tras-la-biopsia-del-ganglio-linf%C3%A1tico-centinela 2026-04-13 https://www.oncobites.tv/news/asociaci%C3%B3n-entre-infiltraci%C3%B3n-de-c%C3%A9lulas-b-y-resultados-de-supervivencia-en-carcinoma-de-c%C3%A9lulas-escamosas-de-cabeza-y-cuello-tras-la-inhibici%C3%B3n-de-pd-1 2026-04-13 https://www.oncobites.tv/news/actualizaci%C3%B3n-de-la-supervivencia-global-a-cuatro-a%C3%B1os-del-estudio-himalaya-en-carcinoma-hepatocelular 2026-04-13 https://www.oncobites.tv/news/destiny-lung01%3A-trastuzumab-deruxtecan-en-pacientes-con-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-metast%C3%A1sico%2C-resultados-principales-de-las-cohortes-con-sobreexpresi%C3%B3n-de-her2 2026-04-13 https://www.oncobites.tv/news/amplificaci%C3%B3n-de-nectin4%3A-predictor-de-respuesta-al-enfortumab-vedotin-en-c%C3%A1ncer-urotelial-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/segunda-l%C3%ADnea-de-tratamiento-en-c%C3%A1nceres-de-v%C3%ADas-biliares%3A-evidencia-de-folfox 2026-04-13 https://www.oncobites.tv/news/gog238%3A-terapia-de-radiaci%C3%B3n-con-o-sin-cisplatino-para-recurrencias-locales-del-c%C3%A1ncer-de-endometrio 2026-04-13 https://www.oncobites.tv/news/incipient%3A-c%C3%A9lulas-carv3-team-e-intraventriculares-en-glioblastoma-recurrente 2026-04-13 https://www.oncobites.tv/news/luces-y-sombras-del-pron%C3%B3stico-con-la-terapia-177lu-psma-para-c%C3%A1ncer-de-pr%C3%B3stata 2026-04-13 https://www.oncobites.tv/news/keynote-564%3A-supervivencia-global-con-pembrolizumab-adyuvante-en-el-carcinoma-de-c%C3%A9lulas-renales 2026-04-13 https://www.oncobites.tv/news/algunos-beneficios-cl%C3%ADnicos-para-mujeres-con-una-met%C3%A1stasis-extracraneal-solitaria-de-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/estudio-cl%C3%ADnico-verifica-relugolix-como-una-opci%C3%B3n-segura-en-el-tratamiento-del-c%C3%A1ncer-de-pr%C3%B3stata-(cp) 2026-04-13 https://www.oncobites.tv/news/prodige-59-ffcd-1707-durigast%3A-folfiri-%2B-durvalumab-con-o-sin-tremelimumab-en-el-tratamiento-de-2-l-del-adenocarcinoma-g%C3%A1strico-o-de-la-uni%C3%B3n-gastroesof%C3%A1gica-avanzado 2026-04-13 https://www.oncobites.tv/news/elcc24-realec%3A-an%C3%A1lisis-interino-del-estudio-observacional-para-evaluar-el-manejo-cl%C3%ADnico-del-mundo-real-y-los-resultados-de-pacientes-con-nsclc-alk%2B-avanzado%2C-tratados-con-alectinib 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma%26raras24-estudio-pm1183-a-014-15%3A-lurbinectedina-m%C3%A1s-irinotec%C3%A1n-en-carcinomas-neuroendocrinos-gastroenteropancre%C3%A1ticos-(gep-necs)-pretratados 2026-04-13 https://www.oncobites.tv/news/elcc24-revelaron-datos-a-largo-plazo-del-estudio-convert-para-c%C3%A1ncer-de-pulm%C3%B3n-de-c%C3%A9lula-no-peque%C3%B1a-limitado 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma%26raras24-c%C3%A1ncer-de-paratiroides%2C-una-revisi%C3%B3n-del-abordaje 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma%26raras24-combinaciones-con-inhibidores-de-mdm2-en-sarcoma 2026-04-13 https://www.oncobites.tv/news/elcc24-m%C3%A1s-all%C3%A1-de-g12c%2C-hay-otras-mutaciones-ras%2Fraf-en-el-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico 2026-04-13 https://www.oncobites.tv/news/elcc24-opciones-de-inmunoterapia-y-terapia-dirigida-para-met%C3%A1stasis-cerebrales-de-cpnm. 2026-04-13 https://www.oncobites.tv/news/elcc24-etop-abc-lung%3A-atezolizumab-m%C3%A1s-bevacizumab-y-quimioterapia-en-el-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-(cpnm)-con-mutaci%C3%B3n-del-egfr-adquirida%2C-resultados-finales. 2026-04-13 https://www.oncobites.tv/news/elcc24-herthena-lung01%2C-resultados-actualizados-de-seguridad-del-patritumab-deruxtecan-(her3-dxd)-en-pacientes-previamente-tratados-con-cpnm-avanzado-mutado-en-egfr 2026-04-13 https://www.oncobites.tv/news/elcc24-consideraciones-de-seguridad-en-conjugados-anticuerpo-f%C3%A1rmaco-(adcs) 2026-04-13 https://www.oncobites.tv/news/ascogi24%3A-nuevos-horizontes-en-la-radioterapia-(rt)-del-c%C3%A1ncer-de-p%C3%A1ncreas-(cp) 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-las-mejores-publicaciones-en-c%C3%A1ncer-de-pr%C3%B3stata-(cp)-durante-el-2023 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma24-una-serie-de-casos-retrospectiva-en-un-centro-de-buenos-aires-sobre-sarcoma-de-ewing-del-sistema-nervioso-central-extra%C3%B3seo 2026-04-13 https://www.oncobites.tv/news/esmosarcoma24-cempen%3A-primer-tratamiento-con-cemiplimab-en-carcinoma-de-c%C3%A9lulas-escamosas-metast%C3%A1sico-de-pene 2026-04-13 https://www.oncobites.tv/news/el-estudio-top-del-ascogi24%3A-el-codebreak-300 2026-04-13 https://www.oncobites.tv/news/esmosarcoma24%3A-cemangio%3A-tratamiento-con-cemiplimab-en-pacientes-con-angiosarcomas-secundarios-localmente-avanzados-y-metast%C3%A1sicos 2026-04-13 https://www.oncobites.tv/news/keynote-b61%3A-pembrolizumab-m%C3%A1s-lenvatinib-como-tratamiento-de-primera-l%C3%ADnea-para-el-carcinoma-de-c%C3%A9lulas-renales-avanzado-de-c%C3%A9lulas-no-claras%2C-ensayo-de-fase-2%2C-multic%C3%A9ntrico-y-de-un-solo-brazo 2026-04-13 https://www.oncobites.tv/news/adelantos-en-el-tratamiento-del-dolor-y-la-fibrosis-en-sobrevivientes-de-c%C3%A1ncer-de-mama-(cm)-con-terapia-de-ox%C3%ADgeno-hiperb%C3%A1rico-(hbot) 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-%C2%BFqu%C3%A9-hacer-en-los-pacientes-con-c%C3%A1ncer-de-pr%C3%B3stata-resistente-a-la-castraci%C3%B3n-en-fase-temprana-que-han-recibido-doble-o-triple-terapia%3F 2026-04-13 https://www.oncobites.tv/news/arneo%3A-degarelix-neoadyuvante%2C-con-o-sin-apalutamida%2C-antes-de-la-prostatectom%C3%ADa-radical-(pr)-para-el-c%C3%A1ncer-de-pr%C3%B3stata-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/%C2%A1%C3%BAnete-y-pon-en-pr%C3%A1ctica-tu-compromiso-con-el-ejercicio!-participa-en-la-ii-carrera-marcha-de-la-seom 2026-04-13 https://www.oncobites.tv/news/prospect%3A-tratamiento-preoperatorio-del-c%C3%A1ncer-rectal-localmente-avanzado 2026-04-13 https://www.oncobites.tv/news/gastripec-i%3A-ensayo-fase-iii-que-eval%C3%BAa-el-efecto-de-la-quimioterapia-intraperitoneal-hipert%C3%A9rmica-(hipec)-en-la-cirug%C3%ADa-citorreductora-(crs)-en-el-c%C3%A1ncer-g%C3%A1strico-(cg)-con-met%C3%A1stasis-peritoneales-sincr%C3%B3nicas-(mps) 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-resultados-de-an%C3%A1lisis-de-subgrupos-de-ev-302%2C-enfortumab-vedotin-(ev)-en-combinaci%C3%B3n-con-pembrolizumab-(p)-frente-a-quimioterapia-(qt)-en-carcinoma-urotelial-metast%C3%A1sico-localmente-avanzado-no-tratado-previamente(la%2Fmuc) 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-rol-de-la-radiaci%C3%B3n-en-el-manejo-del-carcinoma-de-c%C3%A9lulas-renales-(ccr) 2026-04-13 https://www.oncobites.tv/news/elcc24-camel%3A-resultados-a-5-a%C3%B1os-del-estudio-de-fase-3-de-camrelizumab-(camre)-en-1l-con-carboplatino-(carbo)-y-pemetrexed-(pem)-para-el-nsclc-no-escamoso-avanzado 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-desescalaci%C3%B3n-en-c%C3%A1ncer-de-pr%C3%B3stata-(cp)%2C-%C2%BFse-puede-mantener-la-eficacia-en-con-menos-toxicidad%3F 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-el-carcinoma-urotelial-y-sus-estudios-cl%C3%ADnicos-en-terapia-farmacol%C3%B3gica-en-el-2023 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-manejo-multidisciplinario-de-tumores-neuroendocrinos-(tne)-de-c%C3%A9lulas-peque%C3%B1as 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-rol-de-la-inmunoterapia-en-el-carcinoma-urotelial-(cu) 2026-04-13 https://www.oncobites.tv/news/elcc24-inhibidores-de-krasg12c%3A-resultados-cl%C3%ADnicos-y-del-mundo-real-en-el-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-avanzado 2026-04-13 https://www.oncobites.tv/news/la-evidencia-de-los-resultados-de-eficacia-del-estudio-papillon-lo-posiciona-como-nuevo-est%C3%A1ndar 2026-04-13 https://www.oncobites.tv/news/elcc24-%C2%BFtiene-la-biopsia-l%C3%ADquida-un-papel-en-el-monitoreo-de-la-terapia-adyuvante%3F-pros-y-contras 2026-04-13 https://www.oncobites.tv/news/el-estudio-a-resaltar-del-elcc2024%3A-el-pacific-2 2026-04-13 https://www.oncobites.tv/news/elcc24-aspectos-a-tener-en-cuenta-en-el-tratamiento-de-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-nsclc)-en-estadio-i%3A-cirug%C3%ADa-vs.-sbrt-y-terapia-adyuvante 2026-04-13 https://www.oncobites.tv/news/elcc24-evoke-02-sacituzumab-govitecan-%2B-pembrolizumab-en-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-metast%C3%A1sico-(nsclc)-de-1l%2C-resultados-de-eficacia-por-histolog%C3%ADa 2026-04-13 https://www.oncobites.tv/news/elcc24-conjugados-anticuerpo-f%C3%A1rmaco-(adcs)-en-desarrollo%3A-%C2%BFqui%C3%A9n-puede-beneficiarse%3F 2026-04-13 https://www.oncobites.tv/news/elcc24-estrategias-terap%C3%A9uticas-avanzadas-en-el-cuidado-del-c%C3%A1ncer-de-pulm%C3%B3n%3A-enfoque-en-engagers-de-c%C3%A9lulas-t-contra-dll3 2026-04-13 https://www.oncobites.tv/news/elcc24-tropion-lung01%3A-datopotamab-deruxtecan-(dato-dxd)-en-pacientes-con-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-(nsclc)-avanzado%2C-previamente-tratados%2C-con-histolog%C3%ADa-no-escamosa-(nsq) 2026-04-13 https://www.oncobites.tv/news/%C2%BFse-deber%C3%ADa-irradiar-un-c%C3%A1ncer-de-cabeza-y-cuello-escamoso-resecado-cccer%3F 2026-04-13 https://www.oncobites.tv/news/factores-que-afectan-la-supervivencia-en-el-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma%26raras24-an%C3%A1lisis-post-hoc-del-estudio-defi%2C-efecto-de-nirogacestat-en-la-calidad-de-vida-de-pacientes-con-tumores-desmoides 2026-04-13 https://www.oncobites.tv/news/ascogi24%3A-avances-farmacol%C3%B3gicos-en-el-tratamiento-del-c%C3%A1ncer-de-tracto-biliar-(ctb) 2026-04-13 https://www.oncobites.tv/news/entrevista-a-ignasi-belda%2C-ceo-de-miwendo 2026-04-13 https://www.oncobites.tv/news/ttfields-(tumor-treating-fields)%2C-innovando-el-tratamiento-del-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/%C2%BFse-deber%C3%ADa-usar-resonancia-magn%C3%A9tica-junto-con-la-tomograf%C3%ADa-en-pacientes-con-met%C3%A1stasis-hep%C3%A1ticas-por-c%C3%A1ncer-colorrectal%3F 2026-04-13 https://www.oncobites.tv/news/ascogi24-controversias-en-el-tamizaje-del-c%C3%A1ncer-colorrectal-(ccr)%3A-eficacia-frente-a-efectividad-seg%C3%BAn-las-modalidades 2026-04-13 https://www.oncobites.tv/news/investigadora-premiada-por-un-estudio-sobre-vih-y-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/sycai%2C-asistente-m%C3%A9dico-que-ayuda-a-los-radi%C3%B3logos-a-detectar-lesiones-qu%C3%ADsticas-pancre%C3%A1ticas 2026-04-13 https://www.oncobites.tv/news/sunlight%3A-trifluridina-tipiracilo-y-bevacizumab-en-c%C3%A1ncer-colorrectal-metast%C3%A1sico-refractario 2026-04-13 https://www.oncobites.tv/news/%C2%BFes-el-adn-circulante-tumoral-(ctdna)-un-ajuste-perfecto-para-el-c%C3%A1ncer%3F 2026-04-13 https://www.oncobites.tv/news/el-estudio-de-evidencia-real-betas-confirma-la-data-del-ensayo-cl%C3%ADnico-sunlight 2026-04-13 https://www.oncobites.tv/news/ojo-con-el-h.-pylori-porque-afecta-la-respuesta-de-la-inmunoterapia-en-el-c%C3%A1ncer-g%C3%A1strico 2026-04-13 https://www.oncobites.tv/news/ascogi24-intersecciones%3A-tratamiento-de-la-enfermedad-oligometast%C3%A1sica 2026-04-13 https://www.oncobites.tv/news/%C2%A1esmo-pocket-guidelines-desktop%2Fapp-est%C3%A1-listo-para-ser-usado! 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma%26raras24-carcinoma-nut-una-es-rara-neoplasia-maligna%2C-mal-diagnosticada 2026-04-13 https://www.oncobites.tv/news/ascogi24-el-papel-emergente-de-la-inteligencia-artificial-(ia)-y-el-aprendizaje-autom%C3%A1tico-en-la-atenci%C3%B3n-cl%C3%ADnica 2026-04-13 https://www.oncobites.tv/news/las-caracter%C3%ADsticas-del-c%C3%A1ncer-en-2023 2026-04-13 https://www.oncobites.tv/news/revolucionc-estos-son-los-nuevos-est%C3%A1ndares-de-tratamiento-expuestos-en-ascogu-2024 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-optimizaci%C3%B3n-de-estrategias-de-tratamiento-para-pacientes-con-ganglios-linf%C3%A1ticos-p%C3%A9lvicos%2Fretroperitoneales-positivos 2026-04-13 https://www.oncobites.tv/news/tropion-breast01%3A-datopotamab-deruxtecan-(dato-dxd)-frente-a-quimioterapia-en-c%C3%A1ncer-de-mama-(cm)-irresecable-o-metast%C3%A1sico-con-hr%2B%2Fher2-previamente-tratado 2026-04-13 https://www.oncobites.tv/news/el-arte-y-la-ciencia-de-la-inmunoterapia-neoadyuvante-en-c%C3%A1ncer-hep%C3%A1tico 2026-04-13 https://www.oncobites.tv/news/conoce-el-consenso-esmo-sobre-c%C3%A1ncer-de-mama-her2-bajo 2026-04-13 https://www.oncobites.tv/news/prep%C3%A1rese-para-el-seminario-web-gen%C3%B3mica-y-medicina-de-precisi%C3%B3n 2026-04-13 https://www.oncobites.tv/news/inmersi%C3%B3n-en-el-mundo-de-la-oncolog%C3%ADa%2C-oportunidades-para-estudiantes-de-medicina 2026-04-13 https://www.oncobites.tv/news/m%C3%A1s-all%C3%A1-del-c%C3%A1ncer-de-mama%2C-los-f%C3%A1rmacos-inmunoconjugados-abren-puertas-en-otros-tumores. 2026-04-13 https://www.oncobites.tv/news/ascogi24%3A-doc-gc-compara-la-eficacia-de-docetaxel-oxaliplatino-capecitabina%2F5-fluorouracilo-(doc%2Ff)-seguido-de-docetaxel-vs-capox%2Fmfolfox-7-en-c%C3%A1nceres-g%C3%A1stricos-avanzados 2026-04-13 https://www.oncobites.tv/news/atomic-meso%3A-ensayo-cl%C3%ADnico-que-evalu%C3%B3-la-eficacia-de-la-pegargiminasa-m%C3%A1s-quimioterapia-(qt)-de-primera-l%C3%ADnea-en-pacientes-con-mesotelioma-pleural-no-epitelioide-(mpne) 2026-04-13 https://www.oncobites.tv/news/%C2%BFcu%C3%A1l-es-el-papel-de-la-fracci%C3%B3n-tumoral-del-adn-circulante-en-carcinoma-urotelial-avanzado%3F 2026-04-13 https://www.oncobites.tv/news/checkmate-816%3A-validaci%C3%B3n-de-eficacia-de-la-inmunoterapia-en-c%C3%A1ncer-de-pulm%C3%B3n-resecable 2026-04-13 https://www.oncobites.tv/news/descifrando-la-respuesta-inmunol%C3%B3gica-en-c%C3%A1ncer-de-ri%C3%B1%C3%B3n 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-las-mejores-publicaciones-de-tratamiento-de-escalaci%C3%B3n-en-c%C3%A1ncer-de-pr%C3%B3stata-(cp)-durante-el-2023 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma%26raras24-optimizando-el-tratamiento-del-glioblastoma-de-alto-grado%3A-un-an%C3%A1lisis-detallado-de-la-terapia-con-temozolomida-(tmz)-est%C3%A1ndar-vs-prolongada 2026-04-13 https://www.oncobites.tv/news/estrategias-innovadoras-en-carcinoma-de-c%C3%A9lulas-renales-(ccr)%2C-la-inmunoterapia-antes-de-la-nefrectom%C3%ADa 2026-04-13 https://www.oncobites.tv/news/resultados-a-5-a%C3%B1os-del-monarche%3A-abemaciclib-y-terapia-endocrina-(te)-para-el-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/papillon%3A-amivantamab-m%C3%A1s-quimioterapia-en-cpnm-con-inserciones-del-ex%C3%B3n-20-del-egfr 2026-04-13 https://www.oncobites.tv/news/cambio-en-las-recomendaciones-de-mamograf%C3%ADa-sigue-generando-controversia 2026-04-13 https://www.oncobites.tv/news/a-tu-alcance-la-nueva-versi%C3%B3n-de-las-gu%C3%ADas-terap%C3%A9uticas-para-c%C3%A1ncer-de-pulm%C3%B3n-de-c%C3%A9lula-peque%C3%B1a-(cpcp)-asco-ontario-health 2026-04-13 https://www.oncobites.tv/news/ema-aprueba-retifanlimab-para-el-tratamiento-del-carcinoma-de-c%C3%A9lulas-de-merkel-(ccm) 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-estudian-la-prote%C3%ADna-trop-2-como-opci%C3%B3n-novedosa-para-diagn%C3%B3stico-y-tratamiento-del-carcinoma-escamoso-de-pene-(cep) 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma24-capmatinib-en-astrocitoma-con-mutaci%C3%B3n-met%2C-presentaci%C3%B3n-de-un-caso 2026-04-13 https://www.oncobites.tv/news/la-mamograf%C3%ADa-en-mujeres-mayores-y-su-desaf%C3%ADo-en-el-sobrediagn%C3%B3stico-de-c%C3%A1ncer-de-mama 2026-04-13 https://www.oncobites.tv/news/ascgogu24%3A-perspectivas-rurales-y-urbanas-en-pacientes-con-c%C3%A1ncer-de-vejiga 2026-04-13 https://www.oncobites.tv/news/se-est%C3%A1n-investigando-los-biomarcadores-en-la-sangre-que-podr%C3%ADan-ser-utilizados-para-anticipar-el-desarrollo-del-c%C3%A1ncer-de-p%C3%A1ncreas. 2026-04-13 https://www.oncobites.tv/news/%C2%A1atenci%C3%B3n!%2C-gu%C3%ADas-asco-para-el-manejo-de-los-tumores-neuroendocrinos-(tne)-est%C3%A1n-listas 2026-04-13 https://www.oncobites.tv/news/%C2%BFes-viable-atacar-el-tgf-%CE%B2-para-tratar-c%C3%A1nceres-gastrointestinales%3F 2026-04-13 https://www.oncobites.tv/news/%C2%BFest%C3%A1n-las-pruebas-de-la-l%C3%ADnea-germinal-al-alcance-de-todos%3F 2026-04-13 https://www.oncobites.tv/news/conozca-las-recomendaciones-de-asco-para-evaluar-la-funci%C3%B3n-ov%C3%A1rica-en-ensayos-cl%C3%ADnicos 2026-04-13 https://www.oncobites.tv/news/calidad-de-vida-en-sobrevivientes-de-c%C3%A1ncer-de-test%C3%ADculo-(ct)%3A-estudio-a-largo-plazo 2026-04-13 https://www.oncobites.tv/news/estudio-revela-la-respuesta-inmunol%C3%B3gica-con-la-vacuna-covid-19-en-pacientes-con-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/gate2brain%2C-m%C3%A1s-all%C3%A1-de-las-barreras 2026-04-13 https://www.oncobites.tv/news/%C2%A1alerta-cient%C3%ADfica!-la-esmo-lanza-dos-nuevas-revistas-cient%C3%ADficas 2026-04-13 https://www.oncobites.tv/news/sabcs23-menos-mamograf%C3%ADas%2C-misma-seguridad 2026-04-13 https://www.oncobites.tv/news/seom-2023%2C-un-congreso-comprometido-con-las-tendencias-y-la-calidad-de-vida 2026-04-13 https://www.oncobites.tv/news/trialing-te-encuentra-el-estudio-cl%C3%ADnico-para-tu-paciente 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-%C2%BFse-deber%C3%ADa-renombrar-el-c%C3%A1ncer-de-pr%C3%B3stata-(cp)-grupo-1%2C-gleason-6%3F 2026-04-13 https://www.oncobites.tv/news/destiny-pantumor02%3A-resultados-primarios-de-eficacia-y-seguridad-de-trastuzumab-deruxtecan-en-pacientes-con-tumores-s%C3%B3lidos-que-expresan-her2 2026-04-13 https://www.oncobites.tv/news/una-luz-en-el-tratamiento-del-colangiocarcinoma-intrahep%C3%A1tico-(ccih) 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-avances-emergentes-en-c%C3%A1ncer-de-pr%C3%B3stata-(cp)%3A-una-actualizaci%C3%B3n-integral 2026-04-13 https://www.oncobites.tv/news/decodificando-el-c%C3%A1ncer-de-ovario%3A-consenso-en-patolog%C3%ADa%2C-biolog%C3%ADa-molecular-y-manejo-cl%C3%ADnico 2026-04-13 https://www.oncobites.tv/news/imadgist-el-estudio-estrella-de-esmo-sarcoma-y-raras-2024 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma24-abacus%3A-acetato-de-abiraterona-en-el-manejo-del-s%C3%ADndrome-de-cushing-asociado-al-carcinoma-adrenocortical 2026-04-13 https://www.oncobites.tv/news/relaci%C3%B3n-entre-caracter%C3%ADsticas-del-adenocarcinoma-esof%C3%A1gico%2C-fenotipo-y-terapia 2026-04-13 https://www.oncobites.tv/news/singapur-este-2023-es-el-epicentro-de-los-expertos-en-c%C3%A1ncer-de-pulm%C3%B3n. 2026-04-13 https://www.oncobites.tv/news/mejorando-las-pautas-de-tratamiento-para-el-carcinoma-hepatocelular. 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-cada-dos-d%C3%ADas-o-una-vez-a-la-semana%3A-resultados-de-eficacia-a-largo-plazo-del-ensayo-multic%C3%A9ntrico-aleatorizado-de-sbrt-de-pr%C3%B3stata-patriot 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma%26raras24-una-selecci%C3%B3n-de-estudios-random-del-congreso 2026-04-13 https://www.oncobites.tv/news/intrigue%3A-ripretinib-versus-sunitinib-en-el-tumor-del-estroma-gastrointestinal-(tegi) 2026-04-13 https://www.oncobites.tv/news/secuencia-%C3%B3ptima-de-tratamiento-en-el-c%C3%A1ncer-de-mama-metast%C3%A1sico-(cmm)-en-2023 2026-04-13 https://www.oncobites.tv/news/sabcs23%3A-estudio-idea-proporciona-informaci%C3%B3n-relevante-en-el-tratamiento-de-c%C3%A1ncer-de-mama-en-etapa-temprana 2026-04-13 https://www.oncobites.tv/news/actualizaci%C3%B3n-r%C3%A1pida-de-las-gu%C3%ADas-de-manejo-asco-para-c%C3%A1ncer-renal-metast%C3%A1sico-de-c%C3%A9lulas-claras-(crmcc) 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma%26raras24-as%C3%AD-sea-una-enfermedad-rara-no-hay-que-olvidar-al-c%C3%A1ncer-escamoso-de-recto 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-estudios-de-terapia-farmacol%C3%B3gica-que-marcaron-la-diferencia-en-el-2023-sobre-c%C3%A1ncer-de-c%C3%A9lulas-renales-(ccr) 2026-04-13 https://www.oncobites.tv/news/%C2%A1contando-los-d%C3%ADas!-esmo-madrid-2023%2C-el-evento-europeo-oncol%C3%B3gico-del-a%C3%B1o 2026-04-13 https://www.oncobites.tv/news/controversias-y-recomendaciones-en-el-tratamiento-neoadyuvante-del-c%C3%A1ncer-de-es%C3%B3fago-(ce)-y-del-adenocarcinoma-de-la-uni%C3%B3n-gastroesof%C3%A1gica-(acuge) 2026-04-13 https://www.oncobites.tv/news/mariposa-2%3A-amivantamab-y-lazertinib-muestran-beneficios-sin%C3%A9rgicos-en-pacientes-resistentes-a-osimertinib 2026-04-13 https://www.oncobites.tv/news/disparidades-en-c%C3%A1ncer-de-pr%C3%B3stata%3A-hombres-negros-en-la-mira 2026-04-13 https://www.oncobites.tv/news/el-estudio-estrella-de-asgogu24%3A-el-embark 2026-04-13 https://www.oncobites.tv/news/aprenda-los-criterios-de-evaluaci%C3%B3n-de-respuesta-de-la-biopsia-l%C3%ADquida-(bl)-en-tumores-s%C3%B3lidos-(lb-recist) 2026-04-13 https://www.oncobites.tv/news/tbcr043%3A-atezolizumab-en-combinaci%C3%B3n-con-carboplatino-y-desenlaces-de-supervivencia-en-pacientes-con-c%C3%A1ncer-de-mama-triple-negativo-(cmtn) 2026-04-13 https://www.oncobites.tv/news/explorando-la-resistencia-adquirida-y-supervivencia-a-los-inhibidores-de-la-tirosina-quinasa-en-el-c%C3%A1ncer-pulmonar-no-microc%C3%ADtico-(cpnm)-para-alk 2026-04-13 https://www.oncobites.tv/news/modelo-innovador-para-pron%C3%B3stico-en-adenocarcinoma-micropapilar-pulmonar 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-an%C3%A1lisis-interino-del-anticipate-en-pacientes-con-c%C3%A1ncer-de-vejiga-invasivo-a-m%C3%BAsculo-(mibc) 2026-04-13 https://www.oncobites.tv/news/carcinoma-de-vulva-(cv)%2C-conoce-sus-tratamientos-y-perspectivas 2026-04-13 https://www.oncobites.tv/news/e-learning-en-c%C3%A1ncer-de-pr%C3%B3stata-avanzado%3A-actualizaci%C3%B3n-de-terapias-y-estrategias-diagn%C3%B3sticas 2026-04-13 https://www.oncobites.tv/news/una-nueva-terapia-promete-seguridad-y-eficacia-para-tratar-el-hepatocarcinoma-(hc)-que-recae-despu%C3%A9s-de-1ra-l%C3%ADnea-con-atezolizumab%2Fbevacizumab 2026-04-13 https://www.oncobites.tv/news/asco-comparte-estrategias-cl%C3%ADnicas-para-salud-sexual-en-sobrevivientes-de-c%C3%A1ncer 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-la-escasez-de-medicamentos-para-el-carcinoma-urotelial-(cu)%3A-%C2%BFqu%C3%A9-hacer-al-respecto%3F 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-tivozanib-(tivo)-en-el-actual-panorama-del-tratamiento-de-carcinoma-de-c%C3%A9lulas-renal-(ccr) 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-estudio-oncosur-de-fase-i-ii-para-c%C3%A1ncer-de-vejiga-no-m%C3%BAsculo-invasivo-(nmibc)-de-alto-riesgo 2026-04-13 https://www.oncobites.tv/news/osimertinib-confirma-su-efecto-en-la-supervivencia-global-en-el-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/%C3%BAltimas-novedades-en-terapia-de-precisi%C3%B3n-en-colangiocarcinoma 2026-04-13 https://www.oncobites.tv/news/lo-que-promete-la-inmunoterapia-para-el-tratamiento-del-c%C3%A1ncer 2026-04-13 https://www.oncobites.tv/news/esmo-sarcoma24-%C2%BFcu%C3%A1l-es-el-papel-de-la-inmunoterapia-en-el-sarcoma-2024%3F 2026-04-13 https://www.oncobites.tv/news/esmo-y-su-compromiso-con-los-objetivos-de-desarrollo-sostenible-(ods)-2030 2026-04-13 https://www.oncobites.tv/news/%C2%A1ojo%2C-que-el-sabcs-est%C3%A1-a-la-vuelta-de-la-esquina! 2026-04-13 https://www.oncobites.tv/news/terapia-hormonal-%2B-atenci%C3%B3n-multidisciplinaria-en-c%C3%A1ncer-de-pr%C3%B3stata-recurrente 2026-04-13 https://www.oncobites.tv/news/enfortumab-vedotin-en-combinaci%C3%B3n-con-pembrolizumab%3A-nuevo-est%C3%A1ndar-en-el-tratamiento-de-1ra-l%C3%ADnea-de-pacientes-con-carcinoma-urotelial-localmente-avanzado-o-metast%C3%A1sico 2026-04-13 https://www.oncobites.tv/news/la-biopsia-l%C3%ADquida-como-m%C3%A9todo-de-diagn%C3%B3stico-en-el-c%C3%A1ncer-ha-llegado-para-quedarse 2026-04-13 https://www.oncobites.tv/news/aegean%3A-durvalumab-perioperatorio-para-el-c%C3%A1ncer-de-pulm%C3%B3n-no-microc%C3%ADtico-resecable 2026-04-13 https://www.oncobites.tv/news/estudio-iberoamericano-sobre-disfunci%C3%B3n-sexual-en-c%C3%A1ncer-de-pulm%C3%B3n 2026-04-13 https://www.oncobites.tv/news/salvando-dos-vidas%3A-consenso-esmo-para-c%C3%A1ncer-de-mama-durante-el-embarazo 2026-04-13 https://www.oncobites.tv/news/quimioterapia-y-su-relaci%C3%B3n-con-la-calidad-de-vida-en-pacientes-sobrevivientes-de-c%C3%A1ncer-testicular-(ct) 2026-04-13 https://www.oncobites.tv/news/una-luz-para-el-c%C3%A1ncer-de-mama-avanzado-resistente-a-terapia-endocrina-y-quimioterapia 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-impacto-del-origen-racial-en-los-desenlaces-de-la-terapia-con-77lu-psma-617-en-pacientes-con-c%C3%A1ncer-de-pr%C3%B3stata-resistente-a-la-castraci%C3%B3n-metast%C3%A1sico-(cprcm) 2026-04-13 https://www.oncobites.tv/news/%C2%A1extra%2C-extra!%2C-esmo-actualiza-las-gu%C3%ADas-de-manejo-para-c%C3%A1ncer-de-p%C3%A1ncreas 2026-04-13 https://www.oncobites.tv/news/directrices-actualizadas-para-c%C3%A1ncer-de-pulm%C3%B3n-de-c%C3%A9lula-no-peque%C3%B1a-en-estadio-iii 2026-04-13 https://www.oncobites.tv/news/asco-y-la-sso-establecen-directrices-sobre-pruebas-de-l%C3%ADnea-germinal-en-pacientes-con-c%C3%A1ncer-de-mama-(cm) 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-descifrando-el-papel-de-los-inhibidores-de-punto-de-control-(icis)-mediante-perfil-transcripcional-para-carcinoma-urotelial-(cu) 2026-04-13 https://www.oncobites.tv/news/tislelizumab%2C-un-anticuerpo-monoclonal-anti-pd-1%2C-usado-como-tratamiento-de-1ra-l%C3%ADnea-para-el-carcinoma-hepatocelular-(chc) 2026-04-13 https://www.oncobites.tv/news/ascgogu24%3A-el-consorcio-guardian-es-un-estudio-de-evidencia-real-con-enfortumab-vedotin-para-c%C3%A1ncer-urotelial-localmente-avanzado-(cu-la)-y-metast%C3%A1sico-(cum) 2026-04-13 https://www.oncobites.tv/news/gu24-est%C3%A1-cerca 2026-04-13 https://www.oncobites.tv/news/evoluci%C3%B3n-terap%C3%A9utica%2C-estos-tratamientos-presentados-en-ascogi-2024-se-pueden-establecer-como-nuevas-pautas-de-atenci%C3%B3n-m%C3%A9dica 2026-04-13 https://www.oncobites.tv/news/ascogu24%3A-%C2%BFqu%C3%A9-hay-de-nuevo-desde-ascogu23-en-las-gu%C3%ADas-de-manejo-de-pacientes-con-c%C3%A1ncer-de-pr%C3%B3stata-(cp)%3F 2026-04-13 https://www.oncobites.tv/news/beatcc%3A-atezolizumab-m%C3%A1s-bevacizumab-y-quimioterapia-(qt)-para-el-c%C3%A1ncer-cervical-metast%C3%A1sico%2Cpersistente-o-recurrente 2026-04-13